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Chapter 1: Background and Significance 
 
 Introduction 
Complaints of poor or insufficient sleep are common in older adults, with 
up 50% reporting symptoms such as fragmented sleep, difficulty falling asleep, 
early morning awakening and daytime sleepiness1, 2.  Although the biological and 
physiological functions of sleep are not well understood, sleep does appear to 
have a role in several processes, including memory consolidation, energy 
conservation, restoration, endocrine function and brain development.  The 
consequences of insufficient sleep are especially of concern in older adult 
populations, who are often burdened by multiple comorbidities.  Prior research in 
middle-aged and older adult populations has suggested associations between 
poor sleep/sleep-related disorders and depression3, 4, cardiovascular disease5, 5, 
6, frailty7, 8, impaired cognitive functioning9, 10 and mortality8. 
Therefore, adequate sleep is an important aspect of healthy aging in older 
adults, and the field of sleep research is striving to better understand the 
pathways, correlates and consequences of insufficient sleep.  The field also 
faces many challenges, including lack of a consistent and concrete measure of 
sleep disturbances and disorders across studies, inconsistent results and use of 
screening tools that have not been studied in older populations.  This dissertation 
will focus on improving our understanding of the epidemiology of sleep 
disturbances in older adults, by exploring variability in sleep/wake parameters as 
a novel measure of sleep disturbance, assessing the implications of a widely 
used sleep-apnea screening questionnaire in an older adult population, and 
evaluating associations between measures of self-reported and actigraphy 
assessed sleep disturbances and health-related outcomes using a cohort-linked 
to Medicare dataset.  Data from two large cohort studies of older adults will be 
used to address these questions.   
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Burden of Self-Reported Sleep Disturbances in Older Adults: 
 Self-reported sleep disturbances include difficulties getting to sleep, 
staying asleep (sleep fragmentation), early morning awakening and reduced total 
sleep time.  Over 50% of older adults report one or more sleep disturbances1, 11, 
and >22% report waking up feeling unrefreshed1.  Surveys have also shown that 
despite a high prevalence of complaints, older adults typically report getting an 
average of 7 hours of sleep per night1, 11.         
Research has also suggested that that the amount of sleep needed (and 
not necessarily the ability to sleep) naturally declines with older age, and that the 
inability to obtain enough sleep in older adults may be attributed to a higher 
burden of comorbidities, psychiatric conditions (such as depression or dementia), 
medications and life changes (bereavement)11.  Additional research has 
suggested that the sleep patterns of older adults (night-to-night variability) are 
more stable11 than in younger populations, but this has not been directly 
assessed in a community-based population of older adults.             
 
Burden of Sleep Apnea in Older Adults: 
 Sleep disordered breathing (SDB), or sleep apnea, is characterized by 
repetitive partial or complete airway obstruction during sleep.  The prevalence of 
SDB in middle aged adults ranges from 2-4%12, and in older adults from 6-70% 
depending on the definitions being used and characteristics of the population 
studied (referral or community-based)13-18.   In the Outcomes of Sleep Disorders 
in Older Men (MrOS Sleep) cohort study, we found a prevalence of moderate-
severe sleep apnea of 26.4% (Apnea Hypopnea Index>15)18.   
 
Risk Factors for Sleep Apnea: 
 There are several risk factors and correlates of SDB18, 19, including older 
age, non-Caucasian race, obesity, sleepiness, hypertension, snoring, 
cardiovascular disease, nasal congestion, smoking, breathing pauses, male 
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gender, neck circumference>40cm, and alcohol use.  SDB has also been linked 
with several health-related outcomes19 including an increased risk of 
hypertension20-23, stroke6, 24, cardiovascular disease6, 25, lower quality of life26, 27, 
excessive sleepiness19, 28 and mortality13.   
 
Diagnosis and Screening of Sleep Apnea: 
 A diagnosis of obstructive sleep apnea is made by overnight 
polysomnography (PSG), typically performed in a hospital or referral center-
based setting.  PSG studies are expensive, require highly trained personnel, 
equipment and considerable resources for staff, hospitals (or centers performing 
the study) and time since they involve an overnight stay.  There can also be a 
lengthy waiting list to get a PSG depending on the availability and capacity of the 
center.  Therefore, there is a great need for an effective screening tool for use in 
the primary care clinical practice setting to determine which patients most likely 
have SDB and warrant evaluation with polysomnography.    
 Several simple questionnaires have been developed to screen and identify 
patients who have sleep apnea29.  The STOP-Bang is a widely used 
questionnaire, because of its simplicity and high sensitivity, but was developed in 
a surgical population as a way to assess risk of sleep disordered breathing prior 
to giving anesthesia.  In general, screening tools for sleep apnea have performed 
moderately well29, and to our knowledge, only the Berlin has been previously 
studied in a population of older adults30.  Due to the cost and limited resources of 
polysomnography, the need for a reliable and accurate screening tool for sleep 
apnea in older adult populations is warranted. 
 
Health Care Utilization in Older Adults 
 According to the 2007 National Hospital Discharge Survey, older adults 
comprise about 13% of the US population, but account for 37% of all hospital 
discharges31.  Healthcare utilization, and especially inpatient admissions, may be 
4 
 
a good indicator of major disease events, and signal unsuccessful aging in older 
adults.  Examining how factors not available in the medical record or 
administrative claims data such as sleep disturbances, are associated with 
hospitalizations in older adults will increase our understanding of determinants of 
inpatient health care use in the elderly and better quantify the impact that sleep 
disturbances have on health in older adults.   
Therefore, to improve our understanding of the epidemiology of sleep 
disturbances in older adults, this dissertation will explore variability in sleep/wake 
measures as a novel measure of sleep disturbance in older men, assess the 
implications of a widely used sleep-apnea screening questionnaire in a cohort of 
community-dwelling older men, and evaluate associations between measures of 
self-reported and actigraphy assessed sleep disturbances and inpatient 
admissions in a cohort of older women concurrently enrolled in fee-for-service 
Medicare.      
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Chapter 2:  Study Design and Methods 
 
 The Outcomes of Sleep Disorders in Older Men (MrOS Sleep) Study 
 
Cohort Recruitment and Composition 
 The prospective Osteoporotic Fractures in Men (MrOS) study enrolled 
5,994 men aged 65 years and older from March 2000 through April 2002.   The 
study was primarily initiated to better understand the extent to which fracture risk 
is related to bone mass, bone geometry, lifestyle, anthropometric and 
neuromuscular measures and fall propensity, as well as to determine how 
fractures affect quality of life in older men.  Men were recruited from population-
based listings in six areas of the United States: Birmingham, Alabama; the 
Monongahela Valley near Pittsburgh, Pennsylvania; Minneapolis, Minnesota; 
Palo Alto, California; San Diego, California; and Portland, Oregon.  Men with a 
history of bilateral hip replacement ad men who were unable to walk without 
assistance of another person were excluded from study enrollment.  Several 
additional follow up visits and sub studies were conducted following the initial 
baseline exam, with visits occurring approximately every 1-2 years (Figure 1).   
 
Figure 1.  MrOS & Medicare Data Collection Timeline 
 
Medicare claims data currently through 12/31/2007; the renewal grant has funding to purchase additional years 
of claims data (1/1/2008 through 12/31/2015) 
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Medicare MrOS Exams*
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*5,994 men aged 65 and older were enrolled at the baseline exam (2000 to 2002) at the Minneapolis, 
Pittsburgh, Portland, Palo Alto, San Diego, and Birmingham clinical centers. MrOS participants are followed-up 
every 4 months via mail or phone to track endpoints of falls, fractures, prostate cancer, and death. 
 
 From December 2003 through March 2005, a subset of MrOS participants 
were invited to participate in an ancillary study Outcomes of Sleep Disorders in 
Older Men (MrOS Sleep), to better understand how sleep disorders impact health 
related outcomes in older adult men.  To be eligible to participate in the sleep 
ancillary study, participants had to report not using oxygen therapy in the past 
three months, no history of an open tracheotomy, not sleeping with a mouthpiece 
for snoring or sleep apnea in the past three months, or not sleeping with a CPAP 
or BiPAP mask in the last three months.  Some exceptions were made for 
participants who intermittently used CPAP, or who were willing to forgo wearing 
the CPAP or BiPAP mask during the sleep study.  Of the 5,994 men enrolled in 
the MrOS Parent study, 3,135 (>100% of recruitment goal) participated in the 
MrOS Sleep exam.   
The Study of Osteoporotic Fractures in Women (SOF)  
The Study of Osteoporotic Fractures (SOF) is a landmark longitudinal 
epidemiologic study designed to examine risk factors for osteoporotic fractures.  
Women were recruited from four U.S. clinical centers (Baltimore, Maryland; 
Minneapolis, Minnesota; the Monongahela Valley nears Pittsburgh, 
Pennsylvania; and Portland, Oregon)32.  The SOF study enrolled 9,704 
community-dwelling white women aged 65 years and older from 1986-1988.   
Women were excluded if they were unable to walk without assistance, or if they 
had undergone a previous bilateral hip replacement.  Initially African American 
women were excluded from the study due to their low incidence of hip fractures, 
but from 1997-1998, 662 African American women aged 65 years and older were 
recruited33.    
 After completion of the baseline clinic visit, additional follow-up visits were 
conducted approximately every 1-4 years (Figure 2).  This dissertation will utilize 
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data from the Year 16 (or Visit 8) SOF exam that was conducted between 2002 
and 2004.  At this visit, 3,137 women attended a clinic visit and 539 attended a 
home visit.      
 
Linkage to Medicare Claims and Kaiser Permanente Encounter Data 
 Linkage of the SOF cohort to Medicare claims data was completed in 
2008, by submitting social security and/or Medicare (HIC) numbers for SOF 
participants who were alive as of 1/1/1991 (first date that Medicare claims were 
available), to Centers for Medicare and Medicaid Services (CMS).  A linkage was 
determined to be valid if there was an exact match on SSN/HIC, and sufficient 
agreement on DOB, gender, last known residence (ZIP code), and date of death 
(when available).  Medicare data was purchased from January 1991-December 
2010.  Of the 10,366 women enrolled in the SOF study, 9,986 were alive and 
actively enrolled in SOF as of January 1, 1991, and of those 9,228 (92.4%) were 
determined to be valid linkages to Medicare claims data.   
 Women at the SOF Portland site were originally recruited into the SOF 
study through Kaiser Permanente, and thus we observed a high rate of Medicare 
Advantage enrollment at this site (96%).  Linkage of SOF Portland participants to 
Kaiser Permanente inpatient encounter records was completed in 2014 by 
submitting social security numbers to Kaiser Permanente.  Of the 2,464 women 
enrolled at the Portland SOF site who were alive as of 1/1/1991, 2,180 (88.5%) 
were enrolled in a Kaiser Permanente plan.  Kaiser Permanente inpatient 
encounter data was obtained from January 1991-December 2010.  In combining 
Medicare and Kaiser Permanente encounter records we were able to 
successfully link 9,381 (93.9% of 9,986) SOF participants to Medicare and/or 
Kaiser encounter records.        
We required that during the month of the SOF V8 exam, participants be 
observable in claims/encounters data, meaning that they were either enrolled in 
Kaiser, or enrolled in a Part A Medicare plan for which CMS processes all of the 
inpatient claims.  Of the 3,123 women who attended Visit 8 and had technically 
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adequate actigraphy data, 2,103 (67.3%) linked successfully to Medicare and/or 
Kaiser and were enrolled in a Part A plan, or Kaiser plan for at least one month 
after their sleep visit, until death, enrollment in a Medicare Advantage plan, or the 
end of follow up, whichever came first (Figure 4).   
 
 
 
Figure 2.  SOF & Claims Data (Medicare/KPNW) Collection Timeline 
 
 
*Claims data currently available from 1/1/1991 through 12/31/2007; the renewal grant has funding to purchase additional 
years of claims data (1/1/2008 through 12/31/2014) 
†
7,280 Caucasian women were enrolled at the baseline exam at the Minneapolis, Pittsburgh, and Portland clinical centers 
between 1986-1988; an additional 480 African American women were enrolled at the Year 10 exam between 1997-1998 
NOTE: Until Fall 2009, SOF participants were followed-up every 4 months via mail or phone to track endpoints of falls, 
fractures, breast cancer, and deaths. Since Fall 2009, SOF participants have been followed-up every 6 months via 
questionnaire administered over the telephone to collect additional data focused on living situation, health status, and 
functional status. 
 
 
 
 
 
 
 
 
 
 
1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Medicare SOF Exams
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Chapter 3:  Performance of the STOP and STOP-BANG questionnaires in 
detecting moderate-severe sleep disordered breathing in a cohort of older 
men 
 
Objectives:  To evaluate the ability of the STOP-BANG questionnaire to 
accurately identify older men with Obstructive Sleep Apnea (OSA), and to 
examine the association between STOP-BANG scores and excessive daytime 
sleepiness.   
Design:  Cross-sectional study 
Participants:  Two thousand nine hundred fifty three men aged 67 years and 
older enrolled in the Outcomes of Sleep Disorders in Older Men (MrOS Sleep) 
cohort study. 
Measurements:  OSA was assessed via overnight, in-home polysomnograpy, 
and the STOP-BANG questionnaire was recreated using data collected during 
the clinic exam.  Severe OSA was defined as an Apnea Hypopnea Index 
(AHI)>30, and primary analyses examined STOP-BANG scores using a cut point 
of >3.  Secondary analyses examined alternative cut points in OSA severity and 
STOP-BANG scores.  Excessive daytime sleepiness (ESS) was defined as an 
Epworth Sleepiness Scale score >10, and analyses examining associations 
between STOP-BANG and ESS used logistic regression.   
Results:  Severe OSA was prevalent (17.5%) in this population, as were most 
STOP-BANG components of Snoring loudly (41.8%); Tired (45.7%); Observed 
apneas (20.9%); Pressure (50.0%); BMI>35 kg/m2 (3.6%); Age>50 y (100%); 
Neck circumference>40 cm (37.9%); and male gender (100%).  At a cut point of 
>3, the STOP-BANG identified 88.4% of the men as having a high likelihood of 
OSA.  Furthermore, this cut point resulted in a large number of false positives, as 
evidenced by a sensitivity of 94.0% and a specificity of 12.7%, and little impact 
on probability revision as evidenced by a positive predictive value (PPV) that 
approximated the prevalence of OSA (18.6% vs. 17.5% for PPV vs. prevalence 
respectively).  Secondary analyses did not suggest improved functionality with 
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higher STOP-BANG cut points due to the resultant high rate of missed cases and 
indicated that BMI>35 kg/m2 was more accurate in identifying OSA than STOP-
BANG.   
Conclusion:  The STOP-BANG questionnaire has poor discriminatory ability in 
detecting OSA in community-dwelling older men.  Additional research into risk 
factors and characteristics of OSA in older populations is warranted. 
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Introduction: 
 Sleep apnea is a chronic age-related medical condition characterized by 
repeated episodes of pauses in breathing, or shallow/infrequent breathing that 
occur during sleep.   These episodes can last from seconds to minutes, and can 
occur up to 30 or more times per hour34.  Patients with sleep apnea may report 
symptoms of excessive daytime sleepiness, fatigue, snoring, and/or disturbed 
sleep19, 34.  Emerging evidence from primarily middle-aged populations also 
suggests that sleep apnea is associated with and increased risk of mortality35-37, 
hypertension38-41, stroke42, 43, cardiovascular disease43, 44, traffic accidents19, 45, 
cognitive impairment46, 47 and diminished quality of life48, 49.  Studies have also 
suggested that patients with sleep apnea have a higher risk of post-surgical 
complications50.   
 The prevalence of obstructive sleep apnea (OSA) that has been reported 
in the literature varies depending on definition and population.  The  results of 
observational studies have estimated that 17-26% of adult men and 7-14% of 
adult women have at least mild sleep apnea12, 19.  The prevalence of OSA rises 
with increasing age (up to about age 70 years), and as many as 50% or more of 
older adults may have at least mild sleep apnea18.  The prevalence of severe 
OSA is often not the focus of many epidemiologic studies, but was observed to 
be 7.2% in a population of mostly middle-aged adults enrolled in the Sleep Heart 
Health Study51.    
 While sleep apnea is associated with an increased risk of adverse health 
outcomes in middle-aged adults, associations between OSA and outcomes such 
as mortality may be weaker in older populations35, 36, 52, 53.  Findings regarding the 
association in older adults may reflect an underlying difference in the 
pathophysiology of the condition, comorbidities, survival bias or competing 
risks18.  For example, in the Outcomes of Sleep Disorders in Older Men (MrOS 
Sleep) cohort, significant associations were observed between measures of 
severe OSA and greater nocturnal hypoxemia and increased risk of mortality 
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after 3.4 years of follow-up, but there was no association of at least mild OSA 
and moderate/severe OSA with risk of mortality in this cohort52.     
 To date, the gold standard methodology to diagnose sleep apnea requires 
an overnight polysomnogram, which typically, but not always involves an 
overnight stay in an sleep laboratory, and the attachment of several monitors to 
measure breathing, eye movements, brain waves, chest and abdominal 
respiratory effort, oxygen saturation and heart rate.  Overnight polysomnography 
is also expensive, and there can often be lengthy wait lists, which make it 
especially not feasible for pre-operative sleep apnea testing.  Therefore, there is 
a need for a simple initial screening tool that could be used in the busy clinical 
practice setting to identify patients who are at high likelihood of having sleep 
apnea.            
 In an effort to address this need, several check-list style screening risk 
assessment tools have been developed.  The focus of our study was on the 
STOP-BANG questionnaire, due to its simplicity for use, comprehensive criteria 
and existing clinical practice guidelines that recommend its use for sleep apnea 
screening in pre-anesthesia patients 54 55.  Furthermore, results of two meta-
analyses comparing multiple questionnaires both reported that the STOP-BANG 
performs the best.  The first meta-analyses, conducted by Dr. Abrishami and 
colleagues56 evaluated the STOP-BANG, STOP, Berlin, Wisconsin Sleep 
Questionnaire, and American Society of Anesthesiologists (ASA) checklist and 
suggested that the STOP-BANG had higher quality evidence than the other tools 
assessed, was simple to use and had the greatest sensitivity.  Another meta-
analysis published in 2009 evaluated several tools (including many of the same 
studies that were included in the initial meta-analysis) and suggested that the 
STOP-BANG had a high sensitivity, and was an excellent screening test for 
severe OSA, but had an unacceptable false negative rate for the diagnosis of any 
or moderate/severe OSA57.   Both meta-analyses observed significant 
heterogeneity across studies and thus were unable to present pooled results.    
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  The STOP-BANG questionnaire was developed in 2008 as a tool to 
identify pre-anesthesia patients who had undiagnosed sleep apnea50.  It consists 
of eight yes or no questions (scored as 1/0) and summary scores ranging from 0-
8.  The eight components of the STOP-BANG assess presence of Snoring, 
Tiredness, Observed apneas, Pressure (hypertension), BMI, Age, Neck 
circumference and Gender.   The STOP-BANG (as well as the shorter STOP 
questionnaire) was initially validated in a population of 177 preoperative adult 
patients without a prior diagnosis of OSA undergoing elective procedures.  
Participants had a mean age of 55 + 13 years, and about 50% were male.  Using 
a cut off of AHI>30 to define severe sleep apnea (prevalence=22.0%) and a cut 
point of >3 on the STOP-BANG (prevalence=71.2%), results indicated that in this 
population, STOP-BANG had a sensitivity of 100%, specificity of 37.0%, positive 
predictive value (PPV) of 31.0% and negative predictive value (NPV) of 100%. 
Thus,  the STOP-BANG cutpoint of >3 identified all participants who had severe 
OSA, but also 63% of the participants who didn’t have severe OSA as false 
positive50.    
 In a follow-up study of 746 preoperative patients (mean age 60 years, 
49% male, 18.0% prevalence of severe OSA), researchers observed that at a 
cut-point of >3, the sensitivity, specificity, PPV and NPV was observed to be 
94.8%, 27.6%, 22.3% and 96.0% respectively for the identification of severe 
OSA.  They concluded that a cut point of 5 or more might be optimal to identify 
patients with OSA the sensitivity, specificity, PPV and NPV at a cut point of >5 for 
detection of severe OSA was observed to be 56.0%, 74.2%, 32.2% and 88.5%58.  
It is important to note that at this cut point, use of the STOP-BANG resulted in a 
false positive rate of 25.8%, and a false negative rate of 44.0%.    
 Efforts to validate the performance of the STOP-BANG in a more general 
population of middle-aged adults enrolled in the Sleep Heart Health Study 
(SHHS) suggested an even poorer ability to detect individuals with severe OSA.  
In a cohort of 4,770 SHHS participants (mean age 62.4 years, 51.5% male), 
results suggested that at a cut point of >3, the STOP-BANG identified 72.4% of 
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the cohort as having severe OSA, with a sensitivity of 70.4%, specificity of 
59.5%, PPV of 11.9% and NPV of 96.3%.  The prevalence of severe OSA in this 
population was observed to be 7.2%, which was much lower than the number 
identified as having a high likelihood of OSA on the STOP-BANG, which resulted 
in a high false positive rate (40.5%), and missed about one-third of individuals 
with severe OSA51.   
 To our knowledge, the performance of the STOP-BANG in a population of 
older adults has not been directly assessed. Given the higher prevalence of 
sleep apnea and STOP-BANG components in aged adults, it is plausible that the 
ability of this tool to identify patients with OSA may be further diminished beyond 
its performance in younger populations.  On the other hand, the simplicity of this 
tool makes it particularly attractive for use in primary care practice settings to 
evaluate older patients presenting with sleep complaints suggestive of sleep 
apnea to determine need for further testing, such as referring the patient for 
overnight polysomnography.  Hence, a better understanding of the performance 
of this tool in an aged population is essential.     
 In addition, a detailed examination of the association between STOP-
BANG scores and self-reported sleep complaints in an older population may 
provide insight into how well the STOP-BANG questionnaire predicts sleep-
disordered breathing phenotypes that impair daytime functioning. For example, 
excessive daytime sleepiness (ESS) is a measure of propensity for sleep onset, 
and is a key symptom of sleep apnea that often drives patients to seek medical 
care.  The mechanism by which sleep apnea is thought to cause ESS is through 
arousals that result in fragmented  sleep, although studies attempting to elucidate 
this pathway have not confirmed that frequency of arousals explains the variation 
between sleep apnea and ESS59. The association between STOP-BANG and 
excessive daytime sleepiness in older adults is unknown, as well as how this 
association compares to that between OSA defined using AHI and excessive 
daytime sleepiness.  
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 Therefore, the aim of this study was to comprehensively evaluate the 
ability of the STOP-BANG questionnaire to identify older men with and without 
OSA.  A second aim was to examine if higher STOP-BANG scores are 
associated with a measure of excessive daytime sleepiness, a key symptom of 
OSA.  To assess these aims, we measured OSA using overnight, in-home 
polysomnography and recreated the STOP-BANG questionnaire using data 
collected in 2,853 men aged 67 years and older who were enrolled in the 
Outcomes of Sleep Disorders in Older Men (MrOS Sleep) cohort study.   
Methods: 
Study Population 
 Participants in the Osteoporotic Fractures in Men (MrOS) study were 
recruited at six U.S. clinical centers (Birmingham, AL; Minneapolis, MN; Palo 
Alto, CA; Monongahela Valley near Pittsburgh, PA; Portland, OR; and San 
Diego, CA) to complete a baseline examination between March 2000 and April 
2002.  The primary aim of the MrOS study was to identify risk factors for 
osteoporosis and fractures in older community-dwelling men.  To be eligible, men 
had to be able to provide consent, walk without assistance from another person 
or aid, be aged 65 years and older, and not have had bilateral hip replacements.  
A total of 5,994 men were enrolled in MrOS, and details regarding recruitment 
and study design have been published elsewhere60, 61.  
From December 2003 through March 2005, a subset of MrOS participants 
were invited to participate in an ancillary study to identify outcomes of sleep 
disorders in older men (MrOS Sleep).  To be eligible, participants had to report 
not using oxygen therapy in the past three months, have no history of an open 
tracheotomy, report not sleeping with a mouthpiece for snoring or sleep apnea in 
the past 3 months, and not sleeping with a CPAP or BiPAP mask in the last 3 
months.  Approval was obtained from the institutional review board at each site.  
Written informed consent was obtained for all individuals.   
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 Of the 5,994 men enrolled in MrOS, 3,135 (>100% recruitment goal) 
participated in the MrOS Sleep ancillary study. A total of 1,997 men declined 
participation in the sleep study, 150 were not eligible, 344 died prior to the sleep 
study, 36 terminated from the MrOS study before being contacted and 332 were 
not contacted because enrollment goals had been met (Figure 1).  Of the 3,135 
participants who participated in the sleep visit, 2,911 (92.9%) had useable PSG 
data, 179 did not participate in PSG, and 45 had PSG data gathered, but it was 
not technically adequate.  Furthermore, of the 2,911 participants with PSG data, 
2,853 had complete measures of STOP-BANG components and comprise the 
analytical cohort for this paper.   Compared to the 2,853 participants included in 
the analytic cohort, the 1,997 MrOS Study participants who refused participation 
in MrOS Sleep were slightly older at enrollment in the MrOS study (74.0 + 5.9 vs. 
73.0 + 5.5 years, p<.001), more often reported having poor, very poor or fair 
health (14.0% vs. 11.5%, p=0.01), were slightly less likely to be Caucasian race 
(90.1% vs. 91.9%, p=0.025), and did not differ with respect to body mass index 
(27.2 + 3.7 vs. 27.4 + 3.7 kg/m2, p=0.116). 
 
Measurement of Obstructive Sleep Apnea 
Single night, in-home sleep studies using unattended polysomnography 
(Safiro, Compumedics Inc., Melbourne, Australia) were performed successfully 
on 2,911 MrOS Sleep participants.  The PSG recordings were to be gathered 
within 1 month of the clinic visit (mean 6.9 + 15.8 days from visit), with 78% of 
recordings gathered within 1 week of the clinic visit.  Data was gathered in 30-
second epochs.  The recording montage consisted of C3/A2 and C4/A1 
electroencephalograms, bilateral electrooculograms, a bipolar submental 
electromyogram, thoracic and abdominal respiratory inductance 
plethysmography, airflow (using nasal-oral thermocouple and nasal pressure 
cannula), finger pulse oximetry, electrocardiogram, body position (mercury switch 
sensor), and bilateral leg movements (piezoelectric sensors).  Trained certified 
staff members performed home visits for setup of the sleep study units.  After 
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sensors were placed and calibrated, signal quality and impedance were checked, 
and sensors were repositioned as needed to improve signal quality, replacing 
electrodes if impedances were greater than 5kΩ, using approaches similar to 
those in the Sleep Heart Health Study62.  Staff returned the next morning to 
collect the equipment and download the data to the Central Sleep Reading 
Center (Cleveland, OH) for centralized scoring by a trained technician.  
Polysomnography data quality had a failure rate of less than 4% and more than 
70% of studies were graded as being of excellent or outstanding quality.   
 The diagnosis of Sleep apnea was determined using the apnea hypopnea 
index (AHI), which represents the average number of apneas and hypopneas per 
hour of sleep.  Apneas were defined as a complete or almost complete cessation 
of airflow for more than 10 seconds.  Obstructive apneas were scored if 
persistence of effort on abdominal or thoracic inductance plethysmography was 
noted, and central apneas were scored if there was no evident effort on either the 
abdominal and thoracic plethysmography bands.  We did not differentiate 
between obstructive and central apnea in primary analyses, since central apneas 
occurred very infrequently in this cohort (<5%).  Hypopneas were scored using 
SHHS criteria63, requiring a >30% reduction in amplitude of either respiratory 
effort or airflow for more than 10 seconds, and a >3% oxygen desaturation.  
Secondary analyses examined AHI events associated with a >4% oxygen 
desaturation.  Severity of AHI was classified as: 0-4 (none); >5 (Any: 
mild/moderate/severe); >15 (moderate/severe); and >30 (severe).  
 
Self-Reported Sleep Measures 
 Data from the Pittsburgh Sleep Quality Index (PSQI) was used to 
construct STOP-BANG questions for Snore loudly and Observed apneas, as well 
as information on bed partners.  The PSQI is a validated measure of subjective 
sleep quality and sleep disturbances over a 1-month period.  The questionnaire 
is divided into sections that assess subjective sleep quality, sleep latency, sleep 
duration, sleep efficiency, sleep disturbances, use of sleeping medications and 
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daytime dysfunction.  Global PSQI scores range from 0 to 2164, 65.   Data from the 
Functional Outcomes of Sleep Questionnaire (FOSQ) were used to construct 
STOP-BANG questions for Tired.  The FOSQ is a disease specific quality of life 
questionnaire that is used to assess functional status of daily behaviors that are 
impacted as a result of excessive sleepiness.  The questionnaire consists of 26 
items and 4 factor subscales that assess difficulties with activity level, vigilance, 
general productivity and social outcomes66.       
 The Epworth Sleepiness Scale (ESS) is a self-administered questionnaire 
that classifies subjective daytime sleepiness in people with sleep disorders, and 
is a measure of propensity for sleep onset.  Participants are asked to rate how 
likely (from 1 to 3, with 1 being unlikely and 3 being highly likely) they are to doze 
off in eight typical daily situations.  Scores range from 0 to 24, with a standard 
cutoff of greater than 10 indicative of excessive daytime sleepiness67, 68. 
 
Additional Measures 
 At the time of their clinic visit, participants completed several clinical 
measurements and self-administered questionnaires.  Body weight was 
measured using a standard balance beam, or digital scale and height using a 
wall mounted Harpenden stadiometer.  Body mass index (BMI) was calculated 
as kg/m2.  Neck circumference was also measured at the clinic visit and 
expressed in cm.  Participants completed a self-administered questionnaire 
which ascertained information on medical history (including history of 
hypertension/Pressure), current health status, smoking and alcohol use, and 
physical activity.  Information from the MrOS baseline visit was used to assess 
age, race and educational level.   
 
Construction of the STOP-BANG Scores 
 To create the STOP-BANG questionnaire for the purposes of this study, 
we utilized data collected in the MrOS Sleep Visit that was similar but not always 
identical to questions in the STOP-BANG instrument.  A comparison of the 
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questions in STOP-BANG and similar questions collected in MrOS are provided 
in Appendix A.   Snore loudly was considered positive if the participant reported 
having trouble sleeping during the past month because they cough or snore 
loudly (less than once a week, once or twice a week, or three or more times a 
week=Yes, not during the past month=No).  Tired was considered positive if the 
participant reported difficult being as active as they want to be in the morning (or 
afternoon) because they are sleepy or tired (extreme difficulty or moderate 
difficulty or a little difficulty=Yes, No difficulty= No).  Observed apneas were 
considered positive if the participant reported that their bed partner observed that 
during the past month they had long pauses between breaths while asleep (less 
than once a week, or once or twice a week or three or more times a week =Yes, 
not during the past month=no). Pressure was considered positive if the 
participant self-reported having a physician diagnosis of hypertension.  BMI was 
considered positive if the participants’ BMI was greater than 35 kg/m2.  Age was 
considered positive for all participants since the minimum age in the cohort was 
67 years.  Neck circumference was considered positive if greater than 40 cm.  
Male Gender was considered positive for all participants since only males were 
enrolled in the cohort.   
 Sensitivity analyses explored alternative variables available in the MrOS 
Sleep cohort, such as a positive response to Tired if the participant reports 
having difficulty concentration on things because they are sleepy or tired (a little 
difficulty, or moderate difficulty or extreme difficulty=Yes, no difficulty=No), or a 
positive response to Pressure if the participant reports use of antihypertensive 
medications or has a systolic blood pressure>140 mm Hg.  
 Global STOP-BANG scores were calculated by summing the number of 
affirmative answers to each of the questions. 
 
Statistical Analysis 
 The ability of STOPBANG scores to identify men with and without OSA 
was evaluated using epidemiologic parameters of sensitivity, specificity, positive 
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predictive value (PPV), negative predictive value (NPV) and likelihood ratios.  
PPV and NPV estimates provide clinically useful information on the performance 
of a screening tool, given a positive or negative finding.  PPV is defined as the 
probability that participants with a positive test truly have OSA, whereas the NPV 
is the probability that participants with a negative test don’t have OSA.  If the 
PPV roughly equals the prevalence of disease in the cohort (prevalence of OSA 
in this case), and NPV equals 1-prevalence of disease then the screening tool 
yields little or no added value for clinical decision making, beyond the prior 
information that is already known (OSA prevalence in the population).   
 The likelihood ratio uses sensitivity and specificity to determine whether a 
test results in a meaningful change in the probability of the disease.  The 
likelihood ratio positive (LR+) is defined as the ratio of the probability that a 
person who has the disease tests positive divided by the probability that a person 
who does not have the disease tests positive.  Similarly, the likelihood ratio 
negative (LR-) is the ratio of the probability that person who has the disease tests 
negative divided by the probability that a person who does not have the disease 
tests negative.   Likelihood ratios greater than 1 indicate that the test is 
associated with the presence of disease.  A likelihood ratio less than 1 indicates 
that the test is associated with absence of the disease, and likelihood ratios close 
to 1 have little diagnostic value since the prevalence of the disease is equivalent 
to the post-test probability (positive predictive value).   
 For primary analyses we assumed a STOP-BANG cut-point >3 was 
indicative of a positive test, and OSA was defined as an AHI>30.  Secondary 
analyses examined alternative STOP-BANG cut points as well as lower AHI cut 
points (AHI>5 and >15).   
 Logistic regression was used to examine receiver operating characteristic 
(ROC) curves and to calculate the area under the curve (AUC).  The area under 
a ROC curve is used as a measure of how well a test, such as the STOP-BANG, 
can distinguish between two groups (OSA/normal).  For models expressing 
STOP-BANG scores as continuous variables, the AUC represents a global 
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summary statistic of the diagnostic accuracy of the test, irrespective of any 
particular cut point.  For models examining dichotomous cut points in STOP-
BANG scores, the AUC represents the diagnostic accuracy of the test at that 
particular cut point.  Models with AUC statistics of 0.50 do no better than chance 
alone, whereas models with higher AUC statistics do much better than chance, 
and an AUC of 1.0 indicates a perfect test.   
 Secondary analyses assessed the predictive ability of individual STOP-
BANG components, expressed as dichotomous variables based on STOP-BANG 
criteria and in their original form (continuous or categorical) to determine if 
alternative cut points improved the performance of the STOPBANG tool.  
Secondary analyses also examined the association of specific STOP-BANG 
thresholds and severe OSA with odds of excessive daytime sleepiness, as 
defined by an Epworth Sleepiness Scale score of 11 or higher.   Analyses 
examining the odds of excessive daytime sleepiness were adjusted for known  
potential confounders, and included age, site, Caucasian race, smoking status, 
diabetes, history of myocardial infarction, BMI, self-reported sleep quality (PSQI), 
and physical activity (PASE).   
  We performed several sensitivity analyses.   Since results of sensitivity 
analyses were similar to those of the primary analyses, they are not included in 
the results section but can be found in Appendices. These sensitivity analyses 
included examination of OSA using alternate definitions of AHI, such as a more 
stringent desaturation criteria (4% oxygen desaturation criteria) (Appendix B), 
expanding the definition to include all apneic events (Appendix G), excluding 
central sleep apnea events (Appendix H), excluding men with unusual 
occurrences of periodic breathing (i.e. Cheynes-Stroke) (Appendix I), and 
restricting to men who reported having a bed-partner (Appendix J).   
 We also performed several sensitivity analyses redefining and exploring 
alternative cut points in the STOP-BANG components, such as evaluating 
varying combinations of components (Appendix C), redefining the Tired and 
Pressure components (Appendices E and F), using alternative cohort questions, 
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and examining ROC curve and AUC statistics for continuous components of Age, 
BMI and Neck circumference (Appendix D).   
 Furthermore, we examined analyses stratified by excessive daytime 
sleepiness (ESS>10 vs. <10) (Appendix K), and age (>80 vs. <80 years) 
(Appendix L).   Finally, we performed analyses using STOP (Appendix M), 
instead of STOP-BANG, and examined ROC curves and AUC statistics for STOP 
scores (Appendix N).    
Results 
Subject Characteristics and Prevalence of OSA 
 The mean (SD) age of the cohort was 76.4 (5.6) years; 91.2% of the men 
identified themselves as Caucasian, and 86.6% rated their health status as 
excellent/good (Table 1).  Men in the cohort were generally well educated, with 
78.4% having completed at least some years of college education.   
 OSA was common among men in the cohort, with 17.5% of men meeting 
the criteria for severe OSA (AHI>30); 43.4% had at least moderate OSA 
(AHI>15); and 78.8% had at least mild OSA [AHI>5].  With the exception of 
BMI>35 kg/m2, STOP-BANG components were also highly prevalent in this 
population: Snoring loudly (41.8%), Tired (45.7%), Observed apneas (20.9%), 
hypertension/Pressure (50.0%), Neck circumference>40 cm (37.9%), Age>50 
(100%), male gender (100%) and BMI>35 kg/m2 (3.6%).   
 Several baseline characteristics were significantly associated with greater 
AHI severity, including older age, lower education, poorer health status, lower 
physical activity, higher body mass index, larger neck circumference, greater 
excessive daytime sleepiness, and greater prevalence of diabetes (Table 1).  
With the exception of Tired, individual STOP-BANG components were 
significantly associated with greater AHI severity, and there was evidence of 
linear trend (p-trend<.001) across AHI categories for Snore loudly, Observed 
apneas, Pressure, BMI>35 kg/m2, and Neck circumference>40 cm.  Higher total 
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STOP-BANG scores were also significantly associated with greater AHI severity 
(p-value<.001). 
 
Prevalence of STOP-BANG Scores and Components 
     The frequency distribution of total STOP-BANG and STOP scores among 
men in the cohort are presented in Table 2.  STOP-BANG scores ranged from 2-
8 (all participants met the age and male gender components), and 88.4% of men 
had 3 or more components.   STOP scores ranged from 0-4, and 50.1% of men 
endorsed 2 or more STOP components.   
 
Discriminative ability of STOP-BANG to detect OSA 
 The predictive parameters for STOP-BANG scores are presented in Table 
3.  Using the conventional cut point of >3 on the STOP-BANG identified nearly all 
men in the cohort (88.4%) as ‘high risk’ for severe OSA, and had a sensitivity of 
94.0%, a specificity of 12.7%, a PPV of 18.6% and NPV of 90.0% for the 
identification of severe sleep apnea (AHI>30 vs. <30).  Using this cut-point, the 
PPV was very similar to the prevalence of severe OSA in the cohort (18.6% for 
PPV vs. 17.5% for prevalence of OSA), and the NPV (90.9%) was similar to the 
prevalence of not having OSA in the cohort (82.5%).  Furthermore, the area 
under the curve [AUC (95% CI)] using a STOP-BANG score of >3 was 0.53 
(0.52-0.55).   
 Raising the cut point to 7 decreased the sensitivity to 6.4% and specificity 
increased to 97.4%.  Furthermore, the PPV increased from 18.6% to 34.4% (an 
increase of 15%), and the NPV decreased from 90.9% to 83.1% (7.6% 
decrease).  Lastly, the AUC (95% CI) at a cut point of 7 was 0.52 (0.51-0.53) 
(Table 3).   
 In general, results were similar when the definition of OSA was made less 
stringent (AHI>5: Any sleep apnea; and AHI>15: Moderate/severe sleep apnea) 
(Table 3).    
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 The area under the ROC expressing STOP-BANG scores as a continuous 
variable was estimated to be 0.610 (95% CI 0.584-0.637) for severe OSA 
(AHI>30).  A plot of the ROC curve for the prediction of severe OSA is presented 
in Figure 4.   
 
  Discriminative ability of STOP-BANG components to detect OSA 
 Secondary analyses examined the predictive parameters of the individual 
STOP-BANG components, and those results are presented in Table 4.  Overall, 
Snore loudly, Tired, Observed apneas, Pressure (hypertension), BMI and Neck 
circumference had sensitivities of 49.7%, 49.5%, 26.3%, 57.1%, 8.0% and 52.5% 
respectively, and specificities of 59.9%, 55.1%, 80.3%, 51.5%, 97.3% and 65.2% 
respectively.  With the exception of BMI, PPV’s did not differ dramatically from 
the prevalence of OSA in the cohort (PPV’s ranged from 18.9% to 24.2% vs. 
prevalence=17.5%) and NPV’s did not differ from the prevalence of not having 
OSA in the cohort (range 83.3-86.6 vs. prevalence=82.5%).  There was some 
evidence that BMI>35 kg/m2 had a moderate ability to detect severe OSA, with a 
PPV of 38.8% (21% increased predictive probability), but BMI<35 had limited 
ability to identify men without sleep apnea (NPV=83.3% and prevalence of not 
having sleep apnea=82.5%).    
 In general, results were similar when the definition of OSA was made less 
stringent (AHI>5: Any OSA; and AHI>15: Moderate/severe OSA) (Table 4).    
 
Examination of Alternative Cut Points for STOP-BANG Components 
 For each component, we examined alternative cut points and observed 
that results were generally similar, with some cut points demonstrating small, but 
insignificant gains in performance.  Results are presented in Table 5.  For 
example, increasing the cut point for Snore loudly from any loud snoring or 
coughing per week (>0 per week vs. none) to frequent snoring (>3 times per 
week vs. <3 times per week) increased the specificity (59.9% to 86.8%) and also 
resulted in a small increase in PPV (20.8% to 26.0%).  A similar pattern was 
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observed for Observed apneas (specificity increased by 14.6% and PPV 
increased by 6.3%).   
 Since the Tired component in the cohort consisted of two questions 
assessing tiredness in the morning and afternoon, we specifically examined each 
question, and resultant levels separately.  Although the prevalence of extreme 
difficulty in the afternoon due to being tired was only 1.1%, it had the highest 
specificity (99.0%) and PPV (25.0%), yet missed most cases of severe OSA 
(sensitivity=1.6%).     
 In primary analyses, we defined Pressure as a self-report of physician 
diagnosis of hypertension, and in sensitivity analyses we examined varying 
definitions of hypertension based on systolic blood pressure cut points and 
medication use, and results were similar to those of the primary analyses.   
 Despite having a low prevalence (3.6%), results suggested that BMI>35 
kg/m2 had the greatest ability to identify men with OSA as compared with 
alternative cut points (PPV=38.8%), and BMI>25 kg/m2 had the greatest ability to 
identify men who did not have OSA (NPV=89.9%).   More specifically, lowering 
the BMI cut point to >30 kg/m2 and >25 kg/m2 resulted in increased sensitivity 
(5.2%, 27.4% and 79.4% for cut points of >35 kg/m2, >30 kg/m2 and >25 kg/m2 
respectively) and reduced specificity (97.6%, 84.9% and 37.3% respectively).  
We also examined AUC and 95% confidence intervals using continuous BMI, 
and results are presented in appendix D.  The area under the ROC curve for 
continuous BMI was observed to be 0.634 (95% CI 0.607-0.661), which was 
higher than results for continuous STOP-BANG scores (AUC for continuous 
STOP-BANG score was 0.610 (95% CI 0.584-0.637).     
 Neck circumference>40 cm had a sensitivity of 52.5%, specificity of 
65.2%, PPV of 24.2% and NPV of 86.6% in primary analyses (Table 5).  Results 
examining lower cut points based on quartiles resulted in increased sensitivity 
(65.7% and 83.6% for cut points of >39.2 cm and >37.5 cm respectively), and 
decreased specificity (53.1% and 27.4% for cut points of >39.2 cm and >37.5 cm 
respectively).  Furthermore, a cut point of >40 cm was associated with the 
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greatest PPV (24.2%, vs. 22.9% and 19.6% for cut points of >40.0 cm, >39.2 cm 
and >37.5 cm respectively) and the lowest NPV (86.6%, 88.0% and 88.7%).  
Results of ROC curve analyses for the prediction of severe OSA using 
continuous neck circumference are presented in appendix D.  The area under the 
ROC curve for continuous neck circumference was 0.617 (95% CI 0.591-0.644). 
 Although age >76 vs. <76 years and >80 vs. 80 years did not result in 
meaningful improvements in identification of men with and without OSA (Table 
6), we examined AUC analyses using age expressed as a continuous variable.  
Results suggested that the AUC (95% CI) for the prediction of severe OSA for 
continuous age was 0.563 (95% CI 0.535-0.590) (Appendix D).   
 
Evaluation of the STOP Questionnaire for the Detection of Severe OSA 
 We also examined the discriminative ability of the STOP questionnaire to 
identify older men in the cohort with severe OSA, and these results are 
presented in Appendix M.  The standard cut-point of >2 on the STOP 
questionnaire identified half (50.1%) of the cohort as having a high risk for OSA; 
this cut-point had a sensitivity of 60.1%, a specificity of 52.0% a PPV of 21.0% 
and NPV of 86.0% for the identification of severe OSA (AHI>30 vs. <30). Using 
this cut-point, the PPV was very similar to the prevalence of severe OSA in the 
cohort (21.0% vs. 17.5% for PPV vs. prevalence of OSA respectively), and the 
NPV was similar to the prevalence of not having OSA in the cohort (86.0% vs. 
82.5% for NPV vs. prevalence of not having OSA respectively).  Furthermore, the 
area under the curve [AUC (95% CI)] using a STOP score of >2 was 0.56 (0.54-
0.59) (Appendix M).   
 Raising the cut point to 4 decreased the sensitivity to 6.6% and specificity 
increased to 95.9%.  Furthermore, the PPV increased from 21.0% to 25.6%, and 
the NPV decreased from 86.0% to 82.9%.  Lastly, the AUC (95% CI) at a cut 
point of 4 was 0.56 (0.54-0.58).   
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 In general, results were similar when the definition of OSA was made less 
stringent (AHI>5: Any sleep apnea; and AHI>15: Moderate/severe sleep apnea) 
(Appendix M).    
 The area under the ROC curves expressing STOP as a continuous 
variable were estimated to be 0.575 (95% CI 0.549-0.602) for severe OSA 
(AHI>30) (results not shown).  A plot of the ROC curve for continuous STOP 
score and the identification of severe OSA is presented in Appendix N.   
 
Association between OSA (defined using STOP-BANG) vs. AHI, and 
Excessive Daytime Sleepiness 
 Results examining the association between OSA and excessive daytime 
sleepiness are presented in Table 6.  Despite varied prevalence of OSA, in 
general results were similar, albeit stronger, when OSA was defined using 
STOP-BANG criteria rather than AHI.  In multivariable-adjusted models, men with 
a STOP-BANG score >3 had a 71% greater odds of having excessive daytime 
sleepiness than men with STOPBANG scores <3 (OR=1.71, 95% CI 1.09-2.69).  
Similarly, men with a STOPBANG score >7 had a nearly 2.2-fold greater odds of 
excessive daytime sleepiness than men with STOPBANG scores <7 (OR=2.18, 
95% CI 1.31-3.61).  Finally, men with AHI >30 had a 41% increased odds of 
excessive daytime sleepiness than men with AHI<30 (OR=1.41, 95% CI 1.07-
1.88).   
Discussion 
 The objective of this study was to examine how well the STOP-BANG 
questionnaire identified community-dwelling older men with severe OSA, and 
results suggest that while the STOP-BANG had a high sensitivity at a cut point of 
>3 (94%), it also had an unacceptably high false positive rate (87.3%) in this 
population.  Furthermore, use of higher STOP-BANG cut points resulted in high 
specificities (97.4% at a cut point of >5) but unacceptably high false negative 
rates (93.6%).  Furthermore, the STOP-BANG had little impact on probability 
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revision beyond the prevalence of OSA in the cohort.   Therefore, we conclude 
that the STOP-BANG is insufficient for the screening of OSA in older adults.   
 The results of our study also suggested that in this population individual 
STOP-BANG components including Snoring, Tired, Observed apneas, Pressure 
and Age were not strongly predictive of OSA.  Furthermore, the area under the 
ROC curve demonstrate that body mass index and neck circumference had fair 
discriminatory power for detecting severe OSA in older men, with an AUC (95% 
CI) of 0.634 (95% CI 0.607-0.661) for BMI, and 0.617 (95% CI 0.591-0.644) for 
neck circumference.  These results suggest that BMI and neck circumference 
individually are statistically slightly better, but not clinically meaningfully different 
at identifying men with sleep apnea than the STOP-BANG questionnaire in this 
population (AUC, 95% CI for the detection of severe OSA was 0.610, 0.584-
0.637 for STOP-BANG). 
 We also observed significant cross-sectional associations between OSA 
and excessive daytime sleepiness.  Results were stronger when OSA was 
defined using the STOP-BANG, as opposed to AHI.  These results suggest that 
while the STOP-BANG may not be particularly useful for detecting OSA, it is 
strongly associated with excessively sleepiness, and may be picking up on other 
sleep-related disorders in addition to OSA.     
 Our results were weaker, albeit overall similar to those of prior studies in 
selected and middle-aged populations that  evaluated the performance of the 
STOP-BANG questionnaire, including those from the Sleep Heart Health study 
(SHHS)51.   Focusing only on the conventional cut point of >3, the SHHS 
observed a sensitivity and specificity of 70.4%, 59.5% respectively for the 
detection of severe OSA, which varied from our results of 94.0% and 12.7%.  
The prevalence of severe OSA was also lower in the SHHS compared to MrOS 
Sleep (7.2% vs. 17.5%).  While both cohorts consist of community-dwelling 
adults, participants in the SHHS are on average over 10 years younger than 
MrOS Sleep participants (mean age=62.4 y in SHHS vs. 76.4 y in MrOS Sleep).  
Prior studies have suggested that risk factors for OSA are weaker in older, as 
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opposed to middle-aged adults18.   While the SHHS used more stringent criteria 
to define OSA (4% desaturations), we performed sensitivity analyses using this 
criteria and results were unchanged.  Furthermore, the SHHS did not assess the 
performance of the STOP-BANG at alternative cut points.   
 The performance of the STOP-BANG has been previously assessed in 
various selected populations.  In a population of 177 preoperative patients, 
Chung et. al.50 observed a very high sensitivity (100%), and specificity of 37% for 
the identification of patients with severe sleep apnea (AHI >30).  While the cohort 
used for Chung’s analyses was generally younger than MrOS Sleep (mean 
age=55 y) the prevalence of severe OSA was approximately similar (22.0% vs. 
17.5% in MrOS Sleep).   It is difficult to know how participant characteristics 
compare between the MrOS Sleep and the Chung 2008 study, as participants 
included in the Chung study were a convenience sample of patients scheduled to 
undergo elective surgical procedures at two Toronto hospitals.   
 The high sensitivity of the STOP-BANG questionnaire (at a cut point of >3) 
might seem to make it useful for ruling out OSA for negative test results.  
However, its ability as a rule-out tool is greatly hampered by its high false positive 
rate, indicating that the test identifies nearly everyone as having OSA.  
Conversely, at higher cut points, the high specificity of the STOP-BANG appears 
to make it a useful tool for ruling in OSA, but again, this is hampered by its high 
false negative rate that results in many missed cases.  Overall, the questionnaire 
appears to be little better than chance at discriminating OSA in an aged male 
population. 
 Currently, the AASM guidelines69 do not suggest using any screening tool 
for OSA, beyond simpler polysomnograms, and instead state that anyone whom 
OSA is suspected should undergo a comprehensive sleep evaluation.  While 
other screening tools exist, they contain the same general information and there 
is little evidence to suggest that any of them work any better than STOP-BANG56, 
57.   Therefore, more research is needed to better understand the development of 
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OSA and risk factors: especially in older adults, as well as cost effective 
screening tools that can more accurately identify those with sleep apnea.   
 This study has several strengths, including a large sample size, use of 
validated measures of sleep apnea (in-home polysomnography) and self-
reported sleep (ESS).  Furthermore, participants were not selected on the basis 
of a sleep, or any other disorder or medical condition.     
 There are also several important limitations to consider.  The STOP-
BANG questionnaire was created based on similar questions collected in the 
MrOS Sleep study and it is possible that participants completing the 
questionnaire itself might respond differently.  However, most questions used in 
MrOS were also based on self-report from the participant, and so discrepancies 
are unlikely.  Also, results are limited to older, Caucasian, generally healthy and 
highly educated males.  Due to the types of information collected in MrOS, we 
were unable to assess additional sleep-disordered breathing tools including the 
Berlin or ARES Questionnaires.  However, given the results of the two meta 
analyses we previously discussed56, 57, we would not expect these tools to 
perform differently or better in this population.         
  In summary, the STOP-BANG questionnaire has poor discriminatory 
ability in detecting severe OSA in this cohort of community-dwelling older men.   
Additional research into the risk factors and characteristics of OSA in older 
populations is warranted.   
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Tables and Figures 
Figure 3. Roadmap of participants included in analyses
5,994 MrOS 
Participants 
1,997 refused 
participation 
150 were not eligible 
332 not contacted 
344 died prior to 
contact 
36 terminated study 
prior to contact 
3,135 completed 
MrOS Sleep Visit 
2,911 have useable 
PSG data 
2,853 had complete 
measures of STOP-
BANG components 
58 were missing STOP 
BANG components 
179 did not have PSG 
done 
45 had PSG, but it was 
not useable 
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Table 1.  Characteristics of MrOS Sleep cohort by severity of OSA 
Characteristic 
Entire 
Cohort 
(n=2853) 
None 
AHI 0-4 
(n=604) 
Mild 
AHI 5-14 
(n=1012) 
Moderate 
AHI 15-29 
(n=738) 
Severe 
AHI>30 
(n=499) 
P-
value* 
Age, y, mean (SD) 76.4 (5.5) 76.2 (5.6) 76.1 (5.5) 76.3 (5.4) 77.3 (5.5) <.001 
Caucasian, % 91.9 92.1 91.7 91.9 92.4 0.973 
Education, %      <.001 
     Less than HS 5.3 4.6 4.3 6.0 7.4  
     HS diploma/GED 16.3 11.4 15.0 19.5 20.0  
     Some college or beyond 78.4 83.9 80.7 74.5 72.6  
Excellent/good health status, % 86.6 89.2 87.1 86.6 82.6 0.013 
Smoking status, %      0.435 
     Current 2.0 2.5 2.3 1.8 1.2  
     Former 58.6 56.1 60.3 58.6 57.9  
     Never 39.5 41.4 37.5 39.6 40.9  
Physical Activity score, mean (SD) 145.6 (71.2) 144.3 (71.0) 148.1 (72.5) 148.9 (68.7) 137.4 (71.9) 0.023 
Body Mass Index, mean (SD) 27.2 (3.8) 25.7 (3.2) 27.0 (3.7) 27.6 (3.7) 28.8 (4.1) <.001 
Neck circumference, cm, mean (SD) 39.4 (2.8) 38.5 (2.6) 39.3 (2.7) 39.8 (2.7) 40.4 (2.9) <.001 
Excessive daytime sleepiness 
(Epworth >10), % 
13.0 11.4 12.3 13.0 16.4 0.071 
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Comorbid conditions       
Diabetes, % 13.2 9.4 12.9 13.8 17.2 0.002 
Myocardial infarction, % 17.5 15.2 18.5 17.3 18.6 0.351 
STOP-BANG Components       
Snore (loudly), % 41.8 33.1 40.8 45.0 49.7 <.001 
Tired, % 45.7 45.4) 45.1 44.3 49.5 0.299 
Witnessed stop breathing, % 20.9 15.7) 20.6 21.8 26.3 <.001 
Hypertension, % 50.0 43.4) 48.5 52.7 57.1 <.001 
BMI>30, % 3.6 1.0 3.3 3.3 8.0 <.001 
Neck circumference >40 cm, % 37.9 24.5 35.3 42.7 52.5 <.001 
STOP total score, mean (SD) 1.6 (1.1) 1.4 (1.1) 1.5 (1.0) 1.6 (1.1) 1.8 (1.1) <.001 
STOP-BANG total score, mean (SD) 4.0 (1.3) 3.6 (1.2) 3.9 (1.2) 4.1 (1.3) 4.4 (1.3) <.001 
SD=Standard Deviation; HS=High School, PASE= Physical Activity Scale for the Elderly; SDB= Sleep Disordered 
Breathing;  AHI= Apnea Hypopnea Index.  
*P-values were computed using ANOVA, and have 3 d.f. 
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Table 2.  Frequency of STOP and STOPBANG Components 
 
Number of 
components 
STOP-BANG 
N (%) 
STOP 
N (%) 
 N (%) 
Cumulative N 
(%) 
N (%) 
Cumulative N 
(%) 
0 - 0 (0) 482 (16.9) 482 (16.9) 
1 - 0 (0) 942 (33.0) 1424 (49.9) 
2 330 (11.6) 330 (11.6) 839 (29.4) 2263 (79.3) 
3 765 (26.8) 1095 (38.4) 461 (16.2) 2724 (95.5) 
4 804 (28.2) 1899 (66.6) 129 (4.5) 2853 (100) 
5 586 (20.5) 2485 (87.1) - - 
6 275 (9.6) 2760 (96.7) - - 
7 85 (3.0) 2845 (99.7) - - 
8 8 (0.3) 2853 (100) - - 
 
  
35 
 
Table 3.  Predictive parameters of Different STOP-BANG score cut-offs 
STOP-BANG 
score cut-off 
Prevalence 
of OSA (%) 
Sensitivity 
(%) 
Specificity 
(%) 
PPV 
(%) 
NPV 
(%) 
LR+ LR- AUC (95% CI) 
Severe OSA (AHI>30) vs. Moderate/Mild/None (AHI<30)*    
>3 vs. 2 
17.5 
94.0 12.7 18.6 90.9 1.08 0.47 0.53 (0.52-0.55) 
>4 vs. 0-3 73.6 40.9 20.9 88.0 1.24 0.65 0.57 (0.55-0.59) 
>5 vs. 0-4 46.5 69.3 24.3 85.9 1.52 0.77 0.58 (0.56-0.60) 
>6 vs. 0-5 22.0 89.0 29.9 84.4 2.01 0.88 0.56 (0.54-0.57) 
>7 vs. 0-6 6.4 97.4 34.4 83.1 2.47 0.96 0.52 (0.51-0.53) 
Moderate/Severe OSA (AHI>15) vs. Mild/None (AHI<15)*    
>3 vs. 2 
43.4 
91.8 14.1 45.0 69.1 1.07 0.58 0.53 (0.52-0.54) 
>4 vs. 0-3 67.6 43.0 47.6 63.4 1.18 0.75 0.55 (0.53-0.57) 
>5 vs. 0-4 40.3 71.8 52.3 61.1 1.43 0.83 0.56 (0.54-0.58) 
>6 vs. 0-5 18.0 91.0 60.6 59.2 2.01 0.90 0.55 (0.53-0.56) 
>7 vs. 0-6 5.1 98.1 67.7 57.5 2.74 0.97 0.52 (0.51-0.52) 
Any OSA (AHI>5) vs. None (AHI<5)*    
>3 vs. 2 
78.8 
90.2 18.2 80.4 33.3 1.10 0.54 0.54 (0.53-0.56) 
>4 vs. 0-3 64.8 50.2 82.9 27.7 1.30 0.70 0.57 (0.55-0.60) 
>5 vs. 0-4 35.8 75.3 84.4 24.0 1.45 0.85 0.56 (0.54-0.58) 
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>6 vs. 0-5 14.7 93.9 90.0 22.8 2.40 0.91 0.54 (0.53-0.56) 
>7 vs. 0-6 4.0 99.3 95.7 21.7 5.98 0.97 0.52 (0.51-0.52) 
*AHI defined using >3% oxygen desaturation criteria 
PPV=Positive predictive value; NPV=Negative predictive value; LR+=Likelihood Ratio for  positive test; LR-=Likelihood 
ratio for a negative test; AUC=Area under the curve; CI= Confidence Intervals; OSA=Obstructive Sleep Apnea; 
AHI=Apnea Hyponea Index 
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Figure 4.  ROC Curve Results for Continuous STOP-BANG Scores and 
Severe OSA. 
 
 
Straight line depicts no discriminative ability (i.e. Area under the ROC 
Curve= 0.5).  This figure models the area under the ROC curve for 
continuous STOP-BANG scores and severe OSA.  The AUC (95% CI) across 
all cut points was 0.610 (0.584-0.637).
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Table 4.  Predictive parameters of STOP-BANG Components 
STOP-BANG 
score cut-off 
Prevalence 
(%) 
Sensitivity 
(%) 
Specificity 
(%) 
PPV 
(%) 
NPV 
(%) 
LR+ LR- AUC (95% CI) 
Severe OSA (AHI>30) vs. Moderate/Mild/None (AHI<30)    
Snore loudly 41.8 49.7 59.9 20.8 84.9 1.24 0.84 0.55 (0.52-0.57) 
Tired 45.7 49.5 55.1 18.9 83.7 1.10 0.92 0.52 (0.50-0.55) 
Observed apneas 20.9 26.3 80.3 22.0 83.7 1.33 0.92 0.53 (0.51-0.55) 
Hypertensive 50.0 57.1 51.5 20.0 85.0 1.18 0.83 0.54 (0.52-0.57) 
BMI>35 kg/m2 3.6 8.0 97.3 38.8 83.3 3.00 0.95 0.53 (0.51-0.54) 
Neck circum>40 cm 37.9 52.5 65.2 24.2 86.6 1.51 0.73 0.59 (0.56-0.61) 
Moderate/Severe OSA (AHI>15) vs. Mild/None (AHI<15)    
Snore loudly 41.8 46.9 62.1 48.6 60.4 1.24  0.86 0.54 (0.53-0.56) 
Tired 45.7 46.4 54.8 44.0 57.2 1.03 0.98 0.51 (0.49-0.52) 
Observed apneas 20.9 23.6 81.3 49.1 58.2 1.26 0.94 0.52 (0.51-0.54) 
Hypertensive 50.0 54.5 53.4 47.2 60.5 1.17 0.85 0.54 (0.52-1.56) 
BMI>35 kg/m2 3.6 5.2 97.6 62.1 57.4 2.14 0.97 0.51 (0.51-0.52) 
Neck circum>40 cm 37.9 46.7 68.8 53.3 62.7 1.49 0.78 0.58 (0.56-0.59) 
All OSA (AHI>5) vs. None (AHI<5)    
Snore loudly 41.8 44.2 66.9 83.2 24.3 1.33 0.83 0.56 (0.53-0.58) 
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Tired 45.7 45.8 54.6 79.0 21.3 1.01 0.99 0.50 (0.48-0.52) 
Observed apneas 20.9 22.2 84.3 84.0 22.5 1.41 0.92 0.53 (0.52-0.55) 
Hypertensive 50.0 51.8 56.6 81.6 24.0 1.19 0.85 0.54 (0.52-0.56) 
BMI>35 kg/m2 3.6 4.3 99.0 94.2 21.8 4.34 0.97 0.52 (0.51-0.52) 
Neck circum>40 cm 37.9 41.5 75.5 86.6 25.3 1.69 0.77 0.59 (0.57-0.61) 
*AHI defined using 3% desaturation criteria 
PPV=Positive predictive value; NPV=Negative predictive value; LR+=Likelihood Ratio for a positive test; LR-=Likelihood 
Ratio for a negative test; AUC= Area under the curve; OSA=Obstructive Sleep Apnea; AHI=Apnea Hypopnea Index; 
BMI=Body Mass Index 
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Table 5.  Examination of alternative cut-points for STOP-BANG components for the detection of severe OSA 
STOP-BANG Components 
Prevalence 
(%) 
Sensitivity 
(%) 
Specificity 
(%) 
PPV 
(%) 
NPV 
(%) 
LR+ 
(%) 
LR- 
(%) 
Snore loudly        
      >0 per wk vs. none* 41.8 49.7 59.9 20.8 84.9 1.24 0.84 
     >1x per wk vs. <1x per wk 27.1 34.5 74.5 22.3 84.3 1.35 0.88 
     >3x per wk vs. <3x per wk 14.7 21.8 86.8 26.0 84.0 1.66 0.90 
Tired        
Tired in the morning:        
Extreme/moderate/mild difficulty vs. none 17.7 21.8 83.2 21.6 83.4 1.30 0.94 
Moderate/extreme difficulty vs. mild/none 3.7 5.0 96.7 23.6 82.7 1.46 0.98 
Extreme difficulty vs. moderate/mild/none 1.1 1.4 99.0 23.3 82.6 1.44 1.0 
Tired in the afternoon:        
Extreme/moderate/mild difficulty vs. none 41.8 44.9 58.9 18.8 83.5 1.09 0.94 
Moderate/extreme difficulty vs. mild/none 6.8 8.8 93.6 22.6 82.9 1.37 0.97 
Extreme difficulty vs. moderate/mild/none 1.1 1.6 99.0 25.0 82.6 1.57 0.99 
Tired: Any difficulty in morning Or afternoon* 45.7 49.5 55.1 18.9 83.7 1.10 0.92 
Observed apneas        
      >0 per wk vs. none* 20.9 26.3 80.3 22.0 83.7 1.33 0.92 
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     >1x per wk vs. <1x per wk 12.2 16.8 88.7 24.1 83.4 1.50 0.94 
     >3x per wk vs. <3x per wk 5.8 9.4 94.9 28.3 83.2 1.86 0.95 
Pressure        
    SysBP>120 vs. <120  67.2 67.7 32.9 17.6 82.8 1.01 0.98 
    SysBP>140 vs. <140 19.5 19.0 80.4 17.1 82.4 0.97 1.01 
    SysBP>160 vs. <160 3.9 5.6 96.5 25.2 82.8 1.59 0.58 
Any HTN Medication use 50.1 61.3 52.3 21.4 86.5 1.29 0.74 
     ARB user vs. nonuser 9.6 13.6 91.2 24.7 83.3 1.55 0.95 
     Beta blocker user vs. nonuser 28.0 34.1 73.3 21.3 84.0 1.27 0.90 
     Calcium channel blocker user vs. nonuser 15.2 19.2 85.7 22.2 83.4 1.34 0.94 
     Diuretic user vs. nonuser 18.6 23.7 82.5 22.3 83.6 1.35 0.93 
Self-reported HTN vs. none* 50.0 57.1 51.5 20.0 85.0 1.18 0.83 
BMI, kg/m2        
     >25 vs. <25 70.0 82.6 32.7 20.6 89.9 1.23 0.53 
     >30 vs. <30 20.4 35.1 82.7 30.0 85.7 2.02 0.79 
     >35 vs. <35* 3.6 8.0 97.3 38.8 83.3 3.00 0.95 
Age, years        
    >76 vs. <76 28.2 36.1 73.5 22.4 84.4 1.36 0.87 
    >80 vs. <80 50.9 59.7 51.0 20.5 85.7 1.22 0.79 
Neck Circumference, cm        
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     >37.5 vs. <37.5 74.5 83.6 27.4 19.6 88.7 1.15 0.60 
     >39.2 vs. <39.2  50.2 65.7 53.1 22.9 88.0 1.40 0.65 
     >40 vs. <40 * 37.9 52.5 65.2 24.2 86.6 1.51 0.73 
*Indicates the level used in the original calculation of STOP-BANG primary analyses 
PPV=Positive predictive value; NPV=Negative predictive value; LR+=Likelihood Ratio for a positive test; LR-=Likelihood 
Ratio for a negative test; OSA=Obstructive Sleep Apnea; AHI=Apnea Hypopnea Index; BMI=Body Mass Index; wk=week; 
HTN=Hypertension. 
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Table 6.  Associations between STOP-BANG, AHI and Excessive Daytime Sleepiness 
 
 Odds Ratio of Excessive Daytime Sleepiness 
OR (95% CI)* 
 STOPBANG 
 
AHI  
 
 >3 vs. <3 
(n=2,523 with OSA) 
>5 vs. <5 
(n=93 with OSA) 
>30 vs. <30 
(n=499 with OSA) 
OSA, yes vs. no 1.71 (1.09-2.69) 2.18 (1.31-3.61) 1.41 (1.07-1.88) 
Age, per 5 year increase 1.01 (0.91-1.13) 1.02 (0.91-1.13) 1.00 (0.89-1.11) 
Non-White vs. White 1.43 (0.98-2.08) 1.41 (0.97-2.06) 1.39 (0.95-2.02) 
Current vs. never smoker 1.28 (0.61-2.70) 1.31 (0.62-2.76) 1.31 (0.63-2.76) 
Former vs. never smoker 1.03 (0.82-1.30) 1.02 (0.81-1.28) 1.03 (0.82-1.29) 
Diabetic 1.10 (0.80-1.51) 1.11 (0.81-1.52) 1.11 (0.80-1.52) 
Myocardial Infarction 1.02 (0.76-1.36) 0.99 (0.74-1.33) 1.03 (0.77-1.37) 
BMI, per 3.8 kg/m2 1.11 (0.99-1.24) 1.08 (0.96-1.22) 1.11 (0.99-1.24) 
PSQI, per unit increase 1.07 (0.99-1.24) 1.07 (1.04-1.11) 1.08 (1.05-1.11) 
PASE, per 71 unit decrease 1.09 (0.97-1.23) 1.10 (0.97-1.23) 1.09 (0.97-1.23) 
*Models additionally adjusted for clinic site. 
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Chapter 4: The epidemiology of variability in sleep/wake patterns 
in older adults: definitions, prevalence and correlates.  
 
Objectives:  To evaluate the within-person variability of sleep/wake parameters in 
older men, and to examine potential correlates of greater variability in sleep 
measures.   
Design:  Cross-sectional study 
Participants:  Two thousand eight hundred four men aged 67 years and older 
enrolled in the Outcomes of Sleep Disorders in Older Men (MrOS Sleep) cohort 
study with at least five nights of actigraphy data. 
Measurements:  Objectively measured sleep parameters from wrist actigraphy 
were total sleep time, sleep latency, nighttime wakefulness (wake after sleep 
onset), in bed timing and out of bed timing.  Variability was defined as the intra-
individual standard deviation in each of these measures, and greater variability 
was defined as being in the highest quintile of the distribution.  Associations 
between participant characteristics and odds of being in the highest quintile of 
variability were assessed using logistic regression.  
Results:  Substantial within-person variability in sleep parameters was found 
among the cohort of older men. The sleep parameters with the greatest amount 
of within-person variability were sleep latency and nighttime wakefulness; mean 
(SD) variability in sleep latency, nighttime wakefulness, total sleep time, in bed 
timing and out of bed timing were 24 (26); 27(20); 47(24); 37(25) and 39(26) 
minutes respectively.  Several characteristics were associated with greater 
variability, with the strongest factors being African American race, living alone, 
smoking, antidepressant use, benzodiazepine use, depression, greater body 
mass index and greater comorbidity burden.  Lower education, heavy alcohol 
use, not getting up at night to use the bathroom, cognitive impairment and 
greater impairments in Instrumental Activities of Daily living were also associated 
with at least one measure of variability.   
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Conclusion:  Significant within-person variability exists in older, community 
dwelling men, and is associated with several potentially modifiable demographic 
and health-related factors.  Future prospective research studies should examine 
whether variability in sleep-wake patterns is associated with risk of health 
outcomes among older adults, and if so, whether or not interventions aimed at 
reducing variability in sleep improve health outcomes.    
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Introduction: 
 Little is known about the intra-individual variability of sleep, either among 
the general population, or more specifically in older adults who often complain of 
sleep disturbances.  However, establishing regular stable sleep patterns is a 
critical component of behavioral therapy for insomnia11, 70, and night-to-night 
variability has been used as a measure of adherence to a treatment regimen71.   
 There are many reasons why it is important to advance understanding of 
individual variability in measures of sleep-wake patterns.  First, greater variability 
in night-to-night sleep may promote the development of insomnia.  If variable 
sleep patterns result in compensatory behaviors (i.e. catching up on sleep by 
staying in bed longer), then over time these behaviors may lead to conditioned 
arousal, in which the individual has difficulty falling asleep or staying asleep in a 
normal sleep environment, and eventually may result in insomnia72-75.  
 Second, variability in sleep may mask the association of sleep measures 
such as sleep duration with health-related outcomes, including the risk of 
mortality.  Several studies have examined the association between sleep 
duration and mortality, and have reported inconsistent findings52, 76-80.  If 
variability in sleep duration is independently associated with mortality, and this 
hypothesis has not been studied, then variable sleep/wake patterns may be one 
explanation for the inconsistent findings across studies.   
 Self-reported sleep data and objective parameters of sleep-wake patterns 
measured using actigraphy are typically collected over several consecutive 
nights in research studies of sleep.  The traditional analytical approach is to 
characterize sleep/wake parameters as aggregate means which omits 
information on the night-to-night variability of sleep, However, measures of 
variability may provide additional information on disturbed sleep, especially in 
those individuals whose aggregate means appear to be normal, but who 
otherwise complain of sleep-related disturbances.   
 Only a few studies have directly assessed variability of sleep measures. 
These studies have been limited to younger populations81, by small sample 
sizes82, or by selection on the basis of insomnia83.  None of the aforementioned 
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studies have examined potential correlates of variability.  In a study of 669 
participants aged 38-50 years enrolled in the CARDIA study81, investigators 
examined the within-subject and between-subject variability of actigraphic 
measures of sleep duration, sleep latency, sleep efficiency and time in bed.  The 
authors found substantial variation in day-to-day sleep measures within 
individuals in the cohort.  For example, the standard deviation (SD) of sleep 
duration was 1.26 hrs. within individuals and 0.70 hrs. between individuals.  
Likewise, the SD of sleep efficiency was 8.4% in individuals and 8.1% between 
individuals, and the SD of sleep latency was 30.7 minutes within individuals and 
22.2 minutes between individuals.   
 Buysse et. al examined the variability of diary and actigraphic measures of 
sleep in 61 older adults with chronic insomnia and 31 controls83.  Results from 
this case-control study suggested that insomniacs exhibited greater variability on 
most self-reported diary measures of sleep, and on actigraphy measures of 
awakening after sleep onset and sleep efficiency, but did not differ from controls 
with respect to measures of variability in objective measures of sleep duration, 
and sleep latency.  On average, the SD of wake after sleep onset was 22.6 vs. 
19.3 mins (p<.001); sleep efficiency was 7.0% vs. 5.6% (p=0.003); sleep duration 
was 55.6 vs. 53.9 mins (p=0.5); and sleep latency was 26.2 vs. 16.8 mins 
(p=0.13) in insomniacs vs. controls respectively.   
 In summary, the aforementioned studies have observed variability in the 
sleep/wake patterns of adults, but whether or not such variability exists in an 
unselected sample of older community-dwelling adults is uncertain.  Furthermore, 
the associations of demographic and health-related factors with variability in 
sleep/wake parameters and in older adults have not been assessed.   
 Therefore, we conducted a cross-sectional analysis of the Outcomes of 
Sleep Disorders in Older Men (MrOS Sleep) study to examine the characteristics 
and correlates of variability in sleep/wake parameters among community-dwelling 
older men.      
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Methods: 
Study Population 
 The Osteoporotic Fractures in Men (MrOS) study recruited 5,994 
community-dwelling men between March 2000 and April 2002 at six U.S. clinical 
centers (Birmingham, Alabama; Minneapolis, Minnesota; Palo Alto, California; 
Monongahela Valley near Pittsburgh, Pennsylvania; Portland, Oregon and San 
Diego, California).  To be eligible to participate in the MrOS Study, men had to be 
aged 65 years and older, able to walk without assistance and not have had a 
bilateral hip replacement.  Recruitment details and study design have been 
published elsewhere60, 61.  
 From December 2003 through March 2005, MrOS enrollees were invited 
to participate in an ancillary study to identify outcomes of sleep disorders in older 
men.  To be eligible to participate in the Sleep study, participants had to report 
not using oxygen therapy in the past three months, no history of an open 
tracheotomy, not sleeping with a mouthpiece for snoring or sleep apnea in the 
past 3 months, or not sleeping with a CPAP or BiPAP mask in the last 3 months.  
Some exceptions were made for participants who intermittently use CPAP, or 
who were willing to not wear the CPAP mask during the study.  A total of 3,135 
(>100% recruitment goal) were enrolled in the MrOS Sleep ancillary study.  Of 
these, 3,058 men wore a wrist actigraph and had technically adequate actigraphy 
data, and of these 2,804 had at least five nights of measurements and comprised 
the cohort for this analysis.   The institutional review board at each center 
approved the study protocol and written informed consent was obtained from all 
participants. 
Measurement of Sleep/Wake Parameters 
 Activity patterns were measured using an octagonal wrist actigraph 
(Ambulatory Monitoring, Inc., Ardsley, NY), which is a small device resembling a 
wrist watch that is worn on the wrist of the non-dominant hand.  Participants were 
instructed to wear the actigraph continuously for a minimum of five nights (mean 
+ SD = 5.2 + 0.9 nights) and to remove it only for bathing or situations in which it 
might get submerged in water.  Actigraphs contain accelerometers that measure 
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and record movement in 1-minute epochs, and have been shown to provide 
reliable estimates of sleep-wake activity in comparison to polysomnography, 
which is currently the gold standard84.  Data were collected in three modes but 
are reported here based on digital integration mode (also known as proportional 
integration mode)85.  In the MrOS Sleep study, data collected in PIM was most 
correlated with PSG86.  Actigraphy data were transferred to the San Francisco 
Coordinating Center for centralized processing.  Centralized training and 
certification were also required for clinic staff gathering actigraphy data.  Activity 
data from the actigraph was analyzed using Action W-2 software (Ambulatory 
Monitoring, Inc.).      
In addition, participants were also asked to complete a sleep diary for the 
time period in which they wore the actigraphs.  The diaries included information 
on time into and out of bed, as well as times in which the actigraph was removed.  
This information was used in editing the actigraphy data files.   Time periods in 
which participants removed the actigraphs for >10% of the time during the day or 
for over 2 hours during the night are not included in the analyses.   Interscorer 
reliability for editing the actigraphy data has been excellent in our group and 
actigraphic sleep duration has been shown to have good agreement with PSG 
(gold standard)87, 88.  
 Several sleep/wake parameters were computed from the actigraphy data 
and defined as follows:  In bed timing was defined as the time in which the 
participant reported getting into bed and trying to sleep.  In general, this was 
based entirely off from the sleep diary, although adjustments were made in cases 
where the diary data clearly did not match the actigraphy (i.e. reported in bed 
time occurred after sleep onset).  Sleep onset was defined as the time when the 
first 20 minute block containing >19 minutes of sleep began.  Sleep latency was 
the number of minutes from the time the participant reported getting in bed until 
sleep onset.  Wake after sleep onset (WASO), a measure of nighttime 
wakefulness, was the number of minutes scored as wake from sleep onset until 
the end of the last sleep episode while in-bed.  Out of bed timing was the time 
when the participant reported getting out of bed.  In cases where the out of bed 
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time did not match the actigraphy data (i.e. occurred during a period scored as 
sleep), out of bed timing was adjusted to be the last minute scored as sleep.  
Total sleep time was the number of minutes scored as sleep during the in-bed 
interval.  Data for these variables was averaged over the total number of nights 
the actigraph was worn.   
 
Self-Reported Sleep Measures 
 Participants completed the Pittsburgh Sleep Quality Index (PSQI) and the 
Epworth Sleepiness Scale (ESS) questionnaires at their sleep study clinic visit.  
The PSQI is a validated measure of subjective sleep quality and sleep 
disturbances over a 1-month period.  The questionnaire is divided into sections 
that assess subjective sleep quality, sleep latency, sleep duration, sleep 
efficiency, sleep disturbances, use of sleeping medications and daytime 
dysfunction.  Global PSQI scores range from 0 to 21, and a standard cut-off of 
greater than 5 is indicative of poor sleep quality.  This cutoff has a sensitivity of 
89.6% and a specificity of 86.5% in distinguishing good sleepers from poor 
sleepers64, 65. 
 The ESS is a self-administered questionnaire that classifies subjective 
daytime sleepiness in people with sleep disorders.  Participants are asked to rate 
how likely (from 1 to 3, with 1 being unlikely and 3 being highly likely) they are to 
doze off in eight typical daily situations.  Scores range from 0 to 24, with a 
standard cutoff of greater than 10 indicative of excessive daytime sleepiness67, 68. 
 
Other Measures 
 Additional measures were collected on the day of the sleep study clinic 
visit.  All participants completed questionnaire data, which included questions 
about their medical history, current health status, smoking and alcohol use and 
social support.  Comorbidity burden was computed as a sum of the following 
medical conditions:  Parkinson’s disease, chronic kidney disease, chronic 
obstructive pulmonary disease, stroke, diabetes, congestive heart failure, 
myocardial infarction, hypertension and hypercholesterolemia, and expressed as 
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a three-level variable (0,1, 2+ conditions).  Information from the MrOS baseline 
visit (mean (SD) between MrOS baseline and sleep study visits 3.4 (0.5) years) 
was used to assess age, race and education.  At the sleep study visit, body 
weight was measured using a standard balance beam, or digital scale and height 
using a wall mounted Harpenden stadiometer.  BMI was calculated as kg/m2 and 
was expressed as a three-level variable (<25, 25-29, 30+).  Participants were 
asked to bring in all medications used within the past two weeks, and a 
computerized medication coding dictionary was used to categorize the 
medications89.  The Geriatric Depression Scale was used to assess depressive 
symptoms, with scores >6 indicative of depression90.  Functional status was 
measured using information collected on six independent activities of daily living 
(IADL)91, 92 and was expressed as a three-level variable (0,1-2, 3+ impairments).  
Cognitive function was using the Modified Mini-Mental State examination (3MS).  
The 3MS is a global measurement of cognitive function, with components for 
orientation, concentration, praxis and immediate and delayed memory.  Scores 
range from 0 to 100, with higher scores representing better cognitive functioning.  
A cut point of >80 is indicative of cognitive impairment93.  Finally, men were 
asked to record the number of times they typically get up during the night to use 
the bathroom (0, 1,2,3,4, 5 or more), and was expressed as a 4-level categorical 
variable (0, 1-3, 4 or 5 or more) based on its distribution.     
      
Statistical Analysis 
 Our analytic cohort consists of 2,804 men who had at least 5 nights of 
actigraphy data (91.7% of participants with useable actigraphy data).  Differences 
between the analytic cohort and the remaining surviving MrOS population 
(N=1,360) were examined using t-tests for normally distributed continuous 
variables, Wilcoxon rank sum tests for skewed continuous variables and chi-
square tests for categorical variables.   
 The within-person standard deviation (SD) was calculated for each 
sleep/wake parameter using data from each night that the actigraph was worn.  
Higher SD values indicate greater variability in sleep/wake patterns over the 
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measured time period.  The coefficient of variation (CV) for each sleep/wake 
parameter was also computed as an alternative measure of variability, and it was 
calculated as the between-person standard deviation divided by the overall 
between-person mean.   
 Logistic regression models were used to examine associations between 
potential predictor variables and odds of greater variability (being in the highest 
quintile vs. quintiles 1-4).  We first analyzed the data using models adjusted for 
age and clinic site, and then a multivariable adjusted model that included all 
predictors.  Additionally, to examine whether the association between predictors 
and variable sleep/wake parameters was explained by sleep duration, we added 
mean total sleep time to multivariable adjusted models.  Finally, multivariable 
adjusted analyses were repeated expressing variability measures as continuous 
variables and linear regression was used to examine these associations.   
 For models examining associations with sleep latency variability and in-
bed timing variability, additional sensitivity analyses were performed adjusting for 
the quality of the self-reported time to bed.  Since quality of self-reported in bed 
timing did not alter findings, these analyses were not reported.   
 All analyses were conducted using SAS version 9.3 (SAS Institute Inc., 
Cary, North Carolina).   
 
Results 
 The mean (SD) age of the cohort was 76.3 (5.5) years, and 3.7% were 
African American.  Characteristics of the cohort are provided in Table 7.  Of the 
5,994 men originally recruited for the MrOS Study, 1,830 men died prior to the 
MrOS Sleep visit.  Compared to the 1,360 MrOS men who were alive, but were 
not included in the analytic cohort, men in the analytic cohort tended to be 
younger (72.9 vs. 76.0 years for analytic vs. other cohort, p<.001), slightly more 
educated (78.1% vs. 72.1% attended college, p<.001), slightly more likely to live 
with others (87.3% vs. 82.9%, p<.001), and reported fewer impairments in 
Instrumental Activities of Daily Living (0.4 vs. 0.6 mean IADL impairments, 
p<.001),  but did not differ on Caucasian race (91.3% vs. 92.2%, p=0.322).  
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 The distribution of actigraphic sleep/wake variables including mean (SD), 
median, interquartile range, coefficient of variation and within-subject standard 
deviation are provided in Table 8.   In examining the sleep/wake variables 
expressed as averages across the nights in which the participant wore the 
actigraph (mean + SD = 5.3 + 0.7 nights), the greatest amount of variability was 
observed for sleep latency (CV=104.7%), and the least amount for time to bed 
(CV=5.0%).    
 Greater variability was observed in between-persons sleep/wake 
measures rather than within-person, suggesting that nightly sleep measures are 
more similar within individuals (Table 8).  For example, the between-persons 
standard deviation in total sleep time was 1.2 hours (or 72 minutes), and the 
mean within-persons standard deviation was 47 minutes.   Similar patterns were 
observed across all sleep/wake measures.   
 
Independent predictors of greater within person variability in sleep/wake 
parameters (Tables 9 & 10) 
 
 Demographics – Age: In age and site adjusted models (Table 9), older 
age was associated with increased odds of highly variable nighttime 
wakefulness, and lower odds of highly variable in and out of bed timing.  With the 
exception of out of bed timing, these associations persisted in multivariable 
adjusted models (Table 10).   Compared to men aged 67-69 (referent group), 
men aged 80+ had a 58% increased odds of highly variable nighttime 
wakefulness (being in the highest quintile of variability vs. the lower four 
quintiles), and a 56% lower odds of highly variable in bed timing in multivariable 
adjusted models.  Furthermore, compared to the referent group, men aged 75-79 
had 38% lower odds of highly variable out of bed timing.  Age was not associated 
with variability in total sleep time or sleep latency in either age and site, nor 
multivariable adjusted models.   
 Race:  Compared to Caucasians (referent group), African Americans had 
an increased odds of greater variability in all sleep/wake parameters, and men 
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who identified themselves as ‘other’ race had an increased odds of greater 
variability in in-bed timing, in age and site adjusted models.  These associations 
persisted in multivariable-adjusted models.  African Americans had 1.6 to 3.3-fold 
increased odds of being in the highest quintile of variability across all sleep/wake 
measures than Caucasian men in multivariable adjusted models.  Furthermore, 
men who were ‘other’ race had 1.7-fold increased odds of greater variability in in-
bed timing than Caucasian men.   
 Education:  Compared to men who attended college, men who did not 
complete high school had increased odds of greater variability in total sleep time, 
nighttime wakefulness and out of bed timing, whereas men who finished high 
school vs. those who attend college did not have an increased odds of greater 
variability in any sleep/wake parameter in age and site adjusted models.  In 
multivariable adjusted models, men who had less than a high school education 
had a 1.5-fold increased odds of highly variable total sleep time than men who 
attended college, but associations with nighttime wakefulness and out of bed 
timing no longer reached statistical significance.   
 
 Lifestyle- Social Support: Living with others, as opposed to living alone, 
was associated with increased odds of greater variability across all sleep/wake 
parameters in age and site adjusted models.  In multivariable adjusted models 
however, living with others was associated with a 43-84% increased odds of 
greater variability in total sleep time, nighttime wakefulness, sleep latency and in 
bed timing, but was not independently associated with variable out of bed timing.   
 Smoking: Past and current smoking was also associated with increased 
odds of greater variability in nearly all sleep/wake parameters in age and site 
adjusted models.  In multivariable adjusted models, current smokers (vs. never 
smokers) had a 97% increased odds of greater variability in in-bed timing.  
However, despite not reaching statistical significance, the magnitude of other 
point estimates suggested that current smoking might be associated with all 
variability measures (range of OR=1.5 to 1.8). In multivariable adjusted models, 
former smoking was not associated with variability measures.   
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 Alcohol consumption: Greater alcohol consumption (14+ drinks per week 
vs. 0-1) was associated with 73% increased odds of greater variability in 
nighttime wakefulness, but was not associated with other measures of variability 
in age and site adjusted models.  In multivariable adjusted models, this 
association was slightly attenuated, but otherwise remained statistically 
significant (OR=1.62).    
 
 Medications- Antidepressant use:  Men who reported current use of 
antidepressants had about a 2-fold greater odds of highly variable total sleep 
time, sleep latency and out of bed timing in age and site adjusted models.  In 
multivariable adjusted models, these associations were slightly attenuated (1.7 to 
1.8-fold) but remained statistically significant.  Antidepressant use was not 
independently associated with variability in nighttime wakefulness and in-bed 
timing in any models.  
 Benzodiazepine use:   Men who reported using benzodiazepines had a 
1.9 to 2-fold increased odds of greater variability in total sleep time, sleep 
latency, in bed timing and out of bed timing in age and site adjusted models.  
Benzodiazepine use was not associated with variability in nighttime wakefulness 
in age and site adjusted models. Multivariable adjusted models associations 
were slightly attenuated, but benzodiazepine use remained associated with a 1.6 
to 1.8-fold increased odds of greater variability in total sleep time, in bed timing 
and out of bed timing.  Benzodiazepine use was not independently associated 
with night time wakefulness or sleep latency variability in multivariable adjusted 
models.      
Non-benzodiazepine anxiolytic hypnotic use:  Although non-
benzodiazepine anxiolytic hypnotic use was not significantly associated with 
variability in sleep/wake parameters, the magnitude of point estimates suggest 
that non-benzodiazepine anxiolytic hypnotic use may be associated with an 
increased odds of greater variability in sleep latency, total sleep time and in-bed 
timing (34-53% increased odds in age and site adjusted models and 32-64% 
increased odds in multivariable adjusted models).   
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 Anthropometric and physical functioning-   Body Mass Index: Higher 
BMI was associated with increased odds of greater variability in all sleep/wake 
parameters in age and site adjusted models.  In multivariable adjusted models 
compared to men with a body mass index (BMI) less than 25 kg/m2 (referent 
group), men with a BMI of 25-29 kg/m2, had a 1.3 to 1.4-fold increased odds of 
greater variability in total sleep time, nighttime wakefulness and out of bed timing, 
whereas men with a BMI 30+ kg/m2 had a 1.3 to 2.6-fold increased odds of 
greater variability in total sleep time, nighttime wakefulness, sleep latency and in 
bed timing.   
 Impairments in Instrumental Activities of Daily Living (IADLs): Greater 
burden of IADLs were associated with a 1.4 to 2.5-fold increased odds of greater 
variability in all sleep/wake parameters in age and site adjusted models, although 
associations with out of bed timing did not reach statistical significance.  In 
multivariable adjusted models, associations were attenuated, and having 2 or 
more IADL impairments (vs. none) was associated with a 74-77% increased 
odds of greater variability in sleep latency and in-bed timing.  IADL impairments 
were not independently associated with variability in total sleep time, night time 
wakefulness or out of bed timing in multivariable adjusted models.     
 
 Health related factors-  Self-reported health status: Compared to men 
with excellent or good health, having a fair, poor or very poor health status was 
associated with a 1.3 to 1.7 fold increased odds of greater variability in total sleep 
time, nighttime wakefulness, sleep latency and out of bed timing, but was not 
associated with variability in in bed timing.  In multivariable adjusted models, 
these associations were attenuated and no longer reached statistical 
significance.   
 Number of times up to use bathroom: In age and site adjusted models, 
men who reported getting up 5 or more times per night to use the bathroom had 
a 55% increased odds of greater out of bed variability than men who reported 
getting up 1-3 times at night to use the bathroom.  Furthermore, men who 
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reported not getting up to use the bathroom had a 50% lower odds of greater 
variability in nighttime wakefulness than men who reported getting up 1-3 times 
per night.   In multivariable adjusted models, this latter association remained 
statistically significant, but all other associations failed to reach statistical 
significance.   
 Depression: Being depressed as defined by a GDS score >6 was 
associated with 2-fold increased odds of greater variability across all sleep/wake 
parameters in age and site adjusted models.  In multivariable adjusted models, 
these associations were slightly attenuated, but remained statistically significant 
(1.5 to 1.7-fold increased odds).    
Cognitive impairment:   Cognitive impairment (MMSE<80) was associated 
with a 1.3 to 1.8-fold increased odds of greater variability in all sleep/wake 
parameters, but statistical significance was only reached for associations with 
variability in sleep latency in age and site adjusted models.  In multivariable 
adjusted models, none of the associations were statistically significant, but the 
magnitude of the point estimates suggested that cognitive impairment may be 
associated with a 58% increased odds of greater variability in sleep latency.   
 Comorbidity burden:  Greater burden of comorbidity was associated with 
increased odds of greater variability in several measures, in age and site 
adjusted models.   In multivariable adjusted models the strongest associations 
were observed for multimorbidity.  Multimorbidity (2 or more comorbid medical 
conditions) was associated with a 1.4 to 1.7-fold increased odds of greater 
variability in total sleep time, nighttime wakefulness, sleep latency and out of bed 
timing, compared to men with no comorbid medical conditions.   
 
Impact of Mean Total Sleep Time on Multivariable Associations 
 In multivariable adjusted models, mean total sleep time was an 
independent predictor of variability in nighttime wakefulness and sleep latency, 
but not for variability in total sleep time, in-bed timing and out of bed timing.   
Each standard deviation increase in total sleep time (SD=1.2 hrs) was associated 
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with a 60% reduced odds of greater variability in nighttime wakefulness and a 
57% reduced odds of greater variability in sleep latency (Table 11).    
 The addition of mean total sleep time to multivariable adjusted models had 
some impact on predictors associated with greater variability in nighttime 
wakefulness and sleep latency.  After adjusting for mean total sleep time, African 
American race, living alone, current smoking, BMI 25-29 kg/m2 were no longer 
independently associated with variability in nighttime wakefulness.  Furthermore, 
after additional adjustment for mean total sleep time, African American race, 
living alone, current smoking, BMI>30 kg/m2, greater IADL impairments and 
greater burden of comorbidities were no longer independently associated with 
variability in sleep latency.  Although mean total sleep time was not 
independently associated with variability in in and out of bed timing, the addition 
of this measure to those models resulted in associations with greater BMI no 
longer reaching statistical significance.     
 
Associations with continuous variability measures 
 Multivariable adjusted associations between predictors and continuous 
sleep/wake variability measures are presented in Tables 12 and 13.   In general, 
the statistical significance of most of the primary associations were unchanged in 
models expressing variability outcomes as continuous measures.  However, 
some evidence became stronger due to increased power of expressing 
outcomes as continuous, rather than dichotomous variables.  For example, in 
primary models, older age was not associated with increased odds of being in 
the highest quintile of variability in total sleep time.  However, in models 
expressing total sleep time variability as a continuous measure, men aged 75-79 
years had about an average of 4 minutes greater total sleep time variability than 
men aged 67-69 years, in multivariable adjusted models.  Furthermore, 
associations between older age and variability in in-bed timing and out of bed 
timing were strengthened in analyses expressing variability as a continuous, 
rather than categorical variable.  The magnitude of a few other associations were 
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slightly strengthened in these analyses, and included education, alcohol use and 
IADL impairments.   
 Associations between depression and variability in in-bed timing were 
slightly attenuated in models expressing in-bed timing variability as a continuous 
measure, and were no longer statistically significant (p=0.093).   
 
Discussion 
 In this population of older community-dwelling men, these results suggest 
that while the majority of variability in sleep/wake parameters is derived from 
between-persons differences, a substantial amount of within-person variability 
exists.  Furthermore, several demographic, anthropometric, lifestyle, medical, 
medication and physical functioning factors were independently associated with 
measures of greater sleep/wake variability.  Overall, African American race, living 
alone, antidepressant use, depression, greater body mass index and 
multimorbidity were the strongest independent predictors of parameters of 
greater sleep/wake variability.          
 Compared to results of prior studies, our findings suggest that the 
sleep/wake patterns of older men exhibit slightly less variability than that of a 
younger (middle aged) cohort14.  In comparison to the 669 CARDIA participants 
(mean age 42.9 y) included in this prior study, we observed slightly less 
variability (Coefficient of Variation (CV) for total sleep time was 21% vs. 19%, 
and sleep latency 136% vs. 105% for CARDIA vs. MrOS Sleep participants, 
respectively). Additionally, the within-person SD of sleep measures were also 
greater for CARDIA participants (SD total sleep time 86 vs. 47 mins; sleep 
latency 31 vs. 24 mins, for CARDIA vs. MrOS Sleep, respectively).  The study in 
CARDIA participants did not assess variation in bed time, wake time or nighttime 
wakefulness and did not examine associations between potential predictors and 
variability measures.        
 While we are unable to assess directionality and causality in this analysis 
our results also suggest that there may be potentially modifiable determinants of 
sleep variability in older adults including smoking, depression, greater BMI, 
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functional impairments and antidepressant use. These findings might help direct 
the design of future intervention studies aimed at improving sleep among older 
adults. 
 African American race was a strong, independent predictor of greater 
sleep/wake variability in this cohort.  These findings were similarly noted in the 
CARDIA study, although results were not presented.  In CARDIA, investigators 
observed a significant race-sex group effect in models, with white males and 
white females having lower daily variability in sleep/wake parameters than black 
males and black females, though the absolute magnitude of differences across 
race and sex groups was not presented94.  We are not able to assess race-sex 
differences in this study of older men, but we did observe that African American 
men have significantly more variability in sleep than Caucasian men.  These 
findings were independent of several other measures of health, education and 
physical functioning. The associations of race with variability in nighttime 
wakefulness and sleep latency were explained in part, by the average amount of 
total sleep the individual attained during the study period.  In our study, African 
American men slept an average of 28.1 minutes less per night than Caucasian 
men (data not shown), after adjusting for age, clinic site and education. This 
observation that African Americans have worse sleep than Caucasians is 
supported by findings of other studies95.  These results suggest that African 
American men have more variability in night to night nighttime wakefulness, 
which may lead to an overall reduction in the average amount of sleep attained 
over a period of time.   Future analyses are needed to confirm these findings and 
to evaluate the effects of specific socio-economic and lifestyle stressors that may 
have a greater impact on these associations in African American populations.     
 Living alone was also a strong, independent predictor of greater 
sleep/wake variability in this population, and there are several reasons that may 
explain this observation.  While living alone might be an indication of the ability to 
live independently, it may also be indicative of recent bereavement or a lack of 
social support.  Questions regarding lifestyle stressors such as bereavement in 
the past year, were not assessed at the sleep exam.  Given the amount of time 
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between this assessment and the sleep exam, it is uncertain if these measures 
would have any meaningful impact on the associations we observed.  Therefore, 
future research should explore these in greater detail on the extent to which 
lifestyle stressors may impact sleep.     
 Smoking may be associated with greater sleep/wake variability in older 
adults though associations in this study did not reach significance..  In this 
cohort, only 1.9% of men reported being current smokers.  This low prevalence 
contributes to the lack of statistical power, and also makes associations a little 
more difficult to interpret.  Currently there is no literature examining the effects of 
smoking on sleep/wake variability, however smoking is sleep disrupting due to 
the stimulating effects of nicotine, which could promote insomnia and/or variable 
sleep/wake patterns96.      
 Antidepressant use remained a strong, independent predictor of variability 
in total sleep time, sleep latency and out of bed timing in multivariable adjusted 
models.  While some antidepressants are sleep promoting, others may be sleep 
disturbing, and thus these associations consist of a mixture of the two 
possibilities.   Due to a low prevalence of antidepressant use in the cohort (<8%), 
we are unable to examine and compare associations across different classes of 
antidepressants.  Associations with antidepressant use were fairly similar in 
magnitude to those observed for depression.  Given the association between 
depression and insomnia symptoms97 these results raise the question of whether 
insomnia may be underlying this association.  In our study we did not assess 
insomnia, and are unable to examine this possibility further.   
 Benzodiazepine use was also associated with greater variability in total 
sleep time, in bed timing and out of bed timing.  We also had a low prevalence of 
benzodiazepine use in this cohort (4.3%) which prohibits us from exploring 
associations with specific subclasses of medications such as whether the 
association between benzodiazepine use depends on duration of action (i.e. long 
vs short acting agent).   However, benzodiazepines have sedating and sleep-
promoting effects, and their impact on  sleep variability may be a direct result of 
their mechanistic action98.  It is also a possibility that intermittent benzodiazepine 
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use may contribute to greater sleep/wake variability, but this has not been 
confirmed in studies.   
 Higher body mass index was associated with greater variability in nearly 
all sleep/wake measures, although most associations appeared to be due, in part 
to reduced total sleep time.  After additional adjustment for mean total sleep time 
in multivariable adjusted models, associations between BMI and variability in 
sleep latency, in bed timing and out of bed timing were attenuated and no longer 
reached statistical significance.  Associations between being overweight (BMI 25-
29 kg/m2) and nighttime wakefulness were also no longer statistically significant 
with further adjustment for total sleep time.  However, associations between 
being obese (BMI 30+ kg/m2) and greater variability in nighttime wakefulness, as 
well as being overweight or obese and greater variability in total sleep time, 
remained significant.   A prior study in the MrOS cohort observed a strong cross 
sectional association between actigraphy measured short total sleep time and 
greater adiposity, which was explained, in part by an increased prevalence of 
sleep apnea among older men with shortened sleep duration99.  Given these 
results, sleep apnea may be one pathway that may mediate the association 
between higher BMI and greater variability in sleep/wake measures. Future 
projects should explore this potential mechanism for the association.     
 In our cohort, associations between cognitive impairment and variability in 
sleep/wake parameters appear to be due, in large part, to other factors such as 
older age, lower education and poorer health given the attenuation of the 
associations in age and site as compared to multivariable adjusted models.  
Despite this, however, the magnitude of the point estimate for variability in sleep 
latency (OR=1.58) in multivariable adjusted models suggests that an association 
may exist.  In secondary analyses expressing variability measures as continuous 
variables, this association was statistically significant.  Men who were cognitively 
impaired had on average a standard deviation for sleep latency variability that 
was 7.3 minutes greater than men who were not cognitively impaired (mean(SD) 
= 7.3 (2.8), p=0.008).  Since the algorithm to calculate sleep latency involves 
utilizing the daily sleep diaries it is possible that errors in self-reporting, 
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influenced by cognitive impairment, have contributed to increased variability in 
this measure, despite the fact that actigraphy data were edited whenever large 
discrepancies were observed.   This seems unlikely however, since adjusting for 
the quality of the time reported in-bed data (i.e. the amount of disagreement 
between self-report and actigraphy data) did not impact these results.  A prior 
study using data from the Study of Osteoporotic Fractures cohort observed that 
older women who took longer to fall asleep at night had worse cognitive scores 
(0.8% worse MMSE score for every ½ hour increase in sleep latency) that was 
not explained by health and other related factors.  Our findings suggest that 
variability in sleep latency may also be important to consider in this population.  
Future research should explore this further as well as the potential mechanisms 
underlying this association.       
 Greater comorbidity burden, and more importantly multimorbidity, was 
independently associated with an increased odds for greater variability in total 
sleep time, nighttime wakefulness, sleep latency and out of bed timing.  Further 
sensitivity analyses suggested that associations with sleep latency variability 
were largely explained by reduced total sleep time, However other associations 
were not impacted by additional adjustment for mean total sleep time.  There are 
several potential mechanistic pathways that may explain these associations, 
including medication side effects, anxiety, life stressors and the impact of specific 
medical conditions, and more work is needed to better understand these 
associations.   
 In addition to the results highlighted above, several other associations 
were observed, such as that between heavy alcohol use and greater variability in 
nighttime wakefulness and sleep latency, older age and greater WASO variability 
and less variability in bed timing, and lower education with greater total sleep 
time variability.  Each of these should be further examined in future research, 
although not all may be modifiable.   
 There are several strengths worth noting in this study, including a large 
sample size of community-dwelling (non-institutionalized) older men, objective 
estimates of sleep and assessment of multiple potential predictors.  However, 
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there are also some limitations.  Results are not necessarily generalizable to 
other population groups.  This study had a cross-sectional design, and thus we 
are unable to assess causality in any of these associations.   In addition, 
actigraphy is a measure of activity and inactivity, and is not a definitive 
characterization of sleep/wake status.  Actigraphs were worn for at least 5 
consecutive nights, which may be a relatively short time frame to characterize 
variability in sleep/wake patterns, and could be influenced by one extreme value.  
Future studies should examine these associations in studies that collect 
measures of sleep-wake patterns over longer time frames (>2 weeks).  We 
performed multiple comparisons and some of the observed associations may be 
due to chance. 
 In conclusion, we observed significant within-person variability in sleep 
latency and nighttime wakefulness in a cohort of older, community dwelling men.  
We also observed that several demographic and health-related predictors, some 
of which may be modifiable, were significantly associated with greater variability 
in sleep/wake parameters. Future prospective research studies should examine 
whether variability in sleep-wake patterns is associated with risk of adverse 
health outcomes among older adults, and if so, whether or not interventions 
aimed at reducing variability in sleep improve health outcomes.    
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Tables and Figures 
Table 7.  Baseline characteristics of MrOS Participants  
Characteristic Value 
Age groups, y, %  
     67-69 8.9 
     70-74 35.0 
     75-79 28.8 
     80+ 27.3 
Race, %  
     Caucasian 89.9 
     African American 3.7 
     Other 6.4 
Education, %  
     Less than HS 5.4 
     High School 16.4 
     College 78.1 
Lives alone, % 13.2 
Smoking status, %  
    Current 1.9 
    Former 58.9 
     Never 39.1 
Alcohol use, drinks/wk, %  
     0-1 47.2 
     2-13 47.0 
     14+ 5.8 
Number of times up at night to use bathroom, %  
     0 4.4 
     1-3 83.1 
     4 6.2 
     5 or more 6.4 
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Self-reported health status, %  
     Good/excellent 86.6 
     Fair/Poor/Very Poor 13.4 
Antidepressant user, % 7.9 
Benzodiazepine user, % 4.3 
Non-benzodiazepine anxiolytic/hypnotic user, % 1.9 
Depressed (GDS>6), % 6.6 
BMI categories, %  
    <25 (underweight to normal weight) 29.6 
    25-29 (overweight) 49.6 
    30+  (obese) 20.8 
Cognitive impairment (Modified Mini Mental State 
Examination Score <80%), % 
3.5 
Number of impairments in Instrumental Activities 
of Daily Living, % 
 
     0 78.9 
     1-2 16.7 
     3 or more 4.4 
Comorbidity burden, %  
     0 26.2 
     1 31.7 
     2 or more 42.1 
Parkinson’s disease, % 1.2  
Chronic kidney disease, % 1.0 
Chronic obstructive pulmonary disease, % 5.4 
Stroke, % 3.5 
Diabetes, % 13.4 
Congestive heart failure, % 6.0 
Myocardial infarction, % 17.4 
Hypertension, % 50.7 
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     Hypercholesterolemia 42.1 
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Table 8.  Distributions and Variability in Actigraphic Sleep/Wake Parameters in Older Men 
 
Between-subject Within-subject 
Sleep/wake parameter 
Mean (SD) Median (IQR) CV 
Variability 
Mean (SD) 
Time to bed* 10:47 PM (1.3 hrs) 10:44 (10:05-11:28) PM 5.0 37 (25) mins 
Time out of bed* 6:59 AM (1.3 hrs) 6:58 (6:19-7:37) AM 15.5 39 (26) mins 
Total sleep time 6.4 (1.2) hours 6.5 (5.8-7.2) hours 19.2 47 (24) mins 
Nighttime wakefulness 78.2 (43.7) mins 68.7 (46-101) mins 55.8 27 (20) mins 
Sleep latency 30.7 (32.1) mins 21.0 (12-37) mins 104.7 24 (26) mins 
SD=Standard deviation; IQR=Interquartile Range; hrs=hours; mins=minutes. 
*Time parameters are recorded as clock time (HH:MM).  
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Table 9.  Age and site adjusted odds ratios (95% CI) of potential predictors with measures of variability in 
sleep/wake patterns 
 Odds Ratio (95% CI) 
 Measures of high sleep/wake variability (Quintile 5 vs. Quintiles 1-4)* 
 Total sleep 
time 
>63.3 vs. < 63.3 
mins 
Nighttime 
Wakefulness 
>39.4 vs. <39.4 
mins 
Sleep Latency 
>34.7 vs. <34.7 
mins 
In BED 
>53.5 vs. <53.5 
mins 
Out Bed 
>55 vs. <55 
mins 
Age groups, y      
     70-74 vs. 67-69 1.06 (0.75-1.50) 0.95 (0.66-1.37) 0.98 (0.69-1.39) 0.75 (0.54-1.03) 0.87 (0.63-1.21) 
     75-79 vs. 67-69 0.94 (0.66-1.34) 1.04 (0.72-1.51) 0.90 (0.63-1.29) 0.65 (0.46-0.90) 0.74 (0.53-1.04) 
     80+  vs. 67-69 1.06 (0.74-1.52) 1.54 (1.07-2.22) 1.08 (0.76-1.55) 1.50 (0.35-0.70) 0.67 (0.47-0.95) 
Race      
     African American vs. Caucasian 3.63 (2.41-5.47) 2.43 (1.57-3.76) 1.79 (1.14-2.81) 3.13 (2.07-4.73) 3.30 (2.19-4.97) 
     Other vs. Caucasian 1.32 (0.89-1.96) 1.48 (1.00-2.18) 1.06 (0.71-1.60) 1.73 (1.20-2.48) 1.43 (0.96-2.11) 
Education      
     Less than high school vs. College 2.06(1.43-2.97) 1.90 (1.32-2.74) 1.34 (0.91-1.98) 1.44 (0.97-2.14) 1.83 (1.26-2.65) 
     High School vs. College 1.17 (0.90-1.51) 1.12 (0.86-1.45) 1.16 (0.90-1.51) 0.98 (0.75-1.29) 0.99 (0.75-1.29) 
Social Support      
     Lives with others vs. alone 1.75 (1.36-2.25) 1.49 (1.15-1.92) 1.55 (1.20-2.00) 1.98 (1.54-2.55) 1.40 (1.08-1.82) 
Smoking status      
     Former vs. Never 1.10 (0.91-1.34) 1.32 (1.08-1.61) 1.29 (1.06-1.58) 0.97 (0.80-1.17) 1.23 (1.01-1.50) 
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     Current vs. Never 2.06 (1.14-3.71) 1.95 (1.04-3.65) 1.93 (1.05-3.57) 2.41 (1.36-4.27) 1.94 (1.06-3.54) 
Health status      
     Fair/poor/very poor vs. good/excellent 1.60 (1.24-2.05) 1.70 (1.32-2.18) 1.33 (1.03-1.72) 1.18 (0.91-1.54) 1.54 (1.20-1.99) 
Alcohol use, drinks/wk      
     2-13 vs. 0-1 0.84 (0.69-1.02) 0.90 (0.81-1.21) 1.14 (0.94-1.40) 0.89 (0.73-1.09) 1.02 (0.84-1.25) 
     14+ vs. 0-1 0.90 (0.60-1.37) 1.62 (1.11-2.36) 1.29 (0.86-1.93) 1.08 (0.72-1.61) 0.89 (0.58-1.37) 
Number of times up to use bathroom      
     0 vs. 1-3 0.86 (0.53-1.39) 0.50 (0.28-0.89) 0.66 (0.39-1.12) 0.96 (0.61-1.53) 1.03 (0.65-1.62) 
     4 vs. 1-3 1.10 (0.75-1.60) 1.14 (0.78-1.65) 1.09 (0.75-1.59) 1.09 (0.74-1.60) 0.80 (0.53-1.22) 
     5 or more vs. 1-3 1.41 (0.99-2.01) 1.33 (0.93-1.91) 1.23 (0.86-1.77) 1.09 (0.75-1.59) 1.55 (1.09-2.20) 
Antidepressant use      
     User vs. non-user 2.03 (1.50-2.74) 1.17 (0.84-1.64) 1.88 (1.38-2.55) 1.34 (0.97-1.85) 2.14 (1.59-2.89) 
Benzodiazepine use      
     User vs. non-user 2.28 (1.54-3.38) 1.09 (0.69-1.71) 1.81 (1.21-2.73) 1.84 (1.23-2.76) 1.95 (1.30-2.91) 
Non-Benzodiazepine Anxiolytic/Hypnotics      
     User vs. non-user 1.34 (0.71-2.54) 0.80 (0.39-1.67) 1.53 (0.82-2.85) 1.36 (0.72-2.58) 1.11 (0.57-2.18) 
Depressed      
     GDS>6 vs. <6 2.14 (1.55-2.96) 2.09 (1.51-2.89) 2.09 (1.51-2.89) 2.00 (1.44-2.79) 2.23 (1.61-3.09) 
Body Mass Index, kg/m2      
     25-29 vs. <25 1.30 (1.03-1.64) 1.40 (1.10-1.79) 1.21 (0.96-1.53) 1.13 (0.90-1.41) 1.26 (1.01-1.58) 
     30+ vs. <25 1.98 (1.51-2.59) 2.85 (2.17-3.74) 2.03 (1.55-2.65) 1.39 (1.06-1.82) 1.31 (1.00-1.73) 
Cognitive impairment      
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     mMMSE<80 vs. >80 1.41 (0.88-2.25) 1.56 (0.99-2.45) 1.79 (1.15-2.81) 1.30 (0.79-2.11) 1.54 (0.96-2.47) 
IADL impairments      
     1 vs. none 1.38 (1.08-1.75) 1.35 (1.06-1.72) 1.23 (0.96-1.58) 1.39 (1.09-1.77) 1.15 (0.89-1.47) 
     2 or more vs. none 2.16 (1.45-3.22) 1.94 (1.30-2.98) 2.51 (1.70-3.71) 2.38 (1.59-3.58) 1.52 (0.99-2.32) 
Comorbidity burden, %      
     1 vs. 0 1.06 (0.85-1.32) 1.32 (1.07-1.64) 1.28 (1.04-1.59) 1.13 (0.92-1.41) 1.05 (0.84-1.30) 
     2 or more vs. 0 1.84 (1.38-2.45) 2.06 (1.54-2.75) 1.68 (1.25-2.26) 1.32 (0.96-1.79) 1.67 (1.24-2.24) 
All analyses were adjusted for age and clinic site.   
*Each variability outcome is expressed as highest quintile vs. remaining four quintiles 
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Table 10.  Multivariable adjusted associations between potential predictors and variability in sleep/wake 
parameters  
 Odds Ratio (95% CI)** 
 Measures of greatest sleep/wake variability (Quintile 5 vs. Quintiles 1-4)* 
 Total sleep 
time 
>63.3 vs. < 63.3 
mins 
WASO 
>39.4 vs. <39.4 
mins 
Sleep Latency 
>34.7 vs. <34.7 
mins 
In Bed Timing 
>53.5 vs. <53.5 
mins 
Out of Bed 
Timing 
>55 vs. <55 
mins 
Age groups, y      
     70-74 vs. 67-69 1.01 (0.70-1.44) 0.88 (0.60-1.27) 0.96 (0.67-1.38) 0.72 (0.52-1.01) 0.83 (0.59-1.16) 
     75-79 vs. 67-69 0.92 (0.63-1.33) 1.02 (0.70-1.50) 0.88 (0.61-1.28) 0.62 (0.44-0.88) 0.73 (0.51-1.04) 
     80+  vs. 67-69 1.07 (0.73-1.56) 1.58 (1.07-2.34) 1.06 (0.72-1.56) 0.44 (0.31-0.64) 0.69 (0.48-1.01) 
Race      
     African American vs. Caucasian 3.26 (2.09-5.06) 1.98 (1.23-3.19) 1.63 (1.01-2.65) 2.88 (1.86-4.47) 3.13 (2.02-4.85) 
     Other vs. Caucasian 1.27 (0.84-1.93) 1.50 (0.99-2.25) 1.12 (0.73-1.71) 1.71 (1.17-2.51) 1.44 (0.95-2.17) 
Education      
     Less than high school vs. College 1.51 (1.01-2.25) 1.29 (0.86-1.93) 0.96 (0.62-1.47) 1.09 (0.71-1.68) 1.34 (0.89-2.01) 
     High School vs. College 1.02 (0.78-1.34) 0.98 (0.75-1.29) 1.06 (0.81-1.38) 0.90 (0.68-1.19) 0.90 (0.68-1.18) 
Social Support      
     Lives with others vs. alone 1.57 (1.20-2.04) 1.43 (1.09-1.87) 1.45 (1.11-1.89) 1.84 (1.42-2.39) 1.29 (0.98-1.69) 
Smoking status      
     Former vs. Never 1.04 (0.84-1.27) 1.17 (0.95-1.44) 1.19 (0.97-1.46) 0.93 (0.76-1.14) 1.18 (0.96-1.46) 
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     Current vs. Never 1.79 (0.94-3.40) 1.53 (0.78-3.00) 1.72 (0.90-3.26) 1.97 (1.07-3.63) 1.55 (0.81-2.98) 
Health status      
     Fair/poor/very poor vs. good/excellent 1.10 (0.83-1.47) 1.25 (0.94-1.66) 0.90 (0.67-1.21) 0.84 (0.62-1.14) 1.20 (0.90-1.60) 
Alcohol use, drinks/week      
     2-13 vs. 0-1 0.88 (0.72-1.09) 1.08 (0.87-1.33) 1.21 (0.98-1.49) 0.98 (0.80-1.21) 1.10 (0.89-1.35) 
     14+ vs. 0-1 0.98 (0.64-1.51) 1.73 (1.16-2.58) 1.34 (0.88-2.03) 1.20 (0.79-1.81) 0.97 (0.62-1.51) 
Number of times up to use bathroom      
     0 vs. 1-3 0.83 (0.50-1.37) 0.51 (0.28-0.93) 0.67 (0.39-1.15) 0.85 (0.52-1.39) 0.97 (0.60-1.57) 
     4 vs. 1-3 0.99 (0.66-1.48) 1.09 (0.74-1.61) 1.04 (0.70-1.54) 1.00 (0.67-1.50) 0.73 (0.47-1.13) 
     5 or more vs. 1-3 1.34 (0.92-1.95) 1.24 (0.85-1.82) 1.19 (0.82-1.75) 0.98 (0.66-1.46) 1.40 (0.97-2.03) 
Antidepressant use      
     User vs. non-user 1.79 (1.29-2.48) 1.04 (0.72-1.49) 1.67 (1.20-2.32) 1.12 (0.79-1.59) 1.86 (1.35-2.56) 
Benzodiazepine use      
     User vs. non-user 1.76 (1.15-2.69) 0.85 (0.52-1.39) 1.31 (0.84-2.03) 1.58 (1.03-2.43) 1.55 (1.01-2.38) 
Non-Benzodiazepine Anxiolytic/Hyp use      
     User vs. non-user 1.45 (0.76-2.80) 0.90 (0.43-1.91) 1.64 (0.86-3.10) 1.32 (0.68-2.54) 1.18 (0.59-2.35) 
Depressed      
     GDS>6 vs. <6 1.48 (1.03-2.13) 1.61 (1.12-2.32) 1.61 (1.12-2.31) 1.54 (1.06-2.23) 1.65 (1.15-2.38) 
Body Mass Index, kg/m2      
     25-29 vs. <25 1.36 (1.07-1.73) 1.38 (1.08-1.77) 1.22 (0.96-1.54) 1.17 (0.92-1.47) 1.29 (1.02-1.63) 
     30+ vs. <25 1.91 (1.44-2.53) 2.61 (1.97-3.46) 1.95 (1.48-2.57) 1.34 (1.01-1.77) 1.27 (0.95-1.69) 
Cognitive impairment      
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     mMMSE<80 vs. >80 0.86 (0.51-1.47) 1.11 (0.67-1.84) 1.58 (0.97-2.57) 0.93 (0.54-1.60) 1.05 (0.62-1.78) 
IADL impairments      
     1 vs. none 1.09 (0.84-1.42) 1.01 (0.78-1.31) 1.01 (0.77-1.31) 1.26 (0.96-1.64) 0.91 (0.70-1.20) 
     2 or more vs. none 1.27 (0.81-2.00) 1.13 (0.72-1.78) 1.74 (1.13-2.69) 1.77 (1.13-2.78) 0.85 (0.52-1.38) 
Comorbidity burden, %      
     1 vs. 0 0.98 (0.78-1.23) 1.24 (0.99-1.55) 1.25 (1.00-1.56) 1.10 (0.88-1.37) 0.99 (0.79-1.25) 
     2 or more vs. 0 1.39 (1.01-1.90) 1.68 (1.23-2.30) 1.38 (1.00-1.91) 1.11 (0.80-1.56) 1.40 (1.02-1.93) 
*Models adjusted for all covariates presented in above table plus clinic site.  
**Each variability outcome is expressed as highest quintile vs. remaining four quintiles  
Cohort N is 2,776 in above analyses due to some missing covariates  
mMMSE=modified Mini Mental State Examination; IADL=Instrumental Activities of Daily Living 
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Table 11.  Multivariable adjusted models with adjustment for mean total sleep time adjusted odds ratios (95% CI) of 
predictors with measures of variability in sleep/wake patterns 
 Odds Ratio (95% CI) 
 Measures of high sleep/wake variability (Quintile 5 vs. Quintiles 1-4)** 
 Total sleep 
time 
>63.3 vs. < 63.3 
mins 
WASO 
>39.4 vs. <39.4 
mins 
Sleep Latency 
>34.7 vs. <34.7 
mins 
In Bed Timing 
>53.5 vs. <53.5 
mins 
Out Bed 
Timing 
>55 vs. <55 
mins 
Age groups, y      
     70-74 vs. 67-69 1.01 (0.70-1.45) 0.85 (0.57-1.27) 0.95 (0.65-1.40) 0.72 (0.52-1.01) 0.83 (0.59-1.16) 
     75-79 vs. 67-69 0.92 (0.63-1.33) 1.02 (0.68-1.54) 0.86 (0.58-1.27) 0.62 (0.44-0.88) 0.73 (0.51-1.04) 
     80+  vs. 67-69 1.07 (0.73-1.57) 1.64 (1.08-2.48) 1.03 (0.69-1.55) 0.44 (0.31-0.64) 0.69 (0.48-1.01) 
Race      
     African American vs. Caucasian 3.18 (2.04-4.95) 1.60 (0.96-2.67) 1.29 (0.77-2.17) 2.82 (1.81-4.37) 3.04 (1.96-4.72) 
     Other vs. Caucasian 1.25 (0.82-1.90) 1.29 (0.84-2.00) 0.95 (0.61-1.48) 1.69 (1.15-2.48) 1.41 (0.93-2.12) 
Education      
     Less than high school vs. College 1.51 (1.01-2.26) 1.32 (0.85-2.03) 0.94 (0.60-1.49) 1.09 (0.71-1.68) 1.34 (0.89-2.02) 
     High School vs. College 1.02 (0.78-1.34) 0.95 (0.70-1.28) 1.03 (0.77-1.38) 0.89 (067-1.19) 0.89 (0.68-1.18) 
Social Support      
     Lives with others vs. alone 1.54 (1.18-2.01) 1.26 (0.94-1.69) 1.29 (0.96-1.71) 1.82 (1.40-2.36) 1.27 (0.96-1.67) 
Smoking status      
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     Former vs. Never 1.03 (0.84-1.27) 1.15 (0.92-1.44) 1.18 (0.95-1.47) 0.93 (0.76-1.13) 1.18 (0.96-1.45) 
     Current vs. Never 1.74 (0.92-3.31) 1.06 (0.50-2.24) 1.25 (0.61-1.26) 1.92 (1.04-3.55) 1.50 (0.78-2.89) 
Health status      
     Fair/poor/very poor vs. good/excellent 1.10 (0.83-1.48) 1.33 (0.97-1.80) 0.90 (0.66-1.23) 0.84 (0.62-1.14) 1.20 (0.90-1.60) 
Alcohol use, drinks/wk      
     2-13 vs. 0-1 0.88 (0.72-1.09) 1.03 (0.83-1.30) 1.18 (0.95-1.47) 0.98 (0.80-1.20) 1.09 (0.89-1.34) 
     14+ vs. 0-1 0.99 (0.64-1.52) 1.87 (1.21-2.89) 1.36 (0.86-2.14) 1.20 (0.79-1.81) 0.97 (0.62-1.52) 
Number of times up to use bathroom      
     0 vs. 1-3 0.82 (0.50-1.36) 0.41 (0.21-0.78) 0.58 (0.32-1.02) 0.85 (0.52-1.38) 0.96 (0.60-1.55) 
     4 vs. 1-3 0.99 (0.66-1.48) 1.13 (0.74-1.72) 1.07 (0.70-1.63) 1.01 (0.67-1.50) 0.73 (0.47-1.13) 
     5 or more vs. 1-3 1.35 (0.93-1.96) 1.35 (0.90-2.02) 1.26 (0.84-1.89) 0.98 (0.66-1.46) 1.41 (0.97-2.04) 
Antidepressant use      
     User vs. non-user 1.80 (1.30-2.50) 1.12 (0.75-1.68) 1.92 (1.34-2.75) 1.13 (0.79-1.60) 1.88 (1.36-2.59) 
Benzodiazepine use      
     User vs. non-user 1.78 (1.16-2.72) 0.89 (0.52-1.51) 1.49 (0.93-2.39) 1.60 (1.04-2.45) 1.57 (1.02-2.42) 
Non-Benzodiazepine Anxiolytic/Hypnotics      
     User vs. non-user 1.43 (0.75-2.76) 0.75 (0.34-1.63) 1.49 (0.77-2.89) 1.30 (0.68-2.51) 1.16 (0.58-2.31) 
Depressed      
     GDS>6 vs. <6 1.49 (1.03-2.15) 1.82 (1.23-2.69) 1.82 (1.24-2.69) 1.55 (1.06-2.24) 1.67 (1.16-2.40) 
Body Mass Index, kg/m2      
     25-29 vs. <25 1.34 (1.05-1.71) 1.22 (0.94-1.59) 1.06 (0.82-1.36) 1.15 (0.91-1.46) 1.27 (1.01-1.61) 
     30+ vs. <25 1.83 (1.38-2.44) 1.81 (1.33-2.46) 1.31 (0.97-1.78) 1.29 (0.97-1.72) 1.21 (0.90-1.62) 
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Cognitive impairment      
     mMMSE<80 vs. >80 0.87 (0.51-1.48) 1.16 (0.68-1.99) 1.69 (1.01-2.81) 0.93 (0.54-1.60) 1.06 (0.62-1.79) 
IADL impairments      
     1 vs. none 1.09 (0.84-1.41) 0.99 (0.75-1.31) 0.98 (0.74-1.30) 1.25 (0.96-1.63) 0.91 (0.69-1.19) 
     2 or more vs. none 1.26 (0.80-1.97) 0.95 (0.58-1.55) 1.58 (0.99-2.52) 1.75 (1.11-2.75) 0.84 (0.51-1.36) 
Comorbidity burden      
     1 vs. 0 0.98 (0.78-1.23) 1.16 (0.91-1.47) 1.18 (0.93-1.50) 1.09 (0.87-1.37) 0.99 (0.79-1.24) 
     2 or more vs. 0 1.38 (1.00-1.89) 1.63 (1.16-2.29) 1.30 (0.92-1.83) 1.11 (0.79-1.55) 1.39 (1.01-1.92) 
Total sleep time, mins, per SD increase* 0.92 (0.84-1.02) 0.40 (0.36-0.45) 0.43 (0.39-0.48) 0.93 (0.84-1.02) 0.91 (0.82-1.00) 
All analyses were additionally adjusted for clinic site.  Associations significant at P<0.05 level are italicized 
*Standard Deviation for Total Sleep Time = 1.2 hrs, or 72 minutes 
**Each variability outcome is expressed as highest quintile vs. remaining four quintiles 
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Table 12.  Associations between predictors and continuous variability measures of WASO, sleep latency and total sleep 
time 
 
WASO, mins Sleep Latency, mins 
Total sleep time, 
mins 
 Estimate 
(SE) 
P-value 
Estimate 
(SE) 
P-
value 
Estimate 
(SE) 
P-
value 
Intercept 18.54  15.61  42.93  
Age groups, y       
     70-74 vs. 67-69 0.65 (1.36) 0.636 -0.58 (1.82) 0.749 -2.42 (1.66) 0.145 
     75-79 vs. 67-69 1.64 (1.40) 0.239 -1.27 (1.87) 0.497 -3.99 (1.70) 0.019 
     80+  vs. 67-69 4.29 (1.45) 0.003 0.89 (1.94) 0.647 -1.34 (1.77) 0.447 
Race       
     African American vs. Caucasian 9.06 (1.99) <.001 6.44 (2.67) 0.016 13.53 (2.43) <.001 
     Other vs. Caucasian 2.86 (1.58) 0.070 0.37 (2.11) 0.861 2.79 (1.92) 0.147 
Education       
     Less than high school vs. 
College 
2.29 (1.12) 0.041 1.88 (1.50) 0.211 3.58 (1.36) 0.009 
     High School vs. College -0.80 (0.82) 0.327 -0.99 (1.09) 0.367 -2.73 (1.00) 0.006 
Social Support       
     Lives with others vs. alone 4.40 (1.09) <.001 5.11 (1.45) <.001 4.21 (1.32) 0.002 
Smoking status       
     Former vs. Never 1.40 (0.76) 0.068 1.66 (1.02) 0.104 1.75 (0.93) 0.060 
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     Current vs. Never 1.83 (2.73) 0.503 5.36 (3.66) 0.143 8.16 (3.33) 0.014 
Health status       
     Fair/p/vp vs. good/excellent 1.45 (1.16) 0.210 0.82 (1.55) 0.599 0.12 (1.41) 0.932 
Alcohol use, drinks/week       
     2-13 vs. 0-1 0.99 (0.78) 0.206 2.79 (1.05) 0.008 -0.38 (0.96) 0.693 
     14+ vs. 0-1 4.61 (1.62) 0.005 3.05 (2.17) 0.161 -0.23 (1.98) 0.907 
# of times up to use bathroom       
     0 vs. 1-3 -4.45 (1.78) 0.012 -3.08 (2.38) 0.195 -0.65 (2.17) 0.763 
     4 vs. 1-3 1.65 (1.52) 0.278 -0.003 (2.04) 0.999 -1.09 (1.86) 0.557 
     5 or more vs. 1-3 2.85 (1.50) 0.058 1.14 (2.01) 0.571 3.29 (1.83) 0.073 
Antidepressant use       
     User vs. non-user 0.47 (1.40) 0.736 6.73 (1.87) <.001 5.88 (1.70) <.001 
Benzodiazepine use       
     User vs. non-user 2.20 (1.84) 0.231 2.79 (2.46) 0.257 5.53 (2.24) 0.014 
Non-Benzo Anxiolytic/Hyp use       
     User vs. non-user 1.95 (2.65) 0.462 4.81 (3.54) 0.174 4.01 (3.23) 0.214 
Depressed       
     GDS>6 vs. <6 3.31 (1.55) 0.033 3.19 (2.08) 0.125 5.79 (1.89) 0.002 
Body Mass Index, kg/m2       
     25-29 vs. <25 2.82 (0.85) <.001 3.24 (1.14) 0.005 3.13 (1.04) 0.003 
     30+ vs. <25 8.16 (1.08) <.001 9.43 (1.44) <.001 6.61 (1.31) <.001 
Cognitive impairment       
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     mMMSE<80 vs. >80 4.03 (2.06) 0.050 7.33 (2.75) 0.008 0.23 (2.51) 0.928 
IADL impairments       
     1 vs. none 0.70 (1.03) 0.498 0.15 (1.38) 0.911 1.31 (1.25) 0.295 
     2 or more vs. none 4.97 (1.90) 0.009 8.40 (2.54) <.001 7.74 (2.31) <.001 
Comorbidity burden, %       
     1 vs. 0 2.37 (0.85) 0.005 1.03 (1.14) 0.365 0.28 (1.03) 0.790 
     2 or more vs. 0 4.58 (1.31) <.001 3.10 (1.75) 0.076 5.88 (1.59) <.001 
Scale 19.0  25.43  23.15  
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Table 13.  Associations between predictors and continuous variability measures 
of in and out of bed timing 
 In  bed timing, mins Out of bed timing, mins 
 Estimate 
(SE) 
P-value 
Estimate 
(SE) 
P-value 
Intercept 37.73  37.88  
Age groups, y     
     70-74 vs. 67-69 -3.58 (1.73) 0.039 -1.43 (1.79) 0.426 
     75-79 vs. 67-69 -5.61 (1.77) 0.002 -3.38 (1.83) 0.065 
     80+  vs. 67-69 -6.97 (1.84) <.001 -5.09 (1.90) 0.008 
Race     
     African American vs. Caucasian 18.72 (2.53) <.001 12.79 (2.61) <.001 
     Other vs. Caucasian 5.75 (2.00) 0.004 3.39 (2.07) 0.102 
Education     
     Less than high school vs. 
College 
1.89 (1.42) 0.185 
5.82 (1.47) <.001 
     High School vs. College -0.45 (1.04) 0.071 -3.64 (1.07) <.001 
Social Support     
     Lives with others vs. alone 6.85 (1.38) <.001 2.65 (1.43) 0.063 
Smoking status     
     Former vs. Never -0.20 (0.97) 0.839 1.18 (1.00) 0.240 
     Current vs. Never 6.75 (3.47) 0.052 4.77 (3.59) 0.184 
Health status     
     Fair/p/vp vs. good/excellent 1.49 (1.47) 0.313 1.01 (1.52) 0.508 
Alcohol use, drinks/week     
     2-13 vs. 0-1 0.57 (1.00) 0.565 -0.17 (1.03) 0.869 
     14+ vs. 0-1 0.89 (2.06) 0.666 -0.49 (2.13) 0.819 
# of times up to use bathroom     
     0 vs. 1-3 -2.28 (2.26) 0.314 -0.40 (2.34) 0.866 
     4 vs. 1-3 1.20 (1.93) 0.536 -1.86 (2.00) 0.352 
     5 or more vs. 1-3 2.71 (1.91) 0.156 1.38 (1.97) 0.483 
Antidepressant use     
     User vs. non-user 0.39 (1.77) 0.828 5.49 (1.83) 0.003 
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Benzodiazepine use     
     User vs. non-user 5.54 (2.33) 0.018 4.55 (2.41) 0.059 
Non-Benzo Anxiolytic/Hyp use     
     User vs. non-user -2.93 (3.36) 0.383 1.79 (3.47) 0.606 
Depressed     
     GDS>6 vs. <6 3.31 (1.97) 0.093 7.66 (2.04) <.001 
Body Mass Index, kg/m2     
     25-29 vs. <25 1.54 (1.08) 0.155 3.44 (1.12) 0.002 
     30+ vs. <25 3.22 (1.37) 0.018 4.24 (1.41) 0.003 
Cognitive impairment     
     mMMSE<80 vs. >80 1.36 (2.61) 0.603 0.06 (2.70) 0.845 
IADL impairments     
     1 vs. none 2.86 (1.31) 0.028 -0.66 (1.35) 0.625 
     2 or more vs. none 9.26 (2.41) <.001 3.60 (2.49) 0.149 
Comorbidity burden, %     
     1 vs. 0 -0.21 (1.08) 0.847 0.31 (1.11) 0.778 
     2 or more vs. 0 1.60 (1.66) 0.335 6.93 (1.71) <.001 
Scale 24.12  24.93  
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Chapter 5:  The Impact of Sleep Disturbances on Inpatient Health 
Care Utilization in Older Women 
 
Background:  Sleep disturbances are common in aged populations and often 
associated with comorbid medical conditions.  However, little is known about the 
extent to which sleep disturbances impact inpatient health care utilization (HCU), 
especially among an unselected population of community-dwelling older adults. 
Methods:  This analysis included 2,103 women (mean age 84.2+3.9 years) 
enrolled in the Study of Osteoporotic Fractures (SOF).  Sleep parameters were 
assessed at the Year 16 exam (2002-2004) using wrist actigraphy (mean 4.2+0.7 
nights) and by self-report (Pittsburgh Sleep Quality Index (PSQI) and Epworth 
Sleepiness Scale (ESS)).  Sleep disturbances were defined as being in the worst 
quartile of a given sleep measure.  Inpatient HCU was obtained from Medicare 
and/or Kaiser Permanente data.  Risk of being hospitalized and the rate ratio of 
inpatient days during the three years after the clinic exam were estimated using 
logit-Poisson Hurdle Models, and bootstrapping was used to obtain 95% 
confidence intervals for rate ratio outcomes.   
Results:  Significant sleep disruption was observed in this population, with 25.9% 
sleeping less than 6 hours per night, and 50.2% reported poor sleep quality 
(PSQI>5).  1,157 (55%) of the sample was hospitalized during an average of 2.8 
+ 0.6 years of follow-up.   In age and site adjusted models, women in the worst 
quartiles of sleep efficiency, sleep latency, wake after sleep onset (WASO) and 
short total sleep time had a 31-72% greater odds of being hospitalized.  
Associations were largely explained by health status, comorbidities and 
depression.  In analyses restricted to women who were hospitalized, being in the 
worst quartile of sleep efficiency, sleep latency, WASO and Pittsburgh Sleep 
Quality Index (PSQI) were each associated with a 14-24% increased rate of 
inpatient days.  These results were not statistically significant in multivariable 
adjusted models. Sleep efficiency and WASO were each associated with greater 
odds of hospitalization related to CHF (OR=1.98, 95% CI 1.29-3.05 for reduced 
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sleep efficiency and OR=2.48, 95% CI 1.61-3.80 for increased WASO) and 
COPD (OR=2.15, 95% CI 1.19-3.91 for reduced sleep efficiency and OR=2.38, 
95% CI 1.31-4.31 for increased WASO) in multivariable adjusted models.   
Conclusion:  Associations between sleep disturbances and all-cause 
hospitalizations are explained, in a large part by health-related factors such as 
comorbidities, physical functioning, depression and health status, but sleep 
disturbances are independently associated with a greater odds of hospitalizations 
due to COPD and CHF in older women.  Future studies are needed to determine 
whether sleep disturbance is a marker of more severe chronic diseases, or an 
exacerbating factor that results in increased hospitalization risk.  Future studies 
should also examine associations between sleep disturbances and other 
measures of utilization including nursing home, hospice and home health care.   
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Introduction 
Given rising health care costs, high prevalence and chronic nature of 
sleep-related complaints, and association of sleep disorders with comorbid 
medical conditions, the impact of sleep-disturbances on health care utilization 
has been the focus of several studies.  In a 3-month follow-up study of 373 young 
and middle-aged adults enrolled in a Health Maintenance Organization (HMO), 
researchers found that patients with self-reported insomnia complaints had 
greater disability, greater functional impairment, greater number of self-reported 
days in bed, and greater total health care costs, compared to patients without 
sleep complaints 100.   A similarly designed longitudinal study in the UK observed 
that participants with sleep complaints had a 1.7-fold greater odds of healthcare 
use (consult or prescription for insomnia or mood in 12 months following survey), 
and this association was higher among those who also self-reported symptoms 
of anxiety/depression101.    
 Similar patterns of higher healthcare utilization among poor sleepers were 
observed in a cross-sectional study of 12,643 participants conducted in Hungary.  
Researchers observed that participants with self-reported sleep complaints also 
self-reported greater hospitalization days in the past year (11.1 vs. 3.7), and 
greater number of sick leave days (16.8 vs. 10.0) than participants without sleep 
complaints102.   
 These studies have not focused specifically on older adult populations, 
where the burden of sleep disorders and comorbid medical conditions are 
highest.  Most studies have examined associations with a single sleep disorder, 
such as insomnia100-106.  Studies examining more global measures of self-
reported sleep disturbance (such as the Pittsburgh Sleep Quality Index) have 
been performed104, but were conducted in a primarily younger population.  
Furthermore, several prior studies have relied on self-reported measures of 
healthcare utilization102-105, which may be subject to reporting bias.   
 One study of 14,355 older adults enrolled in the Health and Retirement 
Study (HRS) examined associations between self-reported measures of 
insomnia symptoms and self-reported measures of healthcare utilization107. The 
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HRS study observed that participants with one (vs. no) insomnia symptoms had 
a 1.3-fold greater odds of being hospitalized, and that participants with two or 
more insomnia symptoms (vs. none) had a 1.7-fold greater odds of being 
hospitalized.  These associations were independent of age, gender, education, 
race, comorbidities and depression.   To our knowledge, no study has examined 
associations between objective measures of sleep and health-care utilization, 
Furthermore, having the ability to comprehensively adjust for potential mediators 
and/or confounders such as physical functioning, cognitive impairment, health 
status, medications and dementia would also further our understanding of 
associations between sleep and HCU.  Additionally, analyses examining 
associations between specific sleep disturbances and cause-specific inpatient 
admissions may provide further insight into the potential mechanisms that may 
underlie the connections between sleep disturbances and chronic diseases.       
Therefore, to examine whether sleep disturbances are associated with 
overall, as well as cause-specific inpatient health care utilization, we used data 
from the longitudinal Study of Osteoporotic Fractures (SOF), linked with 
Medicare claims and Kaiser Permanente encounters.    
   
Methods 
Participants 
 The Study of Osteoporotic Fractures (SOF) is a landmark longitudinal 
epidemiologic study designed to examine risk factors for osteoporotic fractures.  
Women were recruited from four U.S. clinical centers (Baltimore, Maryland; 
Minneapolis, Minnesota; the Monongahela Valley nears Pittsburgh, 
Pennsylvania; and Portland, Oregon)32.  The SOF study enrolled 9,704 
community-dwelling white women aged 65 years and older from 1986-1988.   
Women were excluded if they were unable to walk without assistance, or if they 
had undergone a previous bilateral hip replacement.  Initially African American 
women were excluded from the study due to their low incidence of hip fractures, 
but from 1997-1998, 662 African American women aged 65 years and older were 
recruited33.    
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 The focus of this analysis will be on data collected at visit 8 (year 16), 
which was conducted from 2002-2004 and invited surviving SOF participants to 
attend.  Of the 10,366 women recruited in SOF, 3,676 attended the visit 8 exam 
(Figure 4).   
 
Measurement of Sleep/Wake Parameters 
 Activity patterns were measured using an octagonal wrist actigraph 
SleepWatch-O (Ambulatory Monitoring, Inc., Ardsley, NY), which is a small 
device resembling a wrist watch that is worn on the wrist of the non-dominant 
hand.   Actigraphs contain accelerometers that measure and record movement in 
1-minute epochs, and have been shown to provide reliable estimates of sleep-
wake activity in comparison to polysomnography, which is currently the gold 
standard84.  Actigraphy data were transferred to the San Francisco Coordinating 
Center for centralized processing.  Centralized training and certification were also 
required for clinic staff gathering actigraphy data.  Activity data from the actigraph 
was analyzed using Action W-2 software (Ambulatory Monitoring, Inc.).   
Actigraphs collect data in 3 modes, with different methodologies and sensitivities 
and thresholds to determine movement.  The University of California at San 
Diego sleep scoring algorithm was used for data collected in the digital 
integration mode (also known as the proportional integration mode, or PIM), and 
time-above-threshold (TAT), and the Cole-Kripke algorithm was used for data 
collected in the zero-crossings mode (ZCM)85.    
Women were asked to wear the actigraph continuously for at least 72 
hours, and to remove it only for bathing or situations in which it might get 
submerged in water.  Time periods in which participants removed the actigraphs 
are not included in the analyses, and if the actigraph was removed for greater 
than 10% of the time during the day or for over 2 hours during the night, the data 
from that night is not included in the analyses.       
 Several sleep/wake parameters were computed from the actigraphy data 
and defined as follows:  total sleep time (the hours per night spent sleeping while 
in bed), sleep efficiency (the percentage of time in bed spent sleeping), sleep 
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latency (the number of minutes from the time when the participant reported 
getting into bed (and attempting to sleep) until sleep onset, wake after sleep 
onset (minutes of wake after sleep onset occurring during the time in bed).  Sleep 
onset was defined as the first 20 continuous minutes of sleep after getting into 
bed.     
 In a subset of SOF participants who had concurrent actigraphy and 
polysomnography (gold standard) data during the same night, the intraclass 
correlation was highest for total sleep time (r=0.76) and more moderate in 
magnitude for sleep efficiency and wake after sleep onset (r=0.61 and 0.58, 
respectively).87   Of the 3,676 women who attended the visit 8 exam, 85% 
(n=3,123) had technically adequate wrist actigraphy data.   
 
Self-Reported Sleep Measures 
 Women enrolled in SOF also completed the Pittsburgh Sleep Quality 
Index (PSQI) and the Epworth Sleepiness Scale (ESS) questionnaires at their 
sleep study visit.  The PSQI is a validated measure of subjective sleep quality 
and sleep disturbances over a 1-month period.  The questionnaire is divided into 
sections that assess subjective sleep quality, sleep latency, sleep duration, sleep 
efficiency, sleep disturbances, use of sleeping medications and daytime 
dysfunction.  Global PSQI scores range from 0 to 21, and a standard cut-off of 
greater than 5 is indicative of poor sleep quality.  This cutoff has a sensitivity of 
89.6% and a specificity of 86.5% in distinguishing good sleepers from poor 
sleepers64, 65. 
 The ESS is a self-administered questionnaire that assesses propensity for 
sleep onset.  Participants are asked to rate how likely (from 1 to 3, with 1 being 
unlikely and 3 being highly likely) they are to doze off in eight typical daily 
situations.  Scores range from 0 to 24, with a standard cutoff of greater than 10 
indicative of excessive daytime sleepiness67, 68. 
 
 
89 
 
Linkage of SOF Cohort Data to Medicare Claims Data and Kaiser 
Permanente Encounter Data 
 Linkage of the SOF cohort to Medicare claims data was completed in 
2008, by submitting social security and/or Medicare (HIC) numbers for SOF 
participants who were alive as of 1/1/1991, to Centers for Medicare and Medicaid 
Services (CMS).  A linkage was determined to be valid if there was an exact 
match on SSN/HIC, and sufficient agreement on DOB, gender, last known 
residence (ZIP code), and date of death (when available).  Medicare data was 
purchased from January 1991-December 2010.  Of the 10,366 women enrolled 
in the SOF study, 9,986 were alive and actively enrolled in SOF as of January 1, 
1991, and of those 9,228 (92.4%) were determined to be valid linkages to 
Medicare claims data.   
 Women at the SOF Portland site were originally recruited into the SOF 
study through Kaiser Permanente, and thus we observed a high rate of Medicare 
Advantage enrollment at this site (96%).  Linkage of SOF Portland participants to 
Kaiser Permanente inpatient encounter records was completed in 2014 by 
submitting social security numbers to Kaiser Permanente.  Of the 2,464 women 
enrolled at the Portland SOF site who were alive as of 1/1/1991, 2,180 (88.5%) 
were enrolled in a Kaiser Permanente plan.  Kaiser Permanente inpatient 
encounter data was obtained from January 1991-December 2010.  In combining 
Medicare claims and Kaiser Permanente encounter records we were able to 
successfully link 9,381 (93.9% of 9,986) SOF participants to Medicare and/or 
Kaiser encounter records.        
We required that during the month of the SOF V8 exam that participants 
be observable in claims/encounters data, meaning that they were either enrolled 
in Kaiser, or enrolled in a Part A Medicare plan for which CMS processes all of 
the inpatient claims.  Of the 3,123 women who attended Visit 8 and had 
technically adequate actigraphy data, 2,103 (67.3%) linked successfully to 
Medicare and/or Kaiser and were enrolled in a Part A plan, or Kaiser plan for at 
least one month from their sleep visit, until death, disenrollment or the end of 
follow up (Figure 4).   
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Inpatient Health Care Utilization 
 Inpatient health care utilization was obtained for the three years following 
the SOF visit 8 exam.  Data on hospitalizations and cumulative inpatient days 
were assessed using the MedPAR file for participants enrolled in a Part A 
Medicare plan, and from Kaiser Permanente inpatient encounters data for 
participants enrolled in a Kaiser plan.  We computed the cumulative inpatient 
days observed during the three years following the clinic visit.     
 
Other Measures 
 Additional measures were collected at the time of the visit 8 exam.  All 
participants completed questionnaire data, which included questions about their 
current health status, smoking, alcohol use and medical history.  Medical 
information included a self-reported history of a physician diagnosis of 
cardiovascular disease (including myocardial infarction, angina, congestive heart 
failure, other heart disease), stroke, diabetes, Parkinson’s disease, Alzheimer’s 
disease, chronic obstructive pulmonary disease and cancer.  A variable was 
created to indicate presence of 0, 1 or 2 or more selected medical conditions.  
Caffeine intake was estimated based on self-report of the average daily number 
of cups of caffeinated coffee, tea or cans of caffeinated soda32.  The Geriatric 
Depression Scale (GDS) was used to assessed depressive symptoms, with 
scores >6 indicative of depression90.  Functional status was measured using 
information collected on six independent activities of daily living (IADL)91, 92, and 
>1 IADL impairments were indicated if a woman reported having any difficult with 
performing any of the 6 IADL abilities (walking 2 to 3 blocks on level ground, 
climb up 10 steps, walk down 10 steps, prepare meals, do heavy housework, and 
shop for groceries or clothes). Tests of physical function included walk speed, 
which is the time in seconds to walk 6 meters at usual pace.  The Mini-Mental 
State Examination108 was administered.  This is a brief, global cognitive function 
test with concentration, language, and memory components designed to screen 
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for cognitive impairment.  The Mini-Mental State Examination scale ranges from 
0 to 30, with higher numbers indicating better performance.  Participants were 
asked to bring in all medications used within the past two weeks, and a 
computerized medication coding dictionary was used to categorize the 
medications89.  Possible dementia was defined as a Mini-Mental State 
Examination score lower than 26, self-reported history of dementia or use of 
medications commonly prescribed for dementia.  Participants were also asked to 
indicate the type of residence they live in (private home/apartment, retirement 
home/senior complex, nursing home, personal care home, other), and an 
indicator was created for independent living in a private home/apartment status.  
Body weight was measured using a standard balance beam, or digital scale and 
height using a wall mounted Harpenden stadiometer.  Body Mass Index (BMI) 
was calculated as kg/m2.   In a subset of women enrolled in fee-for-service 
Medicare, we calculated an Elixhauser Comorbidity Summary Score109 (range 0-
30), and expressed categories of Elixhauser Comorbidities as 0, 1,  2+.   An 
indicator for prior hospitalization indicated that the woman was enrolled in fee-for-
service or Kaiser in the full 12 months prior to Visit 8, and was hospitalized at 
least once during that time.  Information from the SOF baseline visit was used to 
assess age, self-reported race/ethnicity and highest level of education attained.    
 
Statistical Analysis 
In primary analyses, measures of sleep disturbances were expressed as 
dichotomous predictors based on worst quartile.  The following cut points 
pertained to the worst quartile for each sleep/wake parameter: sleep efficiency 
<79.4% vs. >79.4%, sleep latency >53.1 vs. <53.1 minutes, wake after sleep 
onset >100 vs. <100 minutes, short sleep duration <6 hours vs. 6-7.5 hours, long 
sleep duration >7.5 hours vs. 6.0-7.5 hours; PSQI>8 vs. <8; and ESS >7 vs. <7.   
Secondary analyses examined associations between sleep/wake parameters 
and inpatient health care utilization using sleep/wake cut points that have been 
previously published in the Study of Osteoporotic Fractures.  The following cut 
points were specified: sleep efficiency <70% vs. >70%, sleep latency >1 hours 
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vs. <1 hours, awakening after sleep onset >90 vs. <90 mins, and sleep duration 
was expressed as <6 hours (short) vs. 6-8 hours (normal: referent group) vs. >8 
hours (long).   The following cut points were used for self-reported sleep 
disturbances: PSQI>5 vs. <5, ESS >10 vs. <10.    
The cumulative sum of inpatient days during follow up was expressed as a 
count variable.  We examined the association between sleep disturbances and 
odds of being hospitalized, as well as the rate ratio of inpatient days among 
those hospitalized using logit-Poisson hurdle models.  All outcomes involving rate 
ratios used bootstrapping in order to obtain more robust 95% confidence 
intervals, and p-values due to excess heterogeneity.  These models also allowed 
us to compare the mean rates of inpatient days in women with and without sleep 
disturbances, and rate ratios in the entire cohort (hospitalized and not 
hospitalized).  Models included a base model adjusted for age and clinic site, and 
a multivariable adjusted model that included covariates that were associated with 
hospitalizations and/or sleep disturbances using a threshold of p<.10 to 
determine retention in the model.  Analyses utilized data from both Medicare and 
Kaiser data sources.  Sensitivity analyses restricted to individuals enrolled in 
Medicare fee-for-service.  
Secondary analyses will examine the association between sleep 
disturbances and inpatient health care utilization associated with cardiovascular 
disease related events.  Cardiovascular disease related events were defined as 
an inpatient admission with a primary diagnosis of myocardial infarction (ICD-9 
410), stroke (ICD-9 430, 431, 434 or 436), congestive heart failure (428) and 
chronic obstructive pulmonary disease (466, 490-496).  Algorithms for these 
outcomes have been previously validated and are provided in the CMS Chronic 
Condition Warehouse110.   Logistic regression models were used and base 
models were adjusted for age and site, and a model that additionally adjusted for 
health status, comorbidities and walking speed.  All analyses were conducted 
using SAS version 9.3 (SAS Institute Inc., Cary, North Carolina).  In sensitivity 
analyses we also substituted Elixhauser comorbidity score categories for 
comorbidities, in the subset of participants that were enrolled in Medicare fee-for-
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service as Elixhauser comorbidity information was not available in Kaiser 
enrollees.  
Results 
Sleep Disturbances and Characteristics 
 Characteristics of the cohort of 2,103 women are shown in Table 14.  The 
average age was 84.2 years and 11% of the cohort was African American.  
24.8% of women rated their health status as fair, poor or very poor, and 52.8% 
reported having one or impairments in instrumental activities of daily living 
(IADL).   During an average follow-up of 2.8 (0.6) years, 1,157 (55%) women 
were hospitalized at least once.  Among those hospitalized, the mean (SD) for 
cumulative inpatient days was 10.7 (11.4) during the entire follow-up period.  
Characteristics of the cohort by hospitalization status are also presented in Table 
14.  Factors associated with hospitalization included older age, poorer health 
status, smoking, lower alcohol consumption, more IADL impairments, slower 
walk speed, depression, use of antidepressants, use of benzodiazepines, poorer 
cognition, possible dementia, more comorbidities, not living in a private 
home/apartment, and having a hospitalization in the prior year.     
 At the SOF visit 8 exam, sleep disturbances were prevalent.  In the cohort, 
the average total sleep duration was 6.7 (1.3) hours, and 25.9% of women had 
on average less than 6 hours of sleep per night (short sleep duration), and 14.2% 
had more than 8 hours of sleep per night (long sleep duration).  Furthermore, 
20.2% took one hour or longer to fall asleep (prolonged sleep latency), and 
30.8% spent 90 or minutes awake during the night (increased WASO), and 9.8% 
had a sleep efficiency of less than 70% (reduced sleep efficiency).   Furthermore, 
with the exception of excessive daytime sleepiness, greater sleep disturbances 
were associated with increased hospitalization.   
 
Associations between sleep disturbances and inpatient healthcare 
utilization 
 In age and site adjusted models we observed that sleep disturbances 
were associated with an increased odds of being hospitalized in the three years 
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after the sleep exam (Table 15).  Specifically, women in the lowest quartile of 
sleep efficiency had a 1.7-fold greater odds of being hospitalized (OR=1.66, 95% 
CI 1.35-2.05) than women in the top three quartiles of sleep efficiency.  Similarly, 
we observed  an increased odds of being hospitalized among women in the 
worst quartiles of sleep latency (>53.1 m, OR=1.31, 1.07-1.61), WASO (>100 m, 
OR=1.72, 95% CI 1.40-2.13), sleep duration (<6 h, OR=1.37, 95% CI 1.10-1.71) 
and Pittsburgh Sleep Quality Index (>8, OR=1.33, 95% CI 1.08-1.64) in models 
adjusted for continuous age and clinic site.  We did not observe an association 
between sleep duration>7.6 h (quartile 4) and excessive daytime sleepiness>7 
(quartile 4) and odds of being hospitalized in age and site adjusted models.   
 After further adjustment for covariates such as depression, use of 
antidepressants, cognitive functioning, walking speed, health status, impairments 
in instrumental activities of daily living, comorbidities, probable dementia and 
living independently, the magnitude of the associations between sleep 
disturbances and odds of being hospitalized were attenuated (OR range=0.89-
1.27) and no longer statistically significant (p>0.056).    The covariates that were 
the strongest factors in multivariable adjusted models were comorbidities, health 
status and use of antidepressants.   
 Among the 1,157 women who were hospitalized at least once during 
follow-up, we observed that women in the worst quartiles of sleep/wake 
parameters spent, on average a little over one day per year longer in the hospital 
than women in the remaining quartiles (Table 16).  We also observed a greater 
rate ratio of inpatient days among women in the worst quartiles of sleep 
efficiency (Rate Ratio=1.16, 95% CI 1.01-1.32), sleep latency (Rate Ratio=1.15, 
95% CI 1.01-1.32), WASO (Rate Ratio=1.24, 95% CI 1.07-1.41), and Pittsburgh 
Sleep Quality Index (Rate Ratio=1.17, 95% CI 1.02-1.34) in age and site 
adjusted models.  We did not observe a significant association of total sleep time 
and excessive daytime sleepiness with greater inpatient days in age and site 
adjusted models.   
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 Upon further adjustment for covariates, the magnitude of all associations 
were attenuated (rate ratio range = 1.01-1.09) and were no longer statistically 
significant.   
 Sensitivity analyses restricting to a fee-for-service population yielded 
similar results for associations with sleep latency, WASO, total sleep time, PSQI 
and ESS, but not for sleep efficiency (Tables 18 & 19).  In multivariable adjusted 
models, women in the worst quartile of sleep efficiency had a 36% greater odds 
of being hospitalized during follow up than women in the remaining quartiles 
(OR=1.36, 95% CI 1.01-1.83).   
  
Associations between sleep disturbances and cause specific 
hospitalizations 
 We observed that women in the worst quartile of sleep/wake parameters 
had greater odds of being hospitalized with a primary diagnosis of COPD or CHF 
during follow-up than women in the remaining three quartiles, in age and site 
adjusted models (Table 4).  More specifically, women in the worst quartile of 
sleep efficiency (OR=2.74, 95% CI 1.62-4.63), sleep latency (OR=1.74, 95% CI 
1.01-2.99), and WASO (OR=3.24, 95% CI 1.91-5.47) had a greater odds of being 
hospitalized for COPD.  Furthermore, women in the worst quartiles of sleep 
efficiency (OR=2.49, 95% CI 1.71-3.63), sleep latency (OR=1.51, 1.02-2.24), 
WASO (OR=2.94, 95% CI 2.02-4.27), total sleep time (<6 h, OR=2.23, 95% CI 
1.45-3.44) and daytime sleepiness (OR=1.66, 95% CI 1.12-2.45) had a greater 
odds of being hospitalized for CHF, in age and site adjusted models.   Pittsburgh 
sleep quality index was not associated with CHF or COPD hospitalizations, and 
total sleep time and daytime sleepiness were not associated with COPD 
hospitalizations.   
 Although some point estimates suggested that some measures of sleep 
disturbances were associated with a greater odds of hospitalization due to 
myocardial infarction or stroke, results were not statistically significant.   
 Further adjustment for depression, use of antidepressants, walking speed, 
any impairments in instrumental activities of daily living, health status, cognitive 
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functioning, medical conditions, probable dementia and living independently 
attenuated results, but did not alter conclusions.  In multivariable adjusted 
models, measures of night-time wakefulness (sleep efficiency and WASO) were 
associated with greater odds of COPD and greater odds of CHF related 
hospitalizations.  Sleep efficiency<79.4% was associated with a 2-fold greater 
odds of COPD hospitalizations (OR=2.15, 95% CI 1.19-3.91) and CHF 
hospitalizations (OR=1.98, 95% CI 1.29-3.05).  WASO>100 minutes was 
associated with a 2.4-2.5-fold greater odds of COPD hospitalizations (OR=2.38, 
95% Ci 1.31-4.31) and CHF hospitalizations (OR=2.48, 95% CI 1.61-3.80).  We 
also observed that total sleep time <6 hrs (vs. 6.0-7.5 hrs) was associated with a 
1.8-fold increased odds of CHF hospitalization in multivariable adjusted models 
(OR=1.84, 95% CI 1.13-3.01).  We did not observe any other significant findings 
between sleep latency, longer total sleep time (i.e. >7.6 hrs), sleep quality or 
excessive daytime sleepiness and cause-specific hospitalizations in multivariable 
adjusted models.    
 
Sensitivity Analyses 
 Results examining clinically relevant or previously published sleep 
disturbance cut points, adjusting for having one or more hospitalizations in the 
year prior to the SOF visit 8 exam, and substituting the Elixhauser comorbidity 
score for comorbidity burden were similar to primary analyses (data not shown).   
 
Discussion 
 Older women with sleep disturbances, such as reduced sleep efficiency, 
prolonged sleep latency, increased night time wakefulness, short sleep duration 
and poor sleep quality have greater odds of hospitalization.  However, these 
associations are largely explained by a greater burden of comorbidities, poorer 
health status and depression among older women with disturbed sleep.  These 
results suggest that comorbid medical conditions and depression are potentially 
stronger predictors of risk of hospitalization, and sleep disturbances yield no 
additional risk information in this population.   We did observe some evidence 
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that although sleep disturbances may not be independently associated with all-
cause hospitalizations, they are independently associated with a greater risk of 
hospitalizations due to heart failure and hospitalizations due to COPD, and may 
be important predictors of CHF and COPD-related hospitalizations in older 
women.  These findings help to highlight some potential mechanisms involving 
COPD and CHF, and indicate a need for further research and into these 
associations.    
 Prior studies of sleep and inpatient health care utilization have relied on 
self-report of sleep disturbances and/or health care utilization, which may be 
prone to reporting bias107, 111-117.  In general, these studies observed that sleep 
disturbances, especially insomnia symptoms, are associated with a greater risk 
of being hospitalized.  For example, 14,355 older adults from the Health and 
Retirement Study were surveyed about insomnia symptoms and risk of 
hospitalization, use of home health services and health care utilization in the 2 
years prior to the survey107.  The researchers observed significant associations 
between greater burden of insomnia symptoms and odds of hospitalization, in 
that participants reporting one insomnia symptom, and 2 or more symptoms had 
a 1.28-fold and 1.71-fold greater odds of being hospitalized, respectively, than 
participants with no insomnia symptoms.  These associations were greatly 
attenuated, but persisted after adjustment for participant characteristics, including 
demographic variables, comorbidities and depression.  Similar to these findings, 
we also observed significant associations between sleep disturbances and 
hospitalizations in minimally adjusted models (age and clinic site in our study and 
age, gender, race and education in the Health and Retirement study).  However, 
the magnitude of these associations were diminished and no longer statistically 
significant after further adjustment for health related factors, physical functioning, 
cognitive functioning, depression and comorbidities.  Kaufman et. al. also 
adjusted for depression and comorbidities, and observed that their findings were 
not substantially impacted.  In our results, we observed that number of 
comorbidities (0, 1, 2 or more), self-reported health status and antidepressant 
use were the strongest predictors of hospitalizations, independent of sleep 
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disturbances (data not shown).  Kaufman et. al. did not adjust for number of 
comorbidities or health status.  To our knowledge, our study is the first to use 
both objective assessments of sleep and inpatient health care utilization, and to 
adjust for a comprehensive set of confounders and mediators including health 
status, physical and cognitive functioning, depression, and comorbidities.           
 Our results do not provide causal evidence that sleep disturbances 
independently increase risk for all-cause inpatient hospitalizations,.   The 
association between sleep disturbances and all-cause hospitalization is 
explained, in a large part by a variety of patient factors, including depression, 
greater burden of comorbid medical conditions, poorer health status, poorer 
functional status, poorer cognition and use of medications.   
 However, the results of our analyses examining associations between 
sleep disturbances and cause-specific hospitalizations suggest that sleep 
disturbances may be independent predictors of hospitalization due to congestive 
heart failure and hospitalization due to chronic obstructive pulmonary disease.  
Two proposed mechanistic pathways may explain these observed associations.  
In one, sleep may be a marker for more severe or advanced disease, suggesting 
that temporality may be an issue in this study.  In our study, we do not have 
measures of disease severity, such as pulmonary function (for COPD), 
echocardiograms or ejection fraction (for CHF), and are unable to assess this, 
and to our knowledge, no other study has attempted to correlate sleep 
disturbances with disease severity.  There are several reasons why sleep 
disturbances may be a marker for more severe disease progression, particularly 
in patients with CHF and those with COPD.  Sleep disturbances are common 
(~50%) in patients with COPD118 and those with CHF119.   Prior studies have 
suggested that both conditions can reduce sleep quality through medication side 
effects, nocturia, nocturnal dyspnea, coughing, chest pain and difficulty 
breathing118, 119.     
 On the other hand, sleep apnea, a condition characterized by repeated 
pauses in breathing during the night, is also highly prevalent in COPD and CHF 
patients, and may share similar etiologies.  Comorbid sleep apnea and or 
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nocturnal dyspnea and COPD/CHF may result in significantly impaired sleep118.  
Furthermore, there is potential for the two coexisting conditions to exacerbate 
each other (i.e. CHF exacerbates sleep disordered breathing and vice versa)119.    
In our study, we only had measures of sleep disordered breathing on a very 
small subset of participants, and thus were unable to assess the mediating 
effects of sleep apnea on all cause and cause specific hospitalizations.  
Furthermore, given the potential for reverse causality, and bidirectional 
associations between CHF/COPD and sleep disturbances, we are unable to 
further examine the interrelationships between CHF/COPD and sleep 
disturbances with inpatient health care utilization.   
 Taken together, these results signify that in older women, sleep 
disturbances and comorbid medical conditions are closely linked, and this raises 
questions of whether concurrent treatment of sleep disorders and comorbid 
medical conditions improves inpatient health care utilization outcomes in this 
population.  A few randomized studies have examined concurrent treatment of 
sleep disordered breathing and CHF119, and insomnia and COPD120, as well as 
other comorbid conditions, and have generally observed improvement in quality 
of life, sleep quality and/or comorbidity.  However, much more research is 
needed in this area to identify whether concurrent treatments improve health 
outcomes and reduce health care costs in this population.  
 There are several strengths of the current study.  The SOF study is a 
large, well characterized cohort of older women who were not selected on the 
basis of any sleep-related or other conditions.  Additionally, sleep disturbances 
were assessed using validated measures obtained from wrist actigraphy, or self-
reported questionnaires (PSQI and ESS).  Furthermore, information from 
hospitalizations were obtained from linkage with Medicare and/or Kaiser 
Permanente encounter data, which is a systematic and validated sources of 
inpatient health care utilization.  Finally, our results were adjusted for potentially 
important confounders and/or mediators of the sleep-hospitalization pathway, 
including depression, functional impairment and medical conditions.  However, a 
number of limitations should be noted.   Our results were limited to inpatient 
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hospital admissions, and we did not assess associations between sleep 
disturbances and nursing home, hospice or home health care utilization, which 
may be particularly important indicators of health care utilization in older 
populations.  Future studies should try to incorporate these additional measures 
of health care utilization.   Furthermore, sleep disordered breathing was 
assessed in a very small subset of individuals, and we are unable to evaluate the 
effect of sleep apnea on inpatient health care utilization.  We also do not have 
measures of disease severity, and are unable to assess if sleep disturbances are 
a marker of more severe disease.  We did not examine associations between 
sleep disturbances and hospitalizations related to other specific causes besides 
those due to myocardial infarction, stroke, COPD and CHIF, and it is possible 
that other associations may exist.   Finally, results restricted to a fee-for-service 
yielded slightly increased age and clinic site adjusted mean rates of inpatient 
days per year, and slightly stronger associations between sleep efficiency and 
odds of being hospitalized.  We did observe lower hospitalization rates and 
reduced inpatient days among Kaiser enrollees as compared to the Medicare 
fee-for-service population, which might reflect differences in health systems.      
 In conclusion, we observed that associations between sleep disturbances 
and all-cause hospitalizations are mediated by health-related factors such as 
comorbidities, physical functioning, depression and health status, but sleep 
disturbances are independently associated with greater odds of hospitalization 
due to COPD and hospitalization due to CHF in older women.  Future studies are 
needed to determine whether sleep disturbance is a marker of more severe 
disease, or an exacerbating factor.  Future studies should also examine 
associations between sleep disturbances and nursing home, hospice and home 
health care utilization.    
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Tables and Figures 
Figure 5.  Roadmap of Analytical Cohort 
 
 
*Of the 6,690 women who did not attend the Visit 8 exam, 4,392 had died, 1,051 
were questionnaire only status and 1,247 terminated, refused or were otherwise 
unable to attend the visit.   
 
 
 
 
 
 
 
 
 
10,366 women 
enrolled in SOF 
 6,690* SOF women 
did not attend Visit 8 
3,676  SOF women 
attended Visit 8 (clinic 
or home) 
624 women do not 
have measures of 
sleep at Visit 8 
3,052 women have at 
least one measure of 
sleep 
949 women were not 
enrolled in FFS or 
Kaiser 
2,103 (68.9%) linked 
and were enrolled in 
>1 months FFS or 
Kaiser 
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Table 14.  Baseline Characteristics of 2,103 by Hospitalization Status 
  Hospitalization 
Characteristics 
Entire Cohort 
(n=2,103) 
Hospitalized 
(n=1,157) 
Not 
Hospitalized 
(n=946) 
P-Value 
Age, y, mean (SD) 84.2 (3.9) 84.5 (4.0) 83.7 (3.7) <.001 
African American, % 10.7 11.6 9.6 0.148 
Fair, poor or very poor health status, % 24.8 30.7 17.6 <.001 
Current smoker, % 3.1 4.1 1.9 0.004 
Alcoholic drinks per day in the last 30 days, mean 
(SD) 
1.2 (2.9) 1.0 (2.7) 1.4 (3.1) 0.004 
Daily caffeine intake, mg, mean (SD) 149 (153) 150 (155) 148 (149) 0.859 
One or more IADL impairment, % 52.8 61.1 42.6 <.001 
Walk speed, m/s, mean (SD) 0.80 (0.27) 0.75 (0.27) 0.86 (0.24) <.001 
Body Mass Index, kg/m2, mean (SD) 26.9 (5.0) 26.9 (5.2) 26.9 (4.7) 0.947 
GDS score (range 0-15), mean (SD) 2.4 (2.6) 2.8 (2.8) 2.0 (2.3) <.001 
Depression, GDS score >6, % 11.4 14.6 7.6 <.001 
Currently taking antidepressants, % 14.3 17.6 10.4 <.001 
Currently taking benzodiazepines, % 7.2 8.7 5.5 0.006 
MMSE (range 0-30), mean (SD) 27.8 (2.0) 27.6 (2.1) 28.0 (1.8) <.001 
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MMSE<26, % 11.0 13.0 8.7 0.002 
Possible Dementia, % 11.3 13.1 9.2 0.006 
Medical Conditions, %    <.001 
     0 37.1 29.7 46.1  
     1 36.8 36.8 34.9  
     2 or more 26.1 26.1 19.0  
     Stroke 13.8 16.8 10.0 <.001 
     Diabetes 10.6 13.4 7.3 <.001 
     Parkinson’s Disease 0.9 1.0 0.9 0.794 
     Alzheimer’s Disease 1.9 2.2 1.5 0.245 
     COPD 12.3 15.7 8.1 <.001 
     Cardiovascular Disease 34.4 40.9 26.5 <.001 
     Cancer 22.8 23.0 22.5 0.783 
Elixhauser Comorbidity Summary Score, mean 
(SD)* 
2.13 (2.32) 2.60 (2.45) 1.56 (1.89) <.001 
Elixhauser Comorbidity Categories, %*    <.001 
     0 34.5 29.0 41.4  
     1-2 29.4 26.2 33.5  
     3 or more 36.0 44.9 25.2  
Private home/apartment residence, % 75.1 73.5 77.1 0.050 
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Hospitalized in the year prior, % 23.2 28.7 16.4 <.001 
PSQI (range 0-21), mean (SD) 6.2 (3.7) 6.4 (3.8) 5.9 (3.5) 0.003 
PSQI>5, % 50.2 52.1 47.9 0.053 
ESS (range 0-24), mean (SD) 5.6 (3.8) 5.7 (3.9) 5.6 (3.7) 0.620 
ESS>10, % 11.1 11.7 10.3 0.290 
Sleep efficiency, %, mean (SD) 83.5 (10.2) 85.0 (9.2) 82.3 (10.8) <.001 
Sleep efficiency<70%, % 9.8 12.7 6.2 <.001 
Sleep latency, mins, mean (SD) 42.2 (42.3) 45.4 (46.4) 38.3 (36.4) <.001 
Sleep latency >60 mins, % 20.2 22.5 17.4 0.004 
Wake after sleep onset, mins, mean (SD) 78.7 (49.2) 84.8 (52.4) 71.2 (43.9) <.001 
Wake after sleep onset >90 mins, % 30.8 34.8 25.9 <.001 
Total sleep time, hrs, mean (SD) 6.7 (1.3) 6.7 (1.4) 6.8 (1.2) 0.018 
Total sleep time <6 hrs, % 25.9 27.8 23.5 
0.010 
Total sleep time >8 hrs, % 14.2 15.1 13.0 
 
SOF=Study of Osteoporotic Fractures; SD=standard deviation; IADL=instrumental activities of daily living; GDS=Geriatric 
Depression Scale; COPD=chronic obstructive pulmonary disease; MMSE=Mini-Mental State Examination. 
*Available in subset (n=2,065 women) enrolled in FFS for the entire year prior to Visit 8. 
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Table 15.  Association between sleep disturbances and odds of being hospitalized 
Sleep/Wake Disturbance Age and Site adjusted Multivariable Adjusted 
 OR (95% CI) p-value OR (95% CI) p-value 
Sleep efficiency: <79.4 vs. >79.4% 1.66 (1.35-2.05) <.001 1.23 (0.96-1.56) 0.099 
Sleep latency: >53.1 vs. <53.1 m 1.31 (1.07-1.61) 0.010 1.08 (0.86-1.36) 0.498 
WASO:  >100 vs. <100 m 1.72 (1.40-2.13) <.001 1.27 (0.99-1.62) 0.056 
TST:  <6 h vs. 6.0-7.5 h 1.37 (1.10-1.71) 0.008 1.20 (0.94-1.53) 0.136 
TST: >7.6 h vs. 6.0-7.5 h 1.11 (0.90-1.38) 0.329 1.09 (0.86-1.38) 0.488 
PSQI >8 vs. <8 1.33 (1.08-1.64) 0.006 1.06 (0.84-1.33) 0.649 
ESS >7 vs. <7 1.06 (0.86-1.29) 0.598 0.89 (0.71-1.11) 0.285 
OR=Odds Ratio; m=minutes; WASO=Wake after sleep onset; TST=total sleep time; h=hours; PSQI=Pittsburgh Sleep 
Quality Index; ESS=Epworth Sleepiness Scale 
Multivariable Models adjusted for age, clinic site, depression, use of antidepressants, cognitive functioning, 6 meter 
walking speed, self-reported health status, any impairments in instrumental activities of daily living, medical conditions, 
probable dementia, and living independently.     
 
 
 
 
 
 
106 
 
Table 16.  Association between sleep disturbances and rate ratio of inpatient hospital days among those with >1 
hospital admissions  
Sleep/Wake Disturbance 
Mean (95% CI) 
rate of inpatient 
days per year* 
Rate Ratio (95% CI)** 
Age and Site 
adjusted 
Multivariable 
Adjusted† 
Sleep efficiency 
<79.4% 4.22 (3.77-4.69) 1.16 (1.01-1.32) 1.04 (0.94-1.14) 
>79.4% 3.65 (3.38-3.89) 1.0 (ref) 1.0 (ref) 
   p=0.138 p=0.500 
Sleep latency >53.1 m 4.22 (3.77-4.70) 1.15 (1.01-1.32) 1.07 (0.97-1.18) 
 <53.1 m 3.66 (3.40-3.89) 1.0 (ref) 1.0 (ref) 
   p=0.028 p=0.184 
Wake after sleep onset 
>100 m 4.43 (3.93-4.94) 1.24 (1.07-1.41) 1.06 (0.96-1.18) 
<100 m 3.57 (3.32-3.80) 1.0 (ref) 1.0 (ref) 
   p=0.004 p=0.296 
Total Sleep Time 
<6.0 h 3.90 (3.46-4.34) 1.07 (0.91-1.23) 1.02 (0.92-1.14) 
6.0-7.5 hr 3.65 (3.35-3.98) 1.0 (ref) 1.0 (ref) 
>7.6 hr 4.02 (3.56-4.53) 1.10 (0.95-1.28) 1.07 (0.96-1.20) 
   p>0.166 p>0.214 
Pittsburgh Sleep Quality Index 
>8 4.25 (3.77-4.77) 1.17 (1.02-1.34) 1.09 (0.99-1.20) 
<8 3.64 (3.38-3.88) 1.0 (ref) 1.0 (ref) 
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   p=0.016 p=0.100 
Epworth Sleepiness Scale 
>7 3.91 (3.52-4.00) 1.04 (0.91-1.18) 1.01 (0.92-1.11) 
<7 3.77 (3.47-4.34) 1.0 (ref) 1.0 (ref) 
   p=0.606 p=0.876 
*Adjusted for age and clinic site 
**Bootstrapping with 1000 samples used to estimate 95% confidence intervals and p-values 
†Multivariable Models adjusted for :  Age, clinic site, depression, use of antidepressants, cognitive functioning, 6 meter 
walking speed, self-reported health status, any impairments in instrumental activities of daily living, selected medical 
conditions, probable dementia, and living independently    
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Table 17.  Association between sleep disturbances and cause-specific hospitalizations 
Sleep Disturbance 
Myocardial Infarction 
(n = 58) 
Stroke 
(n = 84) 
COPD 
(n = 60) 
CHF 
(n = 124) 
OR (95% CI) 
p-
value 
OR (95% CI) 
p-
value 
OR (95% CI) 
p-
value 
OR (95% CI) 
p-
value 
Sleep efficiency <79.4 vs. >79.4% 
     Model 1 1.34 (0.75-2.40) 0.327 1.14 (0.69-1.86) 0.611 2.74 (1.62-4.63) <.001 2.49 (1.71-3.63) <.001 
     Model 2  1.16 (0.61-2.21) 0.653 0.81 (0.45-1.46) 0.481 2.15 (1.19-3.91) 0.012 1.98 (1.29-3.05) 0.002 
Sleep latency >53.1 vs. <53.1 minutes 
     Model 1 1.73 (0.99-3.03) 0.056 0.87 (0.51-1.47) 0.596 1.74 (1.01-2.99) 0.044 1.51 (1.02-2.24) 0.039 
     Model 2 1.59 (0.86-2.97) 0.142 0.70 (0.38-1.29) 0.255 1.42 (0.77-2.62) 0.265 1.37 (0.88-2.15) 0.167 
WASO >100 vs. <100 minutes 
     Model 1 1.09 (0.59-1.99) 0.789 1.53 (0.95-2.44) 0.078 3.24 (1.91-5.47) <.001 2.94 (2.02-4.27) <.001 
     Model 2 0.90 (0.46-1.77) 0.755 1.19 (0.68-2.06) 0.545 2.38 (1.31-4.31) 0.005 2.48 (1.61-3.80) <.001 
TST <6 vs. 6.0-7.5 hours 
     Model 1 1.41 (0.72-2.76) 0.311 0.95 (0.55-1.63) 0.844 1.26 (0.70-2.27) 0.450 2.23 (1.45-3.44) <.001 
     Model 2 1.29 (0.63-2.61) 0.487 0.84 (0.46-1.56) 0.584 1.01 (0.52-1.96) 0.973 1.84 (1.13-3.01) 0.015 
TST >7.6 vs. 6.0-7.5 hours 
     Model 1 1.58 (0.84-2.98) 0.160 0.98 (0.57-1.68) 0.940 0.75 (0.37-1.52) 0.422 1.38 (0.86-2.22) 0.181 
     Model 2 1.27 (0.63-2.57) 0.509 0.99 (0.55-1.79) 0.984 0.78 (0.37-1.66) 0.518 1.48 (0.88-2.48) 0.141 
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PSQI >8 vs. <8 
     Model 1 1.37 (0.77-2.46) 0.287 1.16 (0.71-1.90) 0.559 1.01 (0.55-1.83) 0.983 1.42 (0.95-2.12) 0.091 
     Model 2 1.04 (0.54-2.01) 0.900 1.26 (0.73-2.17) 0.415 0.68 (0.33-1.40) 0.293 1.19 (0.75-1.88) 0.454 
ESS >7 vs. <7 
     Model 1 1.46 (0.83-2.58) 0.193 0.92 (0.55-1.52) 0.739 1.34 (0.77-2.35) 0.304 1.66 (1.12-2.45) 0.011 
     Model 2 1.16 (0.62-2.15) 0.646 0.77 (0.43-1.38) 0.384 1.14 (0.62-2.10) 0.679 1.37 (0.88-2.11) 0.161 
 
OR=Odds Ratio; m=minutes; WASO=Wake after sleep onset; TST=total sleep time; h=hours; PSQI=Pittsburgh Sleep 
Quality Index; ESS=Epworth Sleepiness Scale 
Model 1 adjusted for age and clinic site 
Model 2 adjusted for age, clinic site, depression, use of antidepressants, cognitive functioning, 6 meter walking speed, 
self-reported health status, any impairments in instrumental activities of daily living, medical conditions, probable 
dementia, and living independently.     
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Table 18.  Association between sleep disturbances and odds of being hospitalized among FFS enrollees 
Sleep/Wake Disturbance Age and Site adjusted Multivariable Adjusted 
 OR (95% CI) p-value OR (95% CI) p-value 
Sleep efficiency: <79.4 vs. >79.4% 1.74 (1.33-2.26) <.001 1.36 (1.01-1.83) 0.042 
Sleep latency: >53.1 vs. <53.1 m 1.25 (0.96-1.61) 0.092 1.00 (0.76-1.33) 0.974 
WASO:  >100 vs. <100 m 1.68 (1.29-2.18) <.001 1.27 (0.94-1.71) 0.118 
TST:  <6 h vs. 6.0-7.5 h 1.49 (1.13-1.96) 0.005 1.34 (0.99-1.80) 0.136 
TST: >7.6 h vs. 6.0-7.5 h 1.17 (0.89-1.53) 0.259 1.11 (0.82-1.49) 0.488 
PSQI >8 vs. <8 1.32 (1.02-1.72) 0.037 0.96 (0.72-1.29) 0.809 
ESS >7 vs. <7 1.01 (0.79-1.31) 0.923 0.88 (0.67-1.17) 0.375 
OR=Odds Ratio; m=minutes; WASO=Wake after sleep onset; TST=total sleep time; h=hours; PSQI=Pittsburgh Sleep 
Quality Index; ESS=Epworth Sleepiness Scale 
Multivariable Models adjusted for age, clinic site, depression, use of antidepressants, cognitive functioning, 6 meter 
walking speed, self-reported health status, any impairment in instrumental activities of daily living, medical conditions, 
probable dementia, and living independently.     
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Table 19.  Association between sleep disturbances and rate ratio of inpatient hospital days among those with >1 
hospital admissions among FFS enrollees 
Sleep/Wake Disturbance 
Mean (95% CI) 
rate of inpatient 
days per year* 
Rate Ratio (95% CI)** 
Age and Site 
adjusted 
Multivariable 
Adjusted† 
Sleep efficiency 
<79.4% 4.81 (3.86-5.62) 1.11 (0.95-1.33) 1.01 (0.89-1.13) 
>79.4% 4.32 (3.49-4.86) 1.0 (ref) 1.0 (ref) 
   0.202 0.882 
Sleep latency >53.1 m 4.78 (3.79-5.62) 1.10 (0.91-1.30) 1.04 (0.91-1.19) 
 <53.1 m 4.36 (3.56-4.89) 1.0 (ref) 1.0 (ref) 
   0.324 0.522 
Wake after sleep onset 
>100 m 5.25 (4.24-6.07) 1.29 (1.07-1.50) 1.06 (0.93-1.21) 
<100 m 4.08 (3.36-4.58) 1.0 (ref) 1.0 (ref) 
   0.020 0.440 
Total Sleep Time 
<6.0 h 4.14 (3.32-4.83) 0.94 (0.78-1.12) 0.94 (0.84-1.07) 
6.0-7.5 hr 4.42 (3.58-5.03) 1.0 (ref) 1.0 (ref) 
>7.6 hr 4.86 (3.82-5.72) 1.10 (0.93-1.33) 1.08 (0.95-1.25) 
   >0.258 >0.246 
Pittsburgh Sleep Quality Index 
>8 5.23 (3.94-6.17) 1.24 (1.01-1.45) 1.12 (0.97-1.26) 
<8 4.22 (3.46-4.77) 1.0 (ref) 1.0 (ref) 
   0.038 0.015 
Epworth Sleepiness Scale 
>7 4.61 (3.62-5.34) 1.05 (0.84-1.27) 1.01 (0.90-1.15) 
<7 4.40 (3.66-4.94) 1.0 (ref) 1.0 (ref) 
   0.712 0.918 
*Adjusted for age and clinic site 
**Bootstrapping with 1000 samples used to estimate 95% confidence intervals and p-values 
†Multivariable Models adjusted for :  Age, clinic site, depression, use of antidepressants, cognitive functioning, 6 meter 
walking speed, self-reported health status, any impairments in instrumental activities of daily living, selected medical 
conditions, probable dementia, and living independently    
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Chapter 6:  Conclusions 
Prior epidemiologic research has shown that sleep disturbances and sleep 
disorders are common in older adults1, 2 and obtaining adequate sleep is an 
important aspect of healthy aging.  Although insufficient sleep has been linked to 
many medical conditions such as depression3, 4, cardiovascular disease5, 5, 6, 
frailty7, 8, impaired cognitive functioning9, 10 and mortality8, additional work is need 
to better understand the mechanistic pathways, correlates and consequences of 
insufficient sleep in an older adult population.  The field also faces many 
challenges, including lack of consistent and concrete measures of sleep 
disturbances and disorders across studies, inconsistent results in similar 
populations and use of screening tools that have not been validated in older 
populations.   
Utilizing data from the Study of Osteoporotic Fractures in Women (SOF), 
and the Outcomes of Sleep Disorders in Older Men (MrOS) cohort studies, this 
dissertation aimed to improve upon our understanding of the epidemiology of 
sleep disturbances in older adults by focusing on three specific areas that need 
additional research.    
 In addressing the first area, this dissertation found that a popular 
questionnaire for assessing risk of sleep apnea (STOP-BANG) has a high 
sensitivity at a cut point of >3 (94%) in an older male population, but also has an 
unacceptably high false positive rate (87.3%).  Furthermore, higher STOP-BANG 
cut points resulted in high specificities (97.4% at a cut point of >5) but 
unacceptably high false negative rates (93.6%) and little impact on probability 
revision beyond the prevalence of OSA in the cohort.   As a result of the work 
presented in this dissertation, we conclude that the STOP-BANG questionnaire is 
insufficient for the screening of OSA in older adults.   
 In addition to answering the question of whether the STOP-BANG 
questionnaire is an effective screening tool, this dissertation also aimed to 
examine how well the individual components of the STOP-BANG predict risk of 
OSA in an older adult male population.  Results suggested that in this population 
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individual STOP-BANG components of Snoring, Tired, Observed apneas, 
Pressure and Age were not strongly predictive of OSA.  Furthermore, body mass 
index and neck circumference had fair discriminatory power for detecting severe 
OSA in older men.  In comparing the area under the curve (AUC) for each of 
these measures, with the AUC for the STOP-BANG questionnaire as a whole, 
these results suggested that BMI and neck circumference individually are only 
slightly better at identifying older men with sleep apnea than the STOP-BANG 
questionnaire.   Secondary analyses examining associations between the STOP-
BANG questionnaire and excessive daytime sleepiness suggest that while the 
STOP-BANG may not be particularly useful for detecting OSA, it is associated 
with excessively sleepiness, and may be affected by other sleep-related 
disorders in this population.     
 Taken as a whole, the results of this first manuscript confirm that the 
STOP-BANG questionnaire is insufficient for detecting OSA in an older male 
population, and that additional research into the risk factors and characteristics of 
OSA is warranted.   
 Identifying and exploring novel measures of sleep disturbances in older 
adults was another area in which this dissertation chose to explore.   While the 
field has chosen to focus on averages, such as the average total sleep time 
during a specified period of time, very little work has focused on whether greater 
variability in sleep could also be a measure of sleep disturbance.  Using data 
from the Outcomes of Sleep Disorders in Older Men (MrOS Sleep) study, this 
dissertation aimed to examine the characteristics and correlates of variability in 
sleep/wake parameters among community-dwelling older men.   Results from 
this study suggested that qualitatively older men appear to exhibit slightly less 
variability in sleep than a slightly younger, middle aged cohort (CARDIA)94, and 
although the majority of variability in sleep/wake parameters is derived from 
comparing measures of sleep between individuals, a substantial amount of intra-
individual variability exists.  Furthermore, several demographic, anthropometric, 
lifestyle, medical, medication and physical functioning factors were independently 
associated with greater sleep/wake variability, and African American race, living 
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alone, antidepressant use, depression, greater body mass index and 
multimorbidity appear to be the strongest independent predictors of greater 
sleep/wake variability in this population.  Since these are potentially modifiable 
factors, these findings help direct the design of future intervention studies aimed 
at improving sleep among older adults.  However, it is important that future 
research explore the mechanisms underlying these associations in order to 
better understand how these factors impact sleep, or how sleep impacts these 
factors in older adults.   
 Finally, the third area this dissertation focused on was improving our 
understanding of the impact that sleep disturbances have on the risk of all-cause 
hospitalizations in an older female population.  Research into developing a 
understanding of this association was warranted, based on prior observation of 
higher rates of health care utilization among adults with insomnia, or self-
reported sleep disturbances.  Using data from the Study of Osteoporotic 
Fractures, including objective assessments of sleep disturbances, and taking 
advantage of the linkage to Medicare Claims and Kaiser encounter data, this 
dissertation aimed to address the question of whether sleep disturbances were 
independently associated with all-cause hospitalizations in older women.    
 The results suggested that sleep disturbances are associated with an 
increased risk of hospitalization, but that results are explained, in a large part by 
health-related factors such as comorbidities, physical functioning, depression and 
health status.  In a further analysis, we discovered that sleep disturbances are 
independently associated with a greater odds of hospitalizations related to COPD 
and CHF in older women, and although we are unable to assess it, obstructive 
sleep apnea, as well as nocturnal dyspnea could underlie these associations.  
Future studies are needed to determine whether improving sleep helps to 
improve health outcomes, such as reductions in COPD and CHF related 
hospitalizations.    Future studies should also examine associations between 
sleep disturbances and nursing home, hospice and home health care utilization.   
 This dissertation is the first to examine these specific topics exclusively in 
older adult populations.  These results provide a foundation from which to 
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develop additional research into better understanding the role that sleep plays in 
affecting the health and successful aging of older adult populations.    
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Appendices 
 
Appendix A.  A Comparison of STOP-BANG Questions and equivalent questions obtained from 
the MrOS cohort 
 
 STOP-BANG MrOS Sleep Study 
Component Definition Definition 
Snore loudly Do you snore loudly (louder 
than talking or loud enough to 
be heard through closed 
doors?) (Yes=Snore loudly) 
During the past month, how often 
have you had trouble sleeping 
because you cough or snore 
loudly? (Less than once a week or 
more = Snore loudly) 
 
Tired Do you often feel tired, 
fatigued, or sleepy during the 
daytime? (Yes= Tired) 
Do you have difficulty being as 
active as you want to be in the 
morning (or afternoon) because you 
are sleepy or tired? 
(Extreme/moderate/a little difficulty 
= Tired) 
 
Observed 
apneas 
Has anyone observed you 
stop breathing during your 
sleep? (Yes=Observed 
apneas) 
Please ask your bed partner how 
often in the past month you have 
had long pauses between breaths 
while asleep? (Less than once a 
week or more = Observed apneas) 
 
Pressure 
(Hypertension) 
Do you have, or are you being 
treated for high blood 
pressure? (Yes=Pressure) 
Has a healthcare provider or doctor 
ever told you that you have 
hypertension or high blood 
pressure? (Yes=Pressure) 
 
BMI  BMI >35 kg/m2 ?(Yes=BMI) BMI >35 kg/m2 ?(Yes=BMI) 
Age  Age >50 y? (Yes=Age) Age >50 y? (Yes=Age) 
Neck 
circumference 
Neck circumference >40 cm? 
(Yes=Neck circumference) 
Neck circumference >40 cm? 
(Yes=Neck circumference) 
Male Gender Male gender? (Yes=Gender) Male gender? (Yes=Gender) 
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Appendix B.  Predictive parameters of Different STOP-BANG score cut-offs 
using a 4% oxygen desaturation criteria 
 
STOP-BANG 
score cut-off 
Sensitivity (%) 
Specificity 
(%) 
PPV (%) NPV(%) 
All OSA (AHI>5) vs. None (AHI<5)   
>3 vs. 2 91.3 16.0 62.7 54.6 
>4 vs. 0-3 67.0 46.6 65.9 47.8 
>5 vs. 0-4 37.7 73.2 68.5 43.2 
>6 vs. 0-5 16.1 92.0 75.5 41.5 
>7 vs. 0-6 4.1 98.0 76.3 39.9 
Moderate/Severe OSA (AHI>15) vs. Mild/None 
(AHI<15) 
  
>3 vs. 2 92.3 12.9 27.5 82.4 
>4 vs. 0-3 72.0 42.1 30.8 80.8 
>5 vs. 0-4 45.9 71.0 36.2 78.6 
>6 vs. 0-5 22.0 90.3 44.8 76.4 
>7 vs. 0-6 6.5 97.9 52.7 74.6 
Severe OSA (AHI>30) vs. Moderate/Mild/None 
(AHI<30) 
  
>3 vs. 2 94.7 12.3 10.6 95.5 
>4 vs. 0-3 73.1 39.6 11.7 93.1 
>5 vs. 0-4 48.6 68.2 14.4 92.4 
>6 vs. 0-5 25.5 88.5 19.6 91.6 
>7 vs. 0-6 6.4 97.1 19.4 90.4 
*Using 4% desaturation criteria 
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Appendix C.  Predictive parameters of STOP-BANG Component Combinations 
STOP-BANG score 
cut-off 
Prevalence 
(%) 
Sensitivity 
(%) 
Specificity 
(%) 
PPV (%) NPV(%) OR (95% CI)** 
Snore loudly + Tired 22.3 25.3 80.0 49.2 58.3 1.35 (1.13-1.62) 
Snore loudly + OA 13.8 16.6 88.3 52.0 58.0 1.54 (1.24-1.92) 
Snore loudly + HTN 22.7 27.8 81.2 53.1 59.5 1.65 (1.38-1.98) 
Snore loudly + BMI 1.9 2.8 98.8 63.0 57.0 2.17 (1.23-3.83) 
Snore loudly + Neck 17.6 23.6 87.1 58.3 59.8 2.23 (1.82-2.74) 
Tired + OA 11.1 12.8 90.2 49.8 57.5 1.41 (1.11-1.79) 
Tired + HTN 23.8 25.8 77.7 46.9 57.8 1.21 (1.02-1.45) 
Tired + BMI 1.9 2.8 98.8 64.8 57.0 2.29 (1.29-4.07) 
Tired + Neck circum 17.5 22.2 86.2 55.2 59.2 1.85 (1.51-2.27) 
OA + HTN 11.3 14.4 91.2 55.5 58.2 1.76 (1.38-2.24) 
OA + BMI 1.0 1.1 99.3 54.2 56.7 1.40 (0.61-3.20) 
OA + NC 9.2 12.3 93.2 59.0 58.1 2.00 (1.53-2.61) 
HTN + BMI 2.7 4.2 98.4 66.7 57.3 2.53 (1.55-4.12) 
HTN + NC 21.7 28.3 83.3 56.5 60.3 2.06 (1.71-2.48) 
BMI + NC 3.3 4.9 97.8 63.2 57.3 2.23 (1.44-3.44) 
Moderate/Severe OSA (AHI>15) vs. Mild/None (AHI<15) 
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*Using 3% desaturation criteria 
**Age and clinic site adjusted 
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Appendix D.  ROC Curve Results for Age, Neck circumference, Body Mass 
Index and Prediction of Severe OSA. 
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Appendix E. Predictive parameters of Different STOPBANG Score cut offs 
by severity of OSA (using 3% criteria) after redefining the TIRED 
component. 
 
Cut points 
Sensitivity 
(%) 
Specificity 
(%) 
PPV (%) NPV (%) 
AHI >5     
>3 vs. 0-2 88.0 21.2 80.6 32.2 
>4 vs. 0-3 60.1 56.1 83.6 27.4 
>5 vs. 0-4 30.8 80.5 85.5 23.8 
>6 vs. 0-5 12.0 96.2 92.1 22.7 
>7 vs. 0-6 2.5 99.5 94.8 21.5 
AHI >15     
>3 vs. 0-2 90.2 17.1 45.4 69.5 
>4 vs. 0-3 63.0 48.2 48.2 63.0 
>5 vs. 0-4 35.6 77.0 54.3 61.0 
>6 vs. 0-5 14.9 93.3 63.0 58.9 
>7 vs. 0-6 3.4 99.0 72.4 57.3 
AHI >30     
>3 vs. 0-2 93.0 15.4 18.9 91.2 
>4 vs. 0-3 69.5 46.1 21.5 87.7 
>5 vs. 0-4 41.5 74.3 25.5 85.7 
>6 vs. 0-5 18.0 91.4 30.8 84.0 
>7 vs. 0-6 4.0 98.4 34.5 82.9 
OSA=Obstructive sleep apnea; PPV=Positive predictive value; NPV=Negative 
predictive value; AHI=Apnea Hypopnea Index.   
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Appendix F.  Predictive parameters of Different STOPBANG Score cut offs 
by severity of OSA (using 3% criteria) after redefining the Pressure 
component 
 
Cut points 
Sensitivity 
(%) 
Specificity 
(%) 
PPV (%) NPV (%) 
AHI >5     
>3 vs. 0-2 93.4 15.1 80.4 38.1 
>4 vs. 0-3 70.5 43.5 82.3 28.4 
>5 vs. 0-4 40.7 72.2 84.5 24.7 
>6 vs. 0-5 16.8 92.6 89.3 23.0 
>7 vs. 0-6 4.2 98.5 91.3 21.6 
AHI >15     
>3 vs. 0-2 94.4 10.5 44.7 71.1 
>4 vs. 0-3 73.6 37.1 47.3 64.7 
>5 vs. 0-4 45.0 67.4 51.4 61.6 
>6 vs. 0-5 20.4 89.5 60.0 59.5 
>7 vs. 0-6 5.3 97.7 63.1 57.4 
AHI >30     
>3 vs. 0-2 96.6 9.4 18.4 92.9 
>4 vs. 0-3 80.0 35.1 20.7 89.2 
>5 vs. 0-4 51.5 64.9 23.7 86.3 
>6 vs. 0-5 24.7 87.3 29.2 84.5 
>7 vs. 0-6 6.6 97.0 32.0 83.1 
OSA=Obstructive sleep apnea; PPV=Positive predictive value; NPV=Negative 
predictive value; AHI=Apnea Hypopnea Index.   
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Appendix G.  Predictive parameters of different STOP-BANG score cut-offs 
including all apneic events 
STOP-
BANG 
score cut-
off 
Prevalence 
of OSA 
(%) 
Sensitivity 
(%) 
Specificity 
(%) 
PPV 
(%) 
NPV (%) 
All OSA (AHI>5) vs. None (AHI<5)* 
>3 vs. 2 
97.6 
88.5 13.0 97.6 2.7 
>4 vs. 0-3 61.8 44.9 97.8 2.8 
>5 vs. 0-4 33.5 68.1 97.7 2.5 
>6 vs. 0-5 13.0 91.3 98.4 2.5 
>7 vs. 0-6 3.3 98.6 98.9 2.5 
Moderate/Severe OSA (AHI>15) vs. Mild/None (AHI<15)* 
>3 vs. 2 
78.9 
89.6 15.8 79.9 28.8 
>4 vs. 0-3 63.8 46.4 81.7 25.5 
>5 vs. 0-4 35.4 73.7 83.4 23.3 
>6 vs. 0-5 14.2 92.0 87.0 22.3 
>7 vs. 0-6 3.8 98.7 91.4 21.5 
Severe OSA (AHI>30) vs. Moderate/Mild/None (AHI<30)* 
>3 vs. 2 
43.4 
91.8 14.1 45.1 69.1 
>4 vs. 0-3 68.0 43.3 47.9 63.7 
>5 vs. 0-4 40.7 72.1 52.8 61.3 
>6 vs. 0-5 17.8 90.9 60.1 59.0 
>7 vs. 0-6 4.8 97.9 63.4 57.3 
*AHI defined using PORDI0P variable that includes all apneic events, including 
subtle snoring. 
PPV=Positive predictive value; NPV=Negative predictive value; OSA=Obstructive 
Sleep Apnea; AHI=Apnea Hypopnea Index  
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Appendix H.  Predictive parameters of Different STOP-BANG score cut-offs 
excluding central sleep apnea events from the definition of OSA 
STOP-
BANG 
score cut-
off 
Prevalence 
of OSA 
(%) 
Sensitivity 
(%) 
Specificity 
(%) 
PPV 
(%) 
NPV (%) 
All OSA (AHI>5) vs. None (AHI<5)* 
>3 vs. 2 
79.6 
90.1 17.9 81.1 31.5 
>4 vs. 0-3 64.3 48.9 83.1 25.9 
>5 vs. 0-4 35.5 74.7 84.6 22.9 
>6 vs. 0-5 14.6 93.8 90.2 21.9 
>7 vs. 0-6 3.9 99.3 95.7 20.9 
Moderate/Severe OSA (AHI>15) vs. Mild/None (AHI<15)* 
>3 vs. 2 
43.9 
91.6 14.1 45.5 68.2 
>4 vs. 0-3 67.7 43.2 48.2 63.1 
>5 vs. 0-4 40.3 71.9 52.8 60.6 
>6 vs. 0-5 18.1 91.1 61.4 58.7 
>7 vs. 0-6 5.0 98.1 67.7 56.9 
Severe OSA (AHI>30) vs. Moderate/Mild/None (AHI<30)* 
>3 vs. 2 
17.1 
93.8 12.7 18.1 90.9 
>4 vs. 0-3 75.4 41.2 20.9 89.0 
>5 vs. 0-4 48.5 69.7 24.7 86.8 
>6 vs. 0-5 23.6 89.3 31.3 85.0 
>7 vs. 0-6 7.0 97.5 36.6 83.6 
*AHI defined using POORDI3 variable that excludes central sleep apnea events. 
PPV=Positive predictive value; NPV=Negative predictive value; OSA=Obstructive 
Sleep Apnea; AHI=Apnea Hypopnea Index 
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Appendix I.  Predictive parameters of Different STOP-BANG score cut-offs 
excluding men with unusual occurrences of periodic breathing (i.e. 
Cheynes-Strokes) 
STOP-
BANG 
score cut-
off 
Prevalence 
of OSA 
(%) 
Sensitivity 
(%) 
Specificity 
(%) 
PPV 
(%) 
NPV (%) 
All OSA (AHI>5) vs. None (AHI<5)* 
>3 vs. 2 
77.7 
90.2 17.9 79.3 34.4 
>4 vs. 0-3 64.6 49.8 81.8 28.8 
>5 vs. 0-4 36.1 75.4 83.7 25.3 
>6 vs. 0-5 15.2 93.9 89.7 24.1 
>7 vs. 0-6 4.1 99.3 95.5 22.9 
Moderate/Severe OSA (AHI>15) vs. Mild/None (AHI<15)* 
>3 vs. 2 
40.7 
92.0 14.0 42.4 71.8 
>4 vs. 0-3 67.9 43.1 45.1 66.2 
>5 vs. 0-4 41.4 71.9 50.3 64.1 
>6 vs. 0-5 19.2 91.0 59.4 62.1 
>7 vs. 0-6 5.5 98.2 67.4 60.2 
Severe OSA (AHI>30) vs. Moderate/Mild/None (AHI<30)* 
>3 vs. 2 
15.1 
94.5 12.7 16.2 92.9 
>4 vs. 0-3 75.2 41.1 18.5 90.3 
>5 vs. 0-4 49.1 69.3 22.2 88.4 
>6 vs. 0-5 24.8 88.9 28.6 86.9 
>7 vs. 0-6 7.2 97.4 32.6 85.5 
*AHI defined using 3% desaturation Criteria. 
Men with unusual occurrences of periodic breathing lasting >10 minutes are 
excluded. 
PPV=Positive predictive value; NPV=Negative predictive value; OSA=Obstructive 
Sleep Apnea; AHI=Apnea Hypopnea Index 
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Appendix J.  Predictive parameters of different STOP-BANG score cut-offs 
restricted to 2,173 men who reported having a bed partner 
STOP-
BANG 
score cut-
off 
Prevalence 
of OSA 
(%) 
Sensitivity 
(%) 
Specificity 
(%) 
PPV 
(%) 
NPV (%) 
All OSA (AHI>5) vs. None (AHI<5)* 
>3 vs. 2 
78.2 
91.3 16.8 80.7 33.8 
>4 vs. 0-3 66.6 46.7 82.6 26.8 
>5 vs. 0-4 38.5 72.1 84.0 23.5 
>6 vs. 0-5 16.7 92.3 89.1 22.5 
>7 vs. 0-6 4.9 99.1 95.5 21.5 
Moderate/Severe OSA (AHI>15) vs. Mild/None (AHI<15)* 
>3 vs. 2 
40.2 
92.4 12.4 44.1 68.4 
>4 vs. 0-3 68.8 39.9 46.1 63.1 
>5 vs. 0-4 42.7 68.6 50.4 61.6 
>6 vs. 0-5 20.3 89.3 58.7 60.0 
>7 vs. 0-6 6.4 97.7 67.1 58.3 
Severe OSA (AHI>30) vs. Moderate/Mild/None (AHI<30)* 
>3 vs. 2 
14.5 
94.0 11.2 17.7 90.2 
>4 vs. 0-3 73.8 38.2 19.5 87.8 
>5 vs. 0-4 48.4 66.2 22.5 86.4 
>6 vs. 0-5 25.1 87.3 28.6 85.2 
>7 vs. 0-6 7.9 96.7 33.0 83.8 
*AHI defined using 3% desaturation criteria 
PPV=Positive predictive value; NPV=Negative predictive value; OSA=Obstructive 
Sleep Apnea; AHI=Apnea Hypopnea Index  
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Appendix K.  Predictive Parameters of STOPBANG cut points stratified by 
Excessive Daytime Sleepiness 
 Sensitivity Specificity PPV NPV 
AHI>5     
ESS 0-10     
>3 vs. 2 89.3 18.3 79.9 31.9 
>4 vs. 2-3 62.9 51.0 82.4 27.4 
>5 vs. 2-4 33.9 76.6 84.1 24.2 
>6 vs. 2-5 13.2 95.0 90.5 23.1 
>7 vs. 2-6 3.2 99.4 95.5 22.0 
ESS>10     
>3 vs. 2 96.4 17.4 83.6 52.2 
>4 vs. 2-3 77.2 43.5 85.7 30.3 
>5 vs. 2-4 48.0 65.2 85.8 22.3 
>6 vs. 2-5 24.8 85.5 88.2 20.6 
>7 vs. 2-6 8.6 98.6 96.3 19.8 
AHI>15     
ESS 0-10     
>3 vs. 2 90.8 14.8 44.2 68.4 
>4 vs. 2-3 65.6 44.4 46.8 63.5 
>5 vs. 2-4 38.2 73.2 51.5 61.4 
>6 vs. 2-5 16.2 92.2 60.8 59.7 
>7 vs. 2-6 4.1 98.4 65.2 58.0 
ESS>10     
>3 vs. 2 97.2 9.3 49.7 78.3 
>4 vs. 2-3 79.2 32.1 51.8 62.6 
>5 vs. 2-4 53.4 61.7 56.2 58.9 
>6 vs. 2-5 28.7 82.4 60.0 55.6 
>7 vs. 2-6 11.2 96.4 74.1 54.1 
AHI>30     
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ESS 0-10     
>3 vs. 2 93.3 13.5 17.9 90.9 
>4 vs. 2-3 71.5 42.5 20.1 88.1 
>5 vs. 2-4 43.7 70.8 23.2 86.2 
>6 vs. 2-5 20.1 90.4 29.7 84.9 
>7 vs. 2-6 5.8 98.0 36.4 83.7 
ESS>10     
>3 vs. 2 97.6 7.3 23.0 91.3 
>4 vs. 2-3 84.2 29.8 25.4 86.9 
>5 vs. 2-4 61.0 58.8 29.6 84.2 
>6 vs. 2-5 31.7 79.6 30.6 80.4 
>7 vs. 2-6 9.8 93.4 29.6 78.5 
*3% Desaturation Criteria 
PPV=Positive predictive value; NPV=Negative predictive value; OSA=Obstructive 
Sleep Apnea; AHI=Apnea Hypopnea Index 
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Appendix L.  Predictive Parameters of STOPBANG cut points by AHI 
severity and stratified by AGE 
 Sensitivity Specificity PPV NPV 
AHI>5     
Age <80 yrs     
>3 vs. 2 91.1 18.0 80.3 35.6 
>4 vs. 2-3 66.7 50.1 83.1 29.1 
>5 vs. 2-4 39.9 74.7 85.3 25.3 
>6 vs. 2-5 16.9 93.2 90.1 23.4 
>7 vs. 2-6 4.7 99.1 95.0 22.1 
Age >80 yrs     
>3 vs. 2 88.0 18.8 80.8 28.7 
>4 vs. 2-3 59.9 50.3 82.4 24.5 
>5 vs. 2-4 25.4 77.0 81.0 21.0 
>6 vs. 2-5 9.2 95.8 89.4 21.4 
>7 vs. 2-6 2.0 100.0 100.0 20.9 
AHI>15     
Age <80 yrs     
>3 vs. 2 92.7 13.4 43.3 72.1 
>4 vs. 2-3 70.2 42.0 46.3 66.4 
>5 vs. 2-4 45.4 69.3 51.3 64.0 
>6 vs. 2-5 20.9 89.6 58.9 61.4 
>7 vs. 2-6 6.2 97.7 66.3 59.4 
Age >80 yrs     
>3 vs. 2 89.6 16.2 49.4 63.0 
>4 vs. 2-3 61.7 45.7 51.0 56.6 
>5 vs. 2-4 29.2 79.1 56.0 55.0 
>6 vs. 2-5 11.7 95.0 68.2 54.1 
>7 vs. 2-6 2.6 99.3 76.9 52.7 
AHI>30     
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Age <80 yrs     
>3 vs. 2 94.7 11.9 16.5 92.3 
>4 vs. 2-3 76.2 39.3 18.8 90.0 
>5 vs. 2-4 51.4 65.9 21.8 88.0 
>6 vs. 2-5 26.0 87.3 27.5 86.5 
>7 vs. 2-6 8.2 96.9 32.5 85.1 
Age >80 yrs     
>3 vs. 2 92.8 15.2 24.0 88.0 
>4 vs. 2-3 68.9 45.4 26.7 83.5 
>5 vs. 2-4 37.8 78.9 34.0 81.5 
>6 vs. 2-5 15.0 93.8 40.9 79.3 
>7 vs. 2-6 3.3 98.9 46.2 78.0 
*3% Desaturation Criteria 
PPV=Positive predictive value; NPV=Negative predictive value; OSA=Obstructive 
Sleep Apnea; AHI=Apnea Hypopnea Index 
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Appendix M.  Predictive parameters of Different STOP score cut-offs 
 
 
Pre-Test 
Pr of OSA 
(%) 
Sensitivity 
(%) 
Specificity 
(%) 
PPV 
(%) 
NPV 
(%) 
LR+ LR- AUC (95% CI) 
All OSA (AHI>5) vs. None (AHI<5)     
>2 vs. 0-1 
78.8 
52.5 58.9 82.7 25.0 1.28 0.81 0.56 (0.54-0.58) 
>3 vs. 0-2 21.8 83.6 83.2 22.3 1.33 0.93 0.53 (0.51-0.54) 
4 vs. 0-3 5.0 97.2 86.8 21.6 1.77 0.98 0.51 (0.50-0.52) 
Moderate/Severe OSA (AHI>15) vs. Mild/None (AHI<15)    
>2 vs. 0-1 
43.4 
55.5 54.0 48.0 61.3 1.21 0.82 0.55 (0.53-0.57) 
>3 vs. 0-2 24.0 81.9 50.3 58.5 1.32 0.93 0.53 (0.51-0.55) 
4 vs. 0-3 6.4 96.9 61.2 57.5 2.06 0.97 0.52 (0.50-0.53) 
Severe OSA (AHI>30) vs. Moderate/Mild/None (AHI<30)    
>2 vs. 0-1 
17.5 
60.1 52.0 21.0 86.0 1.25 0.77 0.56 (0.54-0.59) 
>3 vs. 0-2 27.1 80.7 22.9 83.9 1.40 0.90 0.54 (0.52-0.56) 
4 vs. 0-3 6.6 95.9 25.6 82.9 1.62 0.97 0.56 (0.54-0.58) 
*AHI defined using >3% oxygen desaturation criteria. 
PPV=Positive predictive value;  NPV=Negative predictive value; OSA=Obstructive Sleep Apnea; AHI=Apnea Hypopnea 
Index 
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Appendix N.  ROC Curve Results for STOP Questionnaire and Prediction of 
Severe OSA.   
 
 
 
Straight line depicts no discriminative ability (i.e. Area under the ROC 
Curve= 0.5).  In this model the area under the ROC curve was 0.575 (0.549-
0.602). 
 
 
